



Report of the Committee on

LAW ENFORCEMENT/LEGISLATION

Report of the Committee on Law Enforcement/Legislation

Members Present

David Bowyer (WV), *chair*; Sabrina L. Beck (NE); Alexandra Blasi (KS); Paul Brand (MT); Cheryl “Cheri” Garvin (VA); Kevin Morgan (MD); Tiffany O’Hagan (WI); Stacey Ranucci (RI); Kristen Snair (AZ); Deena Speights-Napata (MD); and Stuart Williams (MN).

Others Present

Janet Getzey Hart, *Executive Committee liaison*; Lemrey “Al” Carter, William Cover, Melissa Becker, Eileen Lewalski, Gertrude “Gg” Levine, Maureen Schanck, Cameron Orr, *NABP staff*.

Introduction

The committee met on February 6-7, 2023, at NABP Headquarters in Mount Prospect, IL.

Review of the Committee Charge

Charge of the committee:

1. Develop model laws and regulations based on resolutions adopted by the members of the association or on reports of task forces or other committees of the association, or as assigned by the Executive Committee.
2. Review and comment on existing legislation and rules governing the practice of pharmacy and the distribution of prescription medications.
3. Recommend to the Executive Committee model pharmacy practice or prescription drug distribution regulations that are needed to improve the protection of the public health.

Background and Discussion

After careful review and deliberation, aside from the *Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model Act)* suggested amendments, the committee force recommended the following:

1. NABP should instruct the 2024 Law Enforcement/Legislation (LE/L) Committee to review the definition of Pharmacist-in-Charge (PIC), as well as the PIC provision in the Model Rules for Outsourcing Facilities.
2. NABP should review cases that are cited in the *Model Act* to ensure that they are current.
3. NABP should convene task force(s) to review the following:
 - a. *Model Act* sections pertaining to discipline and unprofessional conduct; and

- b. *Model Act* sections pertaining to shared services, automated pharmacy systems, remote dispensing sites, and telepharmacy.

The committee began its discussion by acknowledging a July 27, 2022 letter to NABP from the American Pharmacists Association; Council on Radionuclides and Radiopharmaceuticals, Inc; National Association of Nuclear Pharmacies; and Society of Nuclear Medicine and Molecular Imaging encouraging the state boards of pharmacy to adopt United States Pharmacopeial Convention (USP) General Chapter <825>, which will go into effect on November 1, 2023. This letter prompted a review of the relevant section of the *Model Act* by NABP's staff expert on the subject of Nuclear Pharmacy/Radiopharmacy, who recommended changes that reflect the standards outlined in USP <825> and Title 10 of the Code of Federal Regulations (CFR), Section 35.55 (10 CFR 35.55).

The first change was to rename the title and terminology used throughout the section from "Model Rules for Nuclear/Radiologic Pharmacy" to "Model Rules for Nuclear Pharmacy/Radiopharmacy." In addition, the term "Qualified Nuclear Pharmacist" was changed to "Authorized Nuclear Pharmacist" (ANP) to reflect the term defined by the Nuclear Regulatory Commission. The ANP educational requirements were also updated. The committee accepted the recommended changes with the exception of an edit to the educational requirements. The edit clarifies that "a total of" 700 hours in a structured educational program are required, and that they must consist of both 200 hours of classroom and laboratory training and 500 hours of supervised practical experience in a nuclear pharmacy.

USP <825> clarifies that nuclear pharmacies primarily dispense rather than compound drug products. The definitions for Compounding, Preparation with Minor Deviation, and Repackaging were added to the *Model Act* to clarify the differences and to explain that the act of repackaging occurs when a radiopharmaceutical is drawn up into syringes. Members accepted these changes, along with the added definitions for Dispensing and Preparation. They also asked how pharmacy technicians are defined in the Model Rules. Staff explained that pharmacy technicians can be "authorized users" but are not called out in nuclear pharmacy standards.

Container labeling was enumerated in the *Model Act* per USP <825> as a reference. The committee approved this addition, noting that boards of pharmacy can add specifics as applicable to their state. The practice of "kit splitting" and whether it is deemed "compounding" was also discussed. It was noted that, if the practice is deemed compounding, it carries a heavier lift to comply with sample sterility testing.

Finally, in reference to a recommended new paragraph calling for compliance with USP <825>, the committee discussed whether to keep the word "shall." It was determined that the word "shall" is appropriate to indicate that adherence to the USP chapter is mandatory. The remainder of the new paragraph was accepted.



The committee then turned its attention to the amendments recommended by the Task Force to Review *Model Act* Licensing and Disciplinary Language. Members discussed the addition of the term and definition of “Business Entity.” The task force had intended this term to replace “Person” when used in reference to a legal entity as opposed to an individual or human being, as this term is more widely understood in that sense by non-attorneys. Some members noted that the legal term “Person,” however, is commonly accepted in the legal community to encompass both entities and human beings. The committee considered eliminating the definition for “Business Entity” but ultimately opted to keep it as a subset of “Person.” As such, they decided to modify the definition of “Person” to include an individual or a “Business Entity” and agreed to delete the language describing a business entity, as it is included in the “Business Entity” definition. It was determined that the word “Person” would be used throughout the *Model Act* where the language is meant to encompass both business entities and individuals.

The committee agreed with the task force’s recommendations to delete certain terms due to nonuse, such as “Centralized Performance Database,” and replace outmoded terms like “Contraband Drug,” for which the current term is “Illegitimate Product.”

The task force recommended adding the program name “NABP Verify” and its definition to the *Model Act*, which led into a discussion of whether to include references to NABP programs and credentials such as NABP Emergency Passport, NABP Verify™, and Electronic Licensure Transfer Program®. The committee agreed that the names of accreditation programs should be omitted to avoid having to make changes to the *Model Act* if the program names change. NABP licensure programs, on the other hand, were thought to be helpful to keep because these programs are vital to the services the Association provides and are specified in some state laws. It was also noted that boards of pharmacy use the *Model Act* language as a framework and can add their own state-specific requirements or provide for a third-party alternative approved by the board. Members commented that including this alternative may make the language more readily accepted in some states.

The committee modified the recommended definition for “Revocation” to remove the word “permanent,” as some states allow for Persons to have their license reinstated after having had it revoked. The committee accepted the task force’s recommendation to delete the term “Significant Adverse Drug Reaction” and to replace it with the term “Serious Adverse Drug Experience” to mirror the language used in Food and Drug Administration’s Memorandum of Understanding Addressing Certain Distributions of Compounded Drugs. The committee did not agree, however, with the recommended examples in this definition and opted to remove them because the definition was deemed clearer without them.

While reviewing the *Model Act* section on unlawful practice, the committee disagreed with the task force’s decision to delete the language associated with unlawful nonresident practice but agreed with its recommendation to eliminate the term “Telepharmacy Technologies.” It was decided that the term is outdated and that the practice of telepharmacy is included within the practice of



pharmacy. Members agreed to keep the language associated with unlawful nonresident practice, however, for jurisdictional purposes, to give states the ability to take disciplinary actions in such circumstances, which may occur with or without the use of telepharmacy technologies.

Staff inquired whether lengthy footnotes referencing case law are relevant or helpful to include in the *Model Act*. Committee members recommended keeping them for reference in case a challenge to board authority arises. Although some of the cases referenced are old, they may provide the latest information available. When possible, committee members advised they should be reviewed and updated, if necessary, with new case law.

Committee members also discussed how to handle situations involving pharmacists providing pharmacist care services to patients in states where they are not licensed, and whether it is sufficient to report someone to the nonresident board. It was noted that NABP Verify was developed for situations such as this. Staff explained that NABP formerly supported full licensure for all nonresident practice, but with increased demand for license portability, NABP Verify was created to assist the boards in monitoring certain types of nonresident practice.

The committee agreed with the task force's recommendation to move a subsection addressing pharmacy practice experience programs and the accompanying footnotes from the section addressing pharmacist licensure to the section addressing pharmacist experience programs and pharmacist interns and keep the descriptive text, as it may be relevant for boards that still license interns. Members decided to delete the provision addressing specific reciprocity qualifications for licensure transfer because it was deemed outdated and considered extraneous due to the fact that it is included in the NABP Constitution and Bylaws.

After some discussion, the committee agreed to keep recommended new language addressing licensure of dispensing practitioners, determining that some state boards of pharmacy have the authority to license and inspect dispensing practitioners. This is especially important for public protection, members noted, as more practitioners are involved in compounding. The committee also accepted the recommendation to add to Article 4 a new Section 401. Unlawful Practice, so as to be consistent with the format and wording of Article 3, with minor exceptions.

Regarding events that are to be reported to the board of pharmacy, the task force recommended adding any temporary closing of a pharmacy for more than 48 hours. The committee, however, agreed to change "48 hours" to "two consecutive calendar days outside of the Pharmacy's regular operating hours" to address pharmacies that close on weekends.

The committee accepted the amendments recommended by the task force regarding boards requiring complainants to identify themselves provided the board keeps investigative files confidential. It was noted that whistleblower protection provides an additional layer of confidentiality. The committee agreed to revise "sufficient evidence" to "probable cause," as the



latter is the legal standard used in administrative hearings, as well as revising “impaired practice Pharmacist” to “impaired practice licensee” to include technicians and other pharmacy personnel.

Committee members raised a concern about removing pharmacy licensure language outlining designated space requirements for the pharmacist counseling that goes along with dispensing. The committee therefore recommended adding “Dispensing” to the sentence addressing required accoutrements for preparing Prescription Drug Orders.

In the context of pharmacy security, the committee discussed the use of the term “for cause” in the event of separation of employment of an employee. The committee determined that the cause of the separation should have no impact on matters of security and therefore decided to delete the term.

Regarding personnel, committee members noted that some states are moving away from designating a PIC and, instead, are requiring the pharmacist on duty to oversee the pharmacy during that shift. The committee recommended that next year’s LE/L Committee review the definition of PIC. The committee also discussed whether the PIC responsibilities should be limited to avoid a situation in which one pharmacist is designated as the PIC for multiple pharmacies and whether greater responsibility should be placed on the permit holders. The committee also discussed the requirement that Outsourcing Facilities designate a PIC. The committee supported recommending that a task force review PIC provisions and agreed to maintain the current provisions in the *Model Act*.

In reference to requirements for pharmacy labor standards, shift lengths, and breaks, the committee agreed to change the specified time periods from “per day” to “in any 24-hour period.” This clarification prevents a situation in which a pharmacist works until midnight one day but is scheduled for a shift that starts at 12:01 AM the following day.

Regarding unprofessional conduct, committee members raised concerns about a lack of consistency in defining when a board of pharmacy has the authority to take disciplinary action against a licensee. They referred to one section of the *Model Act* that enumerates several specific actions that would authorize a board to act, while another section refers to the board’s authority to issue or deny a license based on “public interest.” As this term could result in disciplinary proceedings based on ambiguous allegations, members recommended the establishment of a task force to review this language.

The committee then transitioned to reviewing amendments recommended by the Task Force to Review Model Rules for the Practice of Pharmacy and Develop a New Pharmacy Practice Model. In the definition for “Practice of Pharmacy,” the committee recommended removing the phrase “to optimize patient outcomes” because it is redundant with the term “outcome,” which is included in the section on “Pharmacist Care Services.”

Members discussed Pharmacist Care Services and noted the omission of the word “ordering” in relation to laboratory tests. The committee recommended adding “ordering” to the language to supplement “interpreting” laboratory tests. They also discussed whether the tasks outlined under Pharmacist Care Services were too broad and perhaps could overlap into other health care professions. Members determined, however, that the language was not exclusive to pharmacists and therefore appropriate. Additionally, the committee noted that the description of Pharmacist Care Services in the Model Rules should match the new definition in the *Model Act*. Members also recommended removing the corresponding footnote and ensuring consistency with use of the phrase “including but not limited to.”

On the topic of Medication Therapy Management, the committee recommended adding discontinuing medication to the actions a pharmacist may take, as well as clarifying that the patient’s prescribing practitioner should be notified along with the primary care physician, as they may be different.

Regarding other definitions, the committee decided to delete the terms and definitions for “Digital Signature” and “Electronic Signature,” noting that the term signature refers to any kind. The committee also approved the recommended change in terminology from “Medication-assisted Treatment (MAT)” to “Medication for Opioid Use Disorder (MOUD)” and within that definition changed “‘whole-patient’ approach” to “holistic approach.” Based on expert feedback afterwards, members later determined the appropriate term is “patient-centered approach.”

In the Model Rules for the Practice of Pharmacy, the committee discussed use of the word “website” and determined that the term also encompasses social media because such platforms are associated with websites. Apps may be, but are not necessarily, associated with a website. To address that question, members noted that, in law, when no legal definition is provided, the standard dictionary definition prevails, and according to a Webster’s dictionary definition, an app would be covered within this term. The committee acknowledged that, as technology changes, the terminology may change as well, but agreed on “website or other digital content” for now.

In some cases, the recommendations of the two task forces conflicted with each other. In those instances, the committee assessed the variances and selected one over the other, sometimes with additional edits. The Task Force to Review Model Rules for the Practice of Pharmacy and Develop a New Pharmacy Practice Model suggested changing all references of “he or she” to “they.” The committee decided it would be better to avoid using pronouns altogether and to use nouns like pharmacist or licensee instead.

Under Section 3. Personnel, the subsection on PIC notifying the board of pharmacy in the case of the installation or removal of Automated Pharmacy Systems includes a strikeout recommended by the Task Force to Review Model Rules for the Practice of Pharmacy and Develop a New Pharmacy Practice Model that was not recommended by the Task Force to Review *Model Act* Licensing and Disciplinary Language. The committee opted to keep this section, noting that automated pharmacy



systems have the potential to impact other systems such as security. The committee also opted to keep the text in the *Model Act* for a future task force to review for appropriateness.

Regarding prescription drug order processing, the committee did not agree with the recommendation from the Task Force to Review Model Rules for the Practice of Pharmacy and Develop a New Pharmacy Practice Model to remove language stating that, to be valid, a prescription drug order must be issued for a legitimate medical purpose by a practitioner acting within the course of legitimate professional practice, determining that the language describing the corresponding responsibility of the pharmacist who fills the prescription should not be deleted.

Regarding emergency refills, the committee changed the language to clarify that a pharmacist may “authorize and dispense,” rather than “Prescribe” a refill of a Prescription Drug, because if the prescription is a refill, the pharmacist is not technically prescribing it. The committee also recommended that language about notifying the prescriber of an emergency refill should remain in case the prescriber intended that the medication be discontinued and not be refilled.

Lastly, the committee agreed with the recommendation that the section on Telepharmacy be reviewed by a future task force.

The revisions recommended by the task forces and identified in other agenda items are denoted by underlines and ~~strikethroughs~~. The recommended revisions by the LE/L Committee are denoted by double underlines and ~~double strikethroughs~~.

Recommended *Model Act* Amendments to Reflect USP General Chapter <825> and 10 CFR 35.55

National Association of Boards of Pharmacy Model State Pharmacy Act

Model Rules for ~~Nuclear Pharmacy~~Nuclear Pharmacy/Radiopharmacy/Radiologic Pharmacy

Section 1. Purpose and Scope.

The Practice of ~~Nuclear Pharmacy~~Nuclear Pharmacy/Radiopharmacy/Radiologic Pharmacy is hereby recognized as a specialty of Pharmacy practice, regulated by State Boards of Pharmacy. As such, the following model rules are included to address those areas specific or unique to this specialty practice. ~~Nuclear Pharmacy~~Nuclear Pharmacy/Radiopharmacy/Radiologic Pharmacy Practice refers to a patient-



NABP

oriented service that embodies the scientific knowledge and professional judgment required to improve and promote health through the assurance of the safe and efficacious use of radiopharmaceuticals and other ~~D~~drugs.

Section 2. Definitions.

- (a) “Authentication of Product History” means, but is not limited to, identifying the purchasing source, the ultimate fate, and any intermediate handling of any Component of a radiopharmaceutical.
- (b) “Qualified Authorized Nuclear Pharmacist” means a currently licensed Pharmacist in the State of practice, who is certified as a Nuclear Pharmacist by the State Board of Pharmacy or by a certification Board recognized by the State Board of Pharmacy, or who meets the following standards:
- (1) Minimum standards of training for “authorized user status” of radioactive material [cite State Radiation Control Agency or NRC licensure guide].
 - (2) ~~Completed a minimum of 200 contact hours of instruction in nuclear Pharmacy and the safe handling and the use of radioactive materials from a program approved by the State Board of Pharmacy, with emphasis in the following areas:~~
 - ~~(i) radiation physics and instrumentation;~~
 - ~~(ii) radiation protection;~~
 - ~~(iii) mathematics of radioactivity;~~
 - ~~(iv) radiation biology; and~~
 - ~~(v) radiopharmaceutical chemistry.~~

~~Attained a minimum of 500 hours of clinical nuclear Pharmacy training under the supervision of a qualified nuclear Pharmacist.~~

Has completed a total of 700 hours in a structured educational program consisting of both:

 - (i) 200 hours of classroom and laboratory training in the following areas—
 - (A) Radiation physics and instrumentation;
 - (B) Radiation protection;
 - (C) Mathematics pertaining to the use and measurement of radioactivity;
 - (D) Chemistry of byproduct material for medical use; and
 - (E) Radiation biology.
 - (ii) 500 hours of supervised practical experience in a nuclear pharmacy involving—
 - (A) Shipping, receiving, and performing related radiation surveys;
 - (B) Using and performing checks for proper operation of instruments used to determine the activity of dosages, survey meters, and, if appropriate, instruments used to measure alpha- or beta-emitting radionuclides;
 - (C) Calculating, assaying, and safely preparing dosages for patients or human research subjects;



- (D) Using administrative controls to avoid medical events in the administration of byproduct material; and
- (E) Using procedures to prevent or minimize radioactive contamination and using proper decontamination procedures.
- (3) Has obtained written attestation, signed by a preceptor authorized nuclear pharmacist, that the individual has satisfactorily completed the requirements in paragraph (b)(1) of this section and is able to independently fulfill the radiation safety-related duties as an authorized nuclear pharmacist.
- ~~(c)~~ “Compounding” means the combining, mixing, pooling, or otherwise altering (excluding preparation with minor deviations) of a conventionally manufactured radiopharmaceutical or synthesizing/formulating a radiopharmaceutical from bulk drug substances and radionuclides. See Preparation with minor deviations.
- ~~(b)(d)~~ “Dispensing” means the manipulation or labeling of a radiopharmaceutical to render it in its final form for administration, typically obtained from a single-dose or multiple-dose container (eg, withdrawing a volume of finished product or preparation from a vial into a syringe). Dispensing is performed under the supervision of a physician or pharmacist and, for radiopharmaceuticals, includes dilution with an appropriate diluent or adjusting the activity in an individual dosage.
- ~~(e)~~ “Internal Test Assessment” means, but is not limited to, conducting those tests of quality assurance necessary to ensure the integrity of the test.
- ~~(e)(f)~~ “Nuclear Pharmacy/Nuclear Pharmacy/Radiopharmacy” means a Pharmacy providing radiopharmaceutical services or, as provided in Section 3 of these Rules, an appropriate area of any Institutional Facility.
- ~~(g)~~ “Preparation” means the act of combining a conventionally manufactured kit with a conventionally manufactured radionuclide following manufacturer’s recommended instructions. Mixing, reconstituting, combining, diluting, or repackaging of a radiopharmaceutical, or other such acts, performed in accordance with directions contained in the FDA-approved labeling.
- ~~(h)~~ “Preparation With Minor Deviations” means the act of preparing a conventionally manufactured kit with a conventionally manufactured radionuclide with volume, and/or radioactivity, and/or step-by-step deviations from the manufacturers recommended labeling while ensuring that the final preparation maintains appropriate radiochemical and radionuclidic purity for the entirety of the BUD. Examples of minor deviations include, but are not limited to, altering the amount of activity or volume added to the vial, changes in step-by-step operations (eg, dilute Tc-99m solution after, rather than before, addition to the vial, use of a venting needle or filter), using alternative devices or equipment (eg, a heating block rather than a hot water bath), and using alternative radiochemical purity testing methods.
- ~~(d)(i)~~ “Qualified Licensed Professional” means a non-Pharmacist individual (such as a physician, nurse, or technologist) who possesses a current state license, if applicable, and who has sufficient training and experience to safely handle and Dispense radiopharmaceuticals as defined by the respective requirements of [cite appropriate Nuclear Regulatory Commission (NRC) or Agreement State and State Board of Pharmacy law(s)].



NABP

- (e) ~~“Qualified Nuclear Pharmacist” means a currently licensed Pharmacist in the State of practice, who is certified as a Nuclear Pharmacist by the State Board of Pharmacy or by a certification Board recognized by the State Board of Pharmacy, or who meets the following standards:~~
- ~~(1) Minimum standards of training for “authorized user status” of radioactive material [cite State Radiation Control Agency or NRC licensure guide].~~
 - ~~(2) Completed a minimum of 200 contact hours of instruction in nuclear Pharmacy and the safe handling and the use of radioactive materials from a program approved by the State Board of Pharmacy, with emphasis in the following areas:~~
 - ~~(i) radiation physics and instrumentation;~~
 - ~~(ii) radiation protection;~~
 - ~~(iii) mathematics of radioactivity;~~
 - ~~(iv) radiation biology; and~~
 - ~~(v) radiopharmaceutical chemistry.~~
 - ~~(3) Attained a minimum of 500 hours of clinical nuclear Pharmacy training under the supervision of a qualified nuclear Pharmacist.~~
- (f)(i) “Radiopharmaceutical Quality Assurance” means, but is not limited to, the performance of appropriate chemical, biological, and physical tests on potential radiopharmaceuticals and the interpretation of the resulting data to determine their suitability for use in humans and animals, including internal test assessment, authentication of Product history, and the keeping of proper records.
- (g)(k) “Radiopharmaceutical Service” means, but shall not be limited to, the procurement, storage, handling, preparation, Labeling, quality assurance testing, Dispensing, Delivery, record keeping, and disposal of radiopharmaceuticals and other Drugs.
- (h)(l) “Radiopharmaceuticals” are radioactive Drugs as defined by Food and Drug Administration and the _____ State Board of Pharmacy [cite appropriate law(s)].
- (m) “Repackaging” means the act of removing a conventionally manufactured radiopharmaceutical from the container in which it was distributed by the original manufacturer and placing it into a different container without further manipulation of the product. Repackaging also includes the act of placing the contents of multiple containers (eg, vials) of the same finished drug product into one container, as long as the container does not include other ingredients. Radiopharmaceutical manipulation in any other way, including reconstitution, dilution, mixing, or combination with another ingredient, is not considered repackaging.

Section 3. General Requirements for Pharmacies Providing Radiopharmaceutical Services.

- (a) ~~Nuclear Pharmacy~~Nuclear Pharmacy/Radiopharmacy License. A license to operate a Pharmacy providing radiopharmaceutical services shall only be issued to an ~~Authorized~~Qualified Nuclear Pharmacist. All personnel performing tasks in the preparation and Distribution of radioactive ~~d~~Drugs shall be under the direct supervision of a ~~Qualified~~Authorized Nuclear Pharmacist. An Authorized ~~Qualified~~ Nuclear Pharmacist shall be responsible for all operations of the Pharmacy



and shall be in personal attendance at all times that the Pharmacy is open for business. In emergency situations when an Authorized Qualified Nuclear Pharmacist is not present, designated Qualified Licensed Professionals may have access to the licensed area. These individuals may prepare single doses of radiopharmaceuticals for the immediate emergency, and must document such activities.

- (b) Nuclear Pharmacies/Radiopharmacies shall have adequate space and equipment, commensurate with the scope of services required and provided, meeting minimal space requirements established for all pharmacies in the State or as otherwise defined by the _____ State Board of Pharmacy.
- (c) The ~~Nuclear Pharmacy~~ Nuclear Pharmacy/Radiopharmacy area shall be secured from unauthorized personnel.
- (d) Nuclear Pharmacies/Radiopharmacies shall maintain records of acquisition, inventory, and disposition of all radioactive ~~Drugs~~ and other radioactive materials in accordance with [cite appropriate Pharmacy and radiological control agency or NRC Statute(s)].
- (e) All pharmacies handling radiopharmaceuticals shall provide a radioactive storage and Product decay area. Detailed floor plans shall be submitted to the State Board of Pharmacy and the State Radiation Control Agency or NRC before approval of the license.
- (f) Radiopharmaceuticals are to be Dispensed only upon a Prescription Drug Order from a Practitioner authorized to possess, use, and Administer radiopharmaceuticals.
- (g) The permit to operate a ~~Nuclear Pharmacy~~ Nuclear Pharmacy/Radiopharmacy is conditioned upon an approved State Radiation Control Agency (RCA) or NRC license. Copies of the RCA or NRC inspection reports shall be made available upon request for Board inspection.
- (h) Labeling
 - (1) No radiopharmaceutical may be Dispensed unless a label is affixed to the immediate container bearing the following information:
 - (i) the standard radiation symbol;
 - (ii) the words "Caution – Radioactive Material"; and
 - (iii) the prescription number.
 - (2) No radiopharmaceutical may be Dispensed unless a label is affixed to the outer or Delivery container bearing the following information:
 - (i) the standard radiation symbol;
 - (ii) the words "Caution – Radioactive Material";
 - (iii) the radionuclide and chemical form;
 - (iv) the activity and date and time of assay;
 - (v) the volume, if in liquid form;
 - (vi) the requested activity and the calibrated activity;
 - (vii) the prescription number;
 - (viii) patient name or space for patient name. Where the patient's name is not available at the time of Dispensing, a 72-hour exemption is allowed to obtain the name of the patient. No later than 72 hours after Dispensing the radiopharmaceutical, the

patient's name shall become a part of the Prescription Drug Order to be retained for a period of three years;

- (ix) the name and address of the ~~nuclear Pharmacy~~ Nuclear Pharmacy/Radiopharmacy;
- (x) the name of the Practitioner; and
- (xi) the lot number of the prescription.

Section 4. Additional Labeling per USP <825>.

The additional requirements specified herein must be considered for the labeling of the inner container (eg, syringe, vial) and the outer shielding (eg, syringe or vial shielding).

The inner container must be additionally labeled with the following:

- (a) For all therapeutic and blood-products, the patient name/identifier
- (b) Radionuclide and chemical form (generic name)
- (c) Radioactivity at the date and time of calibration

The outer shielding must be additionally labeled with the following:

- (a) For all therapeutic and blood-products, the patient name/identifier
- (b) Number of units dispensed (eg, 2 capsules), as applicable
- (c) Product expiration or BUD (see USP <825> Table 7), as applicable
- (d) Any special storage and handling instructions for nonimmediate use (eg, refrigeration, resuspension)
- (e) Route of administration

Section 5. Other Requirements.

All ~~Nuclear Pharmacies/Radiologic Pharmacies~~ Radiopharmacies shall also adhere to the principles outlined in the Rules for Pharmacist Care Services as these pertain to the practice of ~~Nuclear Pharmacy~~ Nuclear Pharmacy/Radiopharmacy.

A Nuclear Pharmacy/Radiopharmacy engaged in the preparation, compounding, dispensing, or repackaging of radiopharmaceuticals for humans or other animals shall comply with USP General Chapter <825>, "Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging."

Recommended Model Act Amendments from the Task Force to Review *Model Act* Licensing and Disciplinary Language and the Task Force to Review *Model Rules for the Practice of Pharmacy* and Develop a New Pharmacy Practice Model

National Association of Boards of Pharmacy

Model State Pharmacy Act

Article I

Title, Purpose, and Definitions

...

Section 104. Definitions for the Practice of Pharmacy and Related Terms.

~~The “Practice of Pharmacy” means, but is not limited to, the interpretation, evaluation, Dispensing, and/or implementation of Medical Orders, and the initiation and provision of Pharmacist Care Services. The Practice of Pharmacy also includes continually optimizing patient safety and quality of services through effective use of emerging technologies and competency-based education.~~

The “Practice of Pharmacy” means, but is not limited to:

1. Interpreting, evaluating, Compounding, Dispensing, and/or Administering Medical Orders;
2. providing Patient Counseling;
3. assessing the patient for the purposes of prescribing Drugs and Devices;
4. initiating and/or providing Pharmacist Care Services ~~to optimize patient outcomes;~~
5. using Continuous Quality Improvement Programs, emerging technologies, and competency-based education to improve patient safety and the quality of services provided;
6. engaging in Collaborative Pharmacy Practice.¹

“Pharmacist Care Services” mean services intended to achieve patient outcomes related to the treatment or prevention of disease, elimination or reduction of symptoms, and promotion of health and wellness.²

Pharmacist Care Services include but are not limited to:

1. Drug Utilization Review
2. Medication Adherence Monitoring Service
3. emergency use Prescribing and Dispensing³
4. Medication therapy management (MTM)

¹ The definition of the “Practice of Pharmacy” is one of the most important, and perhaps one of the most discussed, clauses in the NABP *Model Act*. The definition is purposely expressed in broad terms to provide substantial latitude to the Board of Pharmacy in the adoption of implementing rules. Inclusion of or authorization for specific activities, such as the Administration of Drugs, is purposely not delineated in the definition in order to be empowering and not proscriptive. To assist states in the interpretation of the revised definition of the “Practice of Pharmacy,” the *Model Act* includes the definition of “Pharmacist Care Services” and Model Rules for the Provision of Pharmacist Care Services for those states that need to include specific lists of activities or authorizations due to legislative and/or administrative policies and procedures.

The definition also acknowledges that pharmacy is a dynamic profession and a broad definition of the practice will permit the Board to make necessary changes from time to time to meet the changing practice. Such changes may be affected by new or amended rules, which would be promulgated pursuant to the requirements of the State Administrative Procedures Act, affording all interested parties an opportunity to review and comment on any proposed rules.

~~² Pharmacist Care Services should be provided by all Pharmacists within the Standard of Care commensurate with their abilities, regardless of the practice setting.~~

³ Pharmacists may prescribe Drugs for Emergency Use pursuant to specific statewide protocols or standing orders.



NABP

5. reviewing, selecting, and developing formularies and/or practice guidelines
6. performing drug product selection, substitution, Therapeutic Interchange⁴, prescription adaptation or continuation of therapy
7. ordering, interpreting laboratory tests, and performing Clinical Laboratory Improvement Amendments-waived⁵ lab tests.

“Collaborative Pharmacy Practice” means that Practice of Pharmacy whereby one or more Pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or more Practitioners under protocol and in collaboration with Practitioner(s) to provide patient care services to achieve optimal medication use and desired patient outcomes.

“MTM” includes the following:

1. patient health status assessment and evaluation;
2. medication reconciliation;
3. formulating medication treatment plan;
4. selecting, prescribing, modifying, discontinuing, or Administering Drugs, Devices, vaccines, or Biologicals;
5. monitoring and evaluating the patient’s response to therapy, including safety and effectiveness;
6. performing a comprehensive Drug Utilization Review to identify, resolve, and prevent medication-related problems, including adverse drug events;
7. documenting the care delivered and communicating essential information to the patient’s prescribing practitioner(s) and ~~other~~ primary care providers;
8. providing education, support services, and resources designed to enhance patient adherence with ~~his or her~~ therapeutic regimens, such as Medication Synchronization;
9. coordinating and integrating services within the broader health care management services being provided to the patient; and
10. such other patient care services as may be allowed by law.

Section 105. Definitions.

...

- (k) “Business Entity” means a corporation, subsidiary, partnership, association, organization, affiliate organization, or any other legal entity formed to conduct business.

...

- (l) “Cease and Desist” means an order of the Board prohibiting a licensee or other ~~Business Entity~~ ~~or Person or entity~~ from continuing a particular course of conduct that violates the Pharmacy Practice Act or its rules and regulations.⁶

⁴ Providing it is within the same FDA Drug class and not prohibited by the prescriber.

⁵ Most recent version

⁶ No proof of actual damage is required for issuance of a Cease and Desist order.



NABP

- ...
- (m) ~~“Centralized Performance Database” means aggregate data from a large number of pharmacies concerning Quality Related Events and patients for whom Drug Products and services have been provided at the pharmacies, and from which patient identifiers have been removed.~~
- ...
- (s) ~~“Collaborative Pharmacy Practice” means that Practice of Pharmacy whereby one or more Pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or more Practitioners under protocol and in collaboration with Practitioner(s) to provide patient care services to achieve optimal medication use and desired patient outcomes.~~
- (t) “Collaborative Pharmacy Practice Agreement” means a written or electronic and signed agreement between one or more Pharmacists and one or more Practitioners that provides for Collaborative Pharmacy Practice as defined by law and the Rules of the Board.
- (u) “Common Carrier” means any Business Entity or Person or entity who undertakes, whether directly or by any other arrangement, to transport property including Prescription Drugs for compensation.⁷
- ...
- (e2) ~~“Contraband Drug” means a Drug which is Counterfeit, stolen, Misbranded, obtained by fraud, purchased by a nonprofit institution for its own use and placed in commerce in violation of the own use agreement for that Drug, that has inappropriately entered the Drug supply chain Distribution.~~
- ...
- (d2) “Counterfeit Device” means a Device which, or the container, shipping container, seal, or Product Labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or any likeness thereof, of a Manufacturer, processor, packer, or Distributor other than the Business Entity, Person or Persons who in fact Manufactured, processed, packed, Distributed, or Wholesale Distributed such Device and which thereby falsely purports or is represented to be the Product of, or to have been packed, Distributed, or Wholesale Distributed by, such other Manufacturer, processor, packer, or Distributor.
- (e2) “Counterfeit Drug” means a Drug which, or the container, shipping container, seal, or Product Labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or Device, or any likeness thereof, of a Manufacturer, processor, packer, or Distributor other than the Business Entity or Person or Persons who in fact Manufactured, processed, packed, Distributed, or Wholesale Distributed such Drug and which thereby falsely

⁷ The definition of “Common Carrier” specifically excludes Wholesale Distributors, which are defined separately.



purports or is represented to be the Product of, or to have been packed, Distributed, or Wholesale Distributed by, such other Manufacturer, processor, packer, or Distributor.

...

(g2) “Deliver” or “Delivery” means the actual, constructive, or attempted transfer of a Drug or Device from one ~~Business Entity or~~ Person to another, whether or not for a consideration.

...

(m2) ~~“Digital Signature” means an electronic signature based upon cryptographic methods of originator authentication and computed by using a set of rules and a set of parameters so that the identity of the signer and the integrity of the data can be verified.~~

...

(m2) “Dispenser” means a retail Pharmacy, hospital Pharmacy, a group of chain Pharmacies under common ownership and control that do not act as a Wholesale Distributor, or any other ~~Business Entity or~~ Person authorized by law to Dispense or Administer Prescription Drugs, and the affiliated warehouses or Distribution centers of such entities under common ownership and control that do not act as a Wholesale Distributor.

...

(t2) “Drug Utilization Review (DUR)”⁸ includes but is not limited to the following activities:

- (1) Evaluation of the Prescription Drug Order (s) and patient record(s) for:
 - (i) known allergies;
 - (ii) rational therapy contraindications;
 - (iii) reasonable dose, duration of use, and route of Administration, considering age, gender, and other patient factors;⁹
 - (iv) reasonable directions for use;
 - (v) potential or actual adverse Drug reactions;
 - (vi) Drug-Drug interactions;
 - (vii) Drug-food interactions;
 - (viii) Drug-disease contraindications;
 - (ix) therapeutic duplication;
 - (x) proper utilization (including over- or under-utilization), and optimum therapeutic outcomes; and
 - (xi) abuse/misuse.

⁸ DUR is also known to mean “Drug Use Review”; however, “Drug Utilization Review” is the preferred term.

⁹ A “reasonable” dose, duration of use, and route of administration under “Drug Utilization Review” would be determined by taking into consideration patient-specific factors, including but not limited to, age, gender, and other patient factors, but dependent upon the information about the patient known to the pharmacist.



NABP

- ~~(u2) “Electronic Signature” means an electronic sound, symbol, or process attached to or logically associated with a record and executed or adopted by a Person with the intent to sign the record.¹⁰~~
- (e3) “Health Care Entity” means any ~~Business Entity or~~ Person that provides diagnostic, medical, surgical, dental treatment, or rehabilitative care but does not include any retail Pharmacy or Wholesale Distributor.
- ...
- (u3) “Manufacturer” means a ~~Business Entity~~ Person which may include a Virtual Manufacturer, engaged in the Manufacture of Drugs or Devices.
- (v3) “Manufacturing” means the production, preparation, propagation, conversion, or processing of a Drug or Device, either directly or indirectly, by extraction from substances of natural origin or independently by means of chemical or biological synthesis. Manufacturing includes the packaging or repackaging of a Drug or Device or the labeling or relabeling of the container of a Drug or Device for resale by pharmacies, Practitioners, Business Entities or other Persons.¹¹
- ...
- (d4) ~~“Medication-assisted Treatment (MAT)”~~ “Medication for Opioid Use Disorder (MOUD)” means the use of FDA-approved medications, in combination with counseling and behavioral therapies, to provide a ~~“whole-patient”~~ patient-centered approach to the treatment of substance use disorders Opioid Use Disorder (OUD).¹²
- ~~(e4) “Medication Therapy Management” means a distinct Pharmacist Care Service or group of services that optimize therapeutic outcomes for individual patients. Medication Therapy Management services are independent of, but can occur in conjunction with, the provision of a medication or a medical device. Medication Therapy Management encompasses a broad range of professional activities and responsibilities within the licensed Pharmacist’s scope of practice. These services may include, but are not limited to, the following, according to the individual needs of the patient:~~
- ~~(1) performing or obtaining necessary assessments of the patient’s health status;~~
 - ~~(2) formulating a medication treatment plan;~~
 - ~~(3) selecting, initiating, modifying, or administering medication therapy;~~
 - ~~(4) monitoring and evaluating the patient’s response to therapy, including safety and effectiveness;~~

¹⁰ The term “Electronic Signature” may have different meanings in various State laws and regulations. It is important to distinguish between “Electronic Signatures” and “Digital Signatures,” which provide a much higher level of security for electronically transmitted information.

¹¹ Manufacturing also includes the Compounding of Drugs for office use of which can only be done by an FDA-registered Outsourcing Facility.

¹² The Substance Abuse and Mental Health Services Administration also refers to MAT as “Medications for Opioid Use Disorder” (MOUD), which are FDA-approved medications for the treatment of opioid use disorders and currently include methadone, naltrexone, and buprenorphine.



NABP

- ~~(5) performing a comprehensive medication review to identify, resolve, and prevent medication-related problems, including adverse drug events;~~
- ~~(6) documenting the care delivered and communicating essential information to the patient's other primary care providers;~~
- ~~(7) providing verbal education and training designed to enhance patient understanding and appropriate use of his or her medications;~~
- ~~(8) providing information, support services and resources designed to enhance patient adherence with his or her therapeutic regimens, such as Medication Synchronization;~~
- ~~(9) coordinating and integrating Medication Therapy Management services within the broader health care management services being provided to the patient; and~~
- ~~(10) such other patient care services as may be allowed by law.~~

...

- (j4) "NABP Verify" means an ongoing credentialing and license monitoring service, operated by NABP, that verifies Pharmacists and applicable business entities are licensed in good standing and provides proof of that status.

...

- (p4) "Patient Counseling" means the ~~oral~~ communication by the Pharmacist of information, as defined in the rules of the applicable Board, to the patient or caregiver in person, whenever practicable, or by telephone or other audio/visual means, in order to ensure proper use of Drugs and Devices.

- (b5) "Person" means
- (1) an individual; or
 - (2) a Business Entity, ~~corporation, subsidiary, partnership, association, organization, affiliate organization, or any other legal entity, including government.~~

...

- ~~(v4) "Pharmacist Care Services" means patient health care-related activities provided by a pharmacist within this State or into this State, as defined by the Rules of the Board, with or without the Dispensing of Drugs or Devices, which are intended to achieve outcomes related to the cure or prevention of a disease, elimination or reduction of a patient's symptoms, or arresting or slowing of a disease process.¹³~~

- (w4) "Pharmacist-in-Charge" means a Pharmacist currently licensed in this state who accepts responsibility for the operation of a Pharmacy or an Outsourcing Facility in conformance with all laws and rules pertinent to the Practice of Pharmacy and the Distribution of Drugs, and who is personally in full and actual charge of such Pharmacy and personnel.

...

¹³ Objectives of Pharmacist Care Services include cure of a disease, elimination or reduction of a patient's symptomatology, arresting or slowing of a disease process, or prevention of a disease or symptomatology. Pharmacist Care Services should be provided by all Pharmacists within the Standard of Care to the extent of their abilities regardless of the practice setting.



NABP

- (y4) “Pharmacy” means any licensed facility ~~place~~ within or outside this State where Drugs are Dispensed and/or Pharmacist Care Services are provided to residents of this State.
- (z4) “Pharmacy Benefits Manager” means a ~~Business Entity or~~ Person that Administers the Prescription Drug/Device portion of health insurance plans on behalf of plan sponsors, such as self-insured employers, insurance companies, and health maintenance organizations, and that engages in or directs the Practice of Pharmacy.
- ~~(d5) “Practice Accountability Audit” means an evaluation of the Centralized Performance Database to determine which pharmacies are consistently in violation of criteria and/or standards.~~
- ...
- (k5) “Probation” means a type of disciplinary action that allows for the continuation of practice subject to specific conditions established by the Board and that may include a restriction of Pharmacy practice for a specified period of time.¹⁴
- ...
- ~~(o5) “Professional Performance Evaluation” means a peer review process in which a competency assessment is made of a pharmacist by another pharmacist for the purpose of improving the quality of the evaluated pharmacist’s performance.~~
- ~~(p5) “Prospective Drug Utilization Review (DUR)” means a review of the patient’s Drug therapy and Prescription Drug Order as part of a Drug Utilization Review, as defined in the rules of the Board, prior to Dispensing the Drug.~~
- ...
- (a6) “Repackager” means a ~~Business Entity or~~ Person who owns or operates an establishment that Repackages and relabels a Product or package for:
- (1) further sale; or
 - (2) Distribution without a further Transaction.¹⁵
- ...
- (h6) “Returns Processor” or “Reverse Logistics Provider” means any ~~Business Entity or~~ Person who owns or operates an establishment that dispositions or otherwise processes saleable or nonsaleable Product received from an authorized Trading Partner such that the Product may be processed for credit to the purchaser, Manufacturer, or seller or disposed of for no further Distribution.
- (i6) “Revocation” means the ~~withdrawal~~ permanent rescission of the license to practice pharmacy.
- ...

¹⁴ Licensee may be placed on Probation for a period of time subject to specific conditions determined by the Board. Probation may result from the Board’s decision to stay a license Revocation or Suspension judgment. The licensee may be permitted to continue practice only within conditions established by the Board, and violation of those conditions will end the stay and result in Revocation or Suspension.

¹⁵ Is not intended to include a Pharmacy, Pharmacist, or Outsourcing Facility that Dispenses or Distributes Repackaged Drugs.



NABP

~~(j6)~~ “Serious Adverse Drug Experience” means any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based on appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

...

~~(k6)~~ “Significant Adverse Drug Reaction” means an unexpected adverse drug experience that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. A medical event may also be considered a significant adverse drug reaction when, based on appropriate medical judgment, the medical event places the patient at a significant risk of experiencing any of the outcomes listed above. An adverse drug reaction is unexpected if it has not previously been observed, rather than a reaction that is not anticipated from the pharmacological properties of the pharmaceutical product.

...

(k7) “Temporary Pharmacy Facility” means a facility established as a result of a Public Health Emergency or State of Emergency to temporarily provide Pharmacy services within or adjacent to Declared Disaster Areas or as otherwise determined in the interest of the public by Board action.

...

(a8) “Wholesale Distributor” means any Business Entity Person, which may include a Virtual Wholesale Distributor, (other than a Manufacturer, a Manufacturer’s co-licensed partner, a Third-Party Logistics Provider, or Repackager) engaged in Wholesale Distribution of Prescription Drugs or Devices in or into the State.

Article II Board of Pharmacy

...

Section 203. Qualifications.



NABP

- (a) Each Pharmacist member of the Board of Pharmacy shall at the time of appointment¹⁶:
 - (1) be a resident of this state for not less than six months;
 - (2) be currently licensed and in good standing to engage in the Practice of Pharmacy in this state;
 - (3) be actively engaged in the Practice of Pharmacy in this state; and
 - (4) have five (5) years of experience in the Practice of Pharmacy after licensure.
- (b) Each Certified Pharmacy Technician member of the Board of Pharmacy shall at the time of appointment:
 - (1) be a resident of this state for not less than six months;
 - (2) be currently licensed and in good standing as a Certified Pharmacy Technician in this state;
 - (3) be an actively practicing Certified Pharmacy Technician in this state; and
 - (4) have five (5) years of experience as a Certified Pharmacy Technician after licensure.
- (c) The public member of the Board of Pharmacy shall be a resident of this state who has attained the age of ~~majority~~ 18 years and shall not be, nor shall ever have been, a Pharmacist, a Certified Pharmacy Technician, or a Person who has ever had any direct conflict of interest pertaining to the Practice of Pharmacy or material financial interest in the provision of Pharmacy services or who has engaged in any activity directly related to the Practice of Pharmacy.¹⁷

...

Section 213. Powers and Responsibilities.

- (a) The Board of Pharmacy shall be responsible for the control and regulation of the Practice of Pharmacy in this State including, but not limited to, the following¹⁸:

¹⁶ Section 203(a) of the Act requires that a Pharmacist be engaged in the Practice of Pharmacy at the time of their appointment as a Board member and that they have at least five (5) years of experience in the Practice of Pharmacy in the state prior thereto. Since the Practice of Pharmacy is defined in Section 104 in broad terms, it renders a Pharmacist actively engaged in almost any phase of the practice eligible for appointment. This provides for candidates who have divergent backgrounds and experiences and who are knowledgeable in the affairs of the profession.

However, it should be noted from the definition of Pharmacy Practice in Section 104 that those persons actively engaged in the Practice of Pharmacy would basically be limited to those individuals who are working within settings where Drugs/Devices are Dispensed and Pharmacist Care Services is provided. To include persons who are in positions related to the practice but who are not engaged in Dispensing and Pharmacist Care Services functions would wrongfully cause the inclusion of individuals, such as personnel employed by Drug Manufacturers, Wholesale Distributors, and the like, who may be licensed to practice but who do not practice Pharmacy under the terms of the applicable Practice Act. The determination as to whether or not an individual is actively engaged in the Practice of Pharmacy will undoubtedly be rendered on a case-by-case basis. The general criteria described above, however, would most probably be applicable in making the determination. Under the terms of a Practice Act, which includes a definition of Pharmacy practice, only those persons who are actively engaged in the basic functions set forth in the definition would be individuals "actively engaged in the Practice of Pharmacy."

¹⁷ Specific qualifying criteria for the public member have been deliberately omitted from this section. Reliance has been placed in the Governor to determine what attributes an individual should possess in order to meaningfully serve on a Board of Pharmacy. In order to help ensure that such a member would be truly independent in their judgments, those persons who have a possible substantial relationship with the profession are rendered ineligible by this section.

¹⁸ The "Practice of Pharmacy in this State" includes shipping Prescription Drugs into this State from another jurisdiction. However, this is not meant to be construed as a licensure requirement for every Pharmacist that is employed at a Nonresident Pharmacy unless they are specifically engaged in the Practice of Pharmacy and provide services to residents in this State (see Sections 104 and 401(a) of this Act).



NABP

- (1) the licensing by examination or by ~~license~~ licensure transfer of applicants who are qualified to engage in the Practice of Pharmacy under the provisions of this Act;
- (2) the issuance and renewal of licenses to engage in the Practice of Pharmacy;
- (3) the recognition of the NABP Verify credential for the provision of pharmacy-related services by nonresident Pharmacists;
- ~~(34)~~ the establishment and enforcement of compliance with professional standards and rules of conduct of Pharmacists engaged in the Practice of Pharmacy;
- ~~(45)~~ the determination and issuance of standards for recognition and approval of degree programs of schools and colleges of Pharmacy whose graduates shall be eligible for licensure in this State, and the specification and enforcement of requirements for practical training, including Pharmacy practice experience¹⁹;
- ~~(56)~~ the enforcement of those provisions of this Act relating to the conduct or competence of Pharmacists practicing in this State; the Revocation, Summary Suspension, Suspension, Probation, Censure, or Reprimand of, or the issuance of Warnings or the assessment of Fines/Civil Penalties or Costs/Administrative Costs against licenses to engage in the Practice of Pharmacy; and the issuance of Cease and Desist orders against any Business Entity or Person;
- ~~(67)~~ the licensure and regulation of the training, qualifications, and employment of Pharmacy Interns, Certified Pharmacy Technicians, and Certified Pharmacy Technician Candidates;
- ~~(78)~~ the collection of professional demographic data;
- ~~(89)~~ the right to seize any such Drugs and Devices found by the Board to constitute an imminent danger to the public health and welfare;
- ~~(910)~~ establishing minimum specifications for the physical facilities, technical equipment, environment, supplies, personnel, and procedures for the storage, Compounding and/or Dispensing of such Drugs or Devices, for the monitoring of Drug therapy, and for the Manufacture and Distribution of Drugs and Devices;
- ~~(110)~~ establishing minimum standards for the purity and quality of such Drugs, Devices, and other materials within the Practice of Pharmacy;
- ~~(124)~~ the issuance and renewal of licenses for Pharmacies located within this State, or outside this State if providing services to patients within this State, that Compound or Dispense Drugs or Devices or provide Pharmacist Care Services.

¹⁹ Great care should be exercised by the Boards with respect to this Section. Many states have statutes or rules which provide that approved or accredited degree programs of schools or colleges of Pharmacy are those approved by the Accreditation Council for Pharmacy Education (ACPE). It is a well-established rule of administrative law that any delegation of governmental power must carry with it appropriate limitations and procedural safeguards for affected individuals. Thus, a direct, unequivocal grant of the accreditation function to a private organization, such as ACPE, might be deemed an unauthorized, improper, and invalid delegation of Board or legislative authority. An NABP study of this question discovered at least one case where a court overturned a Board action based upon such invalid delegation to a private body. See *Garces v Department of Registration and Education*, 254 N.E.2d 622 (Ill, 1969). NABP urges all Boards to adopt, in their Rules, the Standards of Accreditation for Doctor of Pharmacy Degree Programs established from time to time by the ACPE, the nationally recognized accrediting agency for Pharmacy degree programs. Of note, ACPE International-Accreditation is awarded based on the ACPE Quality Criteria, which are not equivalent to the ACPE Standards.



NABP

- (132)the issuance and renewal of licenses of all Manufacturers and Distributors of Drugs and Devices located within this State, or outside this State if providing such services within this State;
- (143)inspection at all reasonable hours of the facility and appropriate records of any licensed Person or licensed facility and any Person or facility seeking licensure for the purpose of determining if any provisions of the laws governing licensure, the legal Distribution of Drugs or Devices, or the Practice of Pharmacy are being violated, including the inspection of Protected Health Information.
- (i) Agents duly authorized to conduct inspections, whether agents of the Board or an approved third party, must be competent to inspect the facilities they are assigned to inspect to include training on any applicable State, Federal, and USP standards.
- (ii) The Board of Pharmacy, its officers, inspectors, and representatives shall cooperate with all agencies charged with the enforcement of the laws of the United States, of this State, and of all other states relating to Drugs, Devices, and the Practice of Pharmacy;
- (15) the recognition of the NABP Emergency Passport for Pharmacists, Pharmacy Interns, Certified Pharmacy Technicians, and businesses to practice on a temporary or emergency basis in accordance with state emergency orders;
- (164)establishing minimum standards for maintaining the integrity and confidentiality of prescription information and other patient health care information; and²⁰
- (175)the approval of Pharmacy practice initiatives that improve the quality of or access to Pharmacist Care Services, but which fall outside the scope of present regulations. This subsection shall not be construed to expand the definition of the Practice of Pharmacy as defined in this Act.
- (b) ~~Centralized Performance Database~~
- (1) ~~The Board of Pharmacy shall utilize a Centralized Performance Database. The Centralized Performance Database shall be maintained in such a way as to permit an evaluator to apply Criteria and Standards to data from one pharmacy, and determine whether, over time, outcomes from that pharmacy compare favorably with outcomes from other pharmacies.~~

²⁰ Under this Act, “Protected Health Information” may be used or disclosed without acknowledgement, authorization, or opportunity to agree or object in the situations described in 45 CFR 164.512(a) – (l), and which include:

- As required by law
- For certain public health activities
- For certain health oversight activities
- Pursuant to judicial or administrative proceedings
- For law enforcement purposes
- For military or national security purposes
- As necessary to comply with worker compensation laws
- In situations presenting a serious threat to health or safety

Investigative activities of the Boards of Pharmacy are considered health oversight activities and, therefore, fall under this disclosure exemption.



- (2) ~~The Board of Pharmacy shall conduct a Practice Accountability Audit at least once every six months to identify pharmacies that consistently violate Criteria and/or standards. The Board of Pharmacy shall require that pharmacies so identified provide an explanation of the reason for their consistent violation of Criteria and/or standards.~~
- (be) The Board of Pharmacy shall have such other duties, powers, and authority as may be necessary to the enforcement of this Act and to the enforcement of Board rules made pursuant thereto, which shall include, but are not limited to, the following:
- (1) The Board may join such professional organizations and associations organized exclusively to promote the improvement of the standards of the Practice of Pharmacy for the protection of the health and welfare of the public and/or whose activities assist and facilitate the work of the Board.
 - (2) The Board may receive and expend funds, in addition to its [annual/biennial] appropriation, from parties other than the State, provided:
 - (i) such funds are awarded for the pursuit of a specific objective which the Board is authorized to accomplish by this Act, or which the Board is qualified to accomplish by reason of its jurisdiction or professional expertise;
 - (ii) such funds are expended for the pursuit of the objective for which they are awarded;
 - (iii) activities connected with or occasioned by the expenditures of such funds do not interfere with the performance of the Board's duties and responsibilities, and do not conflict with the exercise of the Board's powers as specified by this Act;
 - (iv) such funds are kept in a separate, special account; and
 - (v) periodic reports are made concerning the Board's receipt and expenditure of such funds.
 - (3) The Board may establish a Bill of Rights for patients concerning the health care services a patient may expect in regard to Pharmacist Care Services.²¹
 - (4) Any investigation, inquiry, or hearing which the State Board of Pharmacy is empowered to hold or undertake may be held or undertaken by or before any member or members of the Board and the finding or order of such member or members shall be deemed to be the order of said Board when approved and confirmed as noted in Section 210(d).
 - (5) Embargo.²²
 - ...
 - (6) The Board may place under seal all Drugs or Devices that are owned by or in the possession, custody, or control of a licensee at the time ~~his or her~~ of license Suspension or Revocation is Suspended or Revoked or at the time the Board refuses to renew ~~his~~ the

²¹ A Patient's Bill of Rights establishes the professional services that a patient may expect when obtaining Drugs or Devices from a Pharmacist. The Bill of Rights would normally contain patient expectations that could translate into standards of professional practice and/or codes of conduct for the Pharmacist. Accordingly, if a Board should choose to establish a Patient's Bill of Rights, the Bill should be consistent with standards of practice, codes of ethics, and regulations that the Board has adopted under the Pharmacy Practice Act. If care is not taken, a Board could inadvertently expand the role and the responsibilities of the Pharmacist through the establishment of a Patient's Bill of Rights.

²² The purpose of this subsection is to ensure quality, purity, and correct Labeling of Drugs, Devices, and other materials.



license. Except as otherwise provided in this section, Drugs or Devices so sealed shall not be disposed of until appeal rights under the Administrative Procedures Act have expired, or an appeal filed pursuant to that Act has been determined. The court involved in an appeal filed pursuant to the Administrative Procedures Act may order the Board, during the pendency of the appeal, to sell sealed Drugs that are perishable. The proceeds of such a sale shall be deposited with that court.

- (7) Except as otherwise provided to the contrary, the Board shall exercise all of its duties, powers, and authority in accordance with the State Administrative Procedures Act.
- (8) In addition to the fees specifically provided for herein, the Board may assess additional reasonable fees for services rendered to carry out its duties and responsibilities as required or authorized by this Act or Rules adopted hereunder. Such services rendered shall include, but not be limited to, the following:
 - (i) issuance of duplicate certificates or identification cards;
 - (ii) mailing lists or reports of data maintained by the Board;
 - (iii) copies of any documents;
 - (iv) certification of documents;
 - (v) notices of meetings;
 - (vi) licensure transfer;
 - (vii) examination Administration to a licensure applicant; and
 - (viii) examination materials.
- (9) Cost Recovery.²³
 - (i) If any order issues in resolution of a disciplinary proceeding before the Board of Pharmacy, the Board may request the _____ to direct any licensee found guilty of a charge involving a violation of any Drug laws or rules, to pay to the Board a sum not to exceed the reasonable costs of the investigation and prosecution of the case and may include a monetary penalty per violation not to exceed _____ ~~and, in any case, not to exceed twenty-five thousand dollars (\$25,000).~~
 - (ii) In the case of a Pharmacy or Wholesale Distributor, the order may be made as to the corporate owner, if any, and as to any Pharmacist, officer, owner, or partner of the Pharmacy or Wholesale Distributor who is found to have had knowledge of or have knowingly participated in one or more of the violations set forth in this section.
 - (iii) The costs to be assessed shall be fixed by the _____ and shall not be increased by the Board; where the Board does not adopt a proposed decision and remands the case to a(n) _____, the _____ shall not increase any assessed costs.
 - (iv) Where an order for recovery of costs is made and timely payment is not made as directed in the Board's decision, the Board may enforce the order for payment in the

²³ The "_____" interspersed throughout this section may be filled with the terms: "administrative law judge," "hearing officer," or "presiding officer," as determined by individual states.



NABP

Court in the county where the administrative hearing was held. This right of enforcement shall be in addition to any other rights the Board may have as to any ~~Business Entity or~~ Person directed to pay costs.

- (v) In any action for recovery of costs, proof of the Board's decision shall be conclusive proof of the validity of the order of payment and the terms for payment.

Article III Licensing

Introductory Comment to Article III

Article III of the Model Act specifies the requirements for initial licensure of Pharmacists, transfer of licensure, and renewal of licenses and registrations. In each of these areas, the Act sets forth basic Criteria and delegates to the Board the authority for implementing those Criteria. The Board does this by utilizing appropriate administrative enforcement mechanisms and by the issuance of specific rules.

Section 301 establishes the basis for this Article by making it unlawful for any unlicensed ~~Business Entity or~~ Person to engage in the Practice of Pharmacy, and by enabling the Board to exact penalties for unlawful practice.

In the area of initial licensure (Section 302), the Board must implement the Act by approving degree programs of Pharmacy, by specifying the examination to be employed (Section 302[b]), by establishing Pharmacy practice experience standards (Section 3032[c]), and by ensuring that all other prerequisites are met by each applicant to whom it issues a license.

The Act also reflects the efforts of NABP to continue uniform standards for transfer of licensure (Section 304).

Section 301. Unlawful Practice.

- (a) Except as otherwise provided in this Act, it shall be unlawful for any individual, ~~whether located in or outside this State, to engage in the Practice of Pharmacy in this State unless currently licensed. to practice under any facet of the provisions of this Act.~~
- (b) ~~It shall be unlawful for any individual located outside this state to engage in the Practice of Pharmacy in this state unless currently licensed to practice or credentialed by NABP Verify.~~²⁴
- (b) The provision of Pharmacist Care Services to an individual in this State, ~~through the use of Telepharmacy Technologies,~~ regardless of the location of the Pharmacist, shall constitute the

²⁴ Unless practicing within a licensed nonresident facility or utilizing Shared Services.



NABP

Practice of Pharmacy and shall be subject to regulation.²⁵ Pharmacists located outside this State who are providing Pharmacist Care Services outside of a licensed Pharmacy to individuals located in this State must register with this State to engage in the nonresident Practice of Pharmacy.

- (c) Licensed Practitioners authorized under the laws of this State to Compound Drugs and to Dispense Drugs to their patients in the practice of their respective professions shall meet the same standards, record-keeping requirements, and all other requirements for the Dispensing of Drugs applicable to Pharmacists.²⁶
- (d) It shall be unlawful for any individual to perform the activities of a Certified Pharmacy Technician or Certified Pharmacy Technician Candidate unless currently licensed to do so under the provisions of this Act.
- (e)
 - (1) The Board may in its own name issue a Cease and Desist order to stop an individual from engaging in an unauthorized Practice of Pharmacy.²⁷
 - (2) Except as otherwise indicated in this Act, any individual who, after due process, shall be found by the Board to have unlawfully engaged in the Practice of Pharmacy shall be subject to a Fine to be imposed by the Board not to exceed \$____ for each offense. Each such violation of this Act or the rules promulgated hereunder pertaining to unlawfully engaging in the Practice of Pharmacy shall also constitute a misdemeanor punishable upon conviction as provided in the criminal code of this State.
 - (3) Except as otherwise indicated in this Act, any individual who, after due process, shall be found by the Board to have unlawfully engaged in the Practice of Pharmacy that resulted in harm to an individual shall be subject to a Fine to be imposed by the Board not to exceed \$____ for each offense. Each such violation of this Act or the rules promulgated hereunder

²⁵ NABP recognizes that protection of the public health should extend across State borders. Accordingly, the NABP *Model Act* incorporates the Practice of Telepharmacy within the scope of the “Practice of Pharmacy” and requires an independently practicing Pharmacist located outside this State to obtain full licensure for providing Pharmacist Care Services from outside the State to patients within the State.

²⁶ Boards of Pharmacy are often confronted with the problem of preventing unlicensed individuals from engaging in one or more facets of the Practice of Pharmacy. The regulation of the Practice of Pharmacy, including the control of unlicensed practice in the profession, has a reasonable and rational relationship to public health, safety, and welfare. See, for example, *State v Wakeen*, 57 N.W.2d 364 (Wis, 1953). cf. *State v VanKeegan*, 113 A.2d 141 (Conn, 1955) and *Williamson v Lee Optical of Oklahoma*, 348 U.S. 483 (1955), concerning prohibitions on the unlicensed practice of ophthalmology. For this reason, vesting the power in the Board to regulate the illicit practice would not appear to violate the constitutional due process requirements. Monetary fines are another enforcement action Boards can utilize to protect the public health. Although monetary fines are not generally considered criminal sanctions, it can be forcibly argued that there are no constitutional barriers impeding the imposition of fines by a Board of Pharmacy. See, for example, *Helvering v Mitchell*, 303 U.S. 376 (1938); *City of Waukegan v Pollution Control Board*, 311 N.E.2d 146 (Ill, 1974); *County Council for Montgomery County v Investors Funding Corp*, 312 A.2d 225 (Md, 1973); and *Rody v Hollis*, 500 P.2d 97 (Wash, 1972).

One area that could present a serious question of law in regard to Section 301(b), however, involves the constitutional limitation on the delegation of authority to administrative agencies. It is likely that the delegation contemplated in Article III of the *Model Act* would be valid in a majority of jurisdictions. See, for example, *Jordan v Board of Insurance*, 334 S.W. 2d 278 (Tex, 1960); *Sutherland v Ferguson*, 397 P. 2d 335 (Kan, 1964); and *Kovack v Licensing Board of City of Waterville*, 173 A. 2d 554 (Me, 1961); see generally L. Davis, *Administrative Law Treatise*, Section 2.10 (1970 Suppl.). Be cautioned, however, that certain jurisdictions require very specific standards in a delegation of authority that could render Section 301(b) constitutionally suspect. See, for example, *People v Tibbits*, 305 N.E. 2d 152 (Ill, 1973); *Sarasota County v Barg*, 302 So. 2d 737 (Fla, 1974). In these jurisdictions, revisions of Article III may be necessary.

²⁷ It is contemplated that Boards will report a Person who is providing Pharmacist Care Services in its jurisdiction without first obtaining a nonresident license or NABP Verify credential to the Board of which the Person is licensed.

pertaining to unlawfully engaging in the Practice of Pharmacy that resulted in harm to an individual shall also constitute a felony punishable upon conviction as provided in the criminal code of this State.

Section 302. Qualifications for Pharmacist Licensure by Examination.

- (a) To obtain a license to engage in the Practice of Pharmacy, an applicant for licensure by examination shall:
- (1) have submitted an application in the form prescribed by the Board of Pharmacy;
 - (2) have attained the age of 18 years~~majority~~;
 - (3) have graduated and received the first professional degree from a college or school of Pharmacy that has been approved by the Board of Pharmacy;²⁸ or have graduated from a foreign college of Pharmacy²⁹, completed a transcript verification program, taken and passed a college of Pharmacy equivalency examination program, and completed a process of communication-ability testing as defined under Board of Pharmacy regulations so that it is ensured that the applicant meets standards necessary to protect public health and safety;³⁰
 - (4) have completed a Pharmacy practice experience program or other program that has been approved by the Board of Pharmacy, or demonstrated to the Board's satisfaction that experience in the Practice of Pharmacy which meets or exceeds the minimum Pharmacy practice experience requirements of the Board;
 - (5) have successfully passed an examination or examinations approved by the Board of Pharmacy within five attempts;
 - (6) have undergone a state and federal fingerprint-based criminal background check as specified by State law or Board rule; and
 - (7) have paid the fees specified by the Board of Pharmacy for the examination and any related materials and have paid for the issuance of the license.

²⁸ It is contemplated that Boards will approve those programs whose standards are at least equivalent to the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs. This would include college-structured pharmacy practice experience programs and continuing education programs. See the footnote to Section 213(a)(4) above for further discussion of the Board's proper role in the accreditation process.

²⁹ Graduates of a professional pharmacy degree program based outside the US and its territories that have been awarded Precertification, Provisional Certification, or Certification by ACPE are not eligible for US pharmacy licensing exams (NAPLEX or MPJE) and must complete the Foreign Pharmacy Graduate Examination Committee (FPGEC) program to be eligible to take the pharmacy licensing exams in the US. Similarly, graduates from an ACPE-accredited post-baccalaureate pharmacy program where the initial pharmacy degree is from a pharmacy program that is not an entry-level, ACPE-accredited pharmacy program, must complete the FPGEC program. [NOTE: ACPE will be changing the terminology that will be used within the ACPE International Services Program. As of January 1, 2023, the ACPE International Services Program will offer "International-Accreditation," "International Pre-Accreditation," and "Provisional International-Accreditation" to qualifying pharmacy degree programs outside the United States of America and its Territories. These will replace ACPE's current "Certification," "Precertification" and "Provisional Certification" statuses.]

³⁰ Boards should avoid mention of specific examinations or other contracted services in their practice act and regulations to avoid challenges related to an unconstitutional delegation of authority. It is contemplated that Boards will utilize the Foreign Pharmacy Graduate Equivalency Examination* (FPGEE) as part of their assessment of pharmacy education equivalence.

(b) Examinations.

- (1) The examinations for licensure, which include a pharmacy practice examination and a jurisprudence examination, required under Section 302(a)(7) of the Act, shall be provided by a testing provider approved by the Board³¹. If applicable, state-specific compounding examinations shall be administered by the Board. The content and subject matter of the pharmacy practice examination shall be determined by the examination provider approved by the Board and the Board shall determine the content and subject matter of each state-specific compounding and jurisprudence examination.
- (2) The examinations shall be prepared to measure the competence of the applicant to engage in the Practice of Pharmacy. The examination provider may employ, cooperate, and contract with any organization or consultant in the preparation and grading of an examination, but the Board shall retain the sole discretion and responsibility for determining which applicants are eligible for licensure.

~~Pharmacy Practice Experience Programs and Other Training Programs.³²~~

- ~~(1) All applicants for licensure by examination shall obtain practical experience in the Practice of Pharmacy concurrent with or after college attendance, or both, under such terms and conditions as the Board shall determine.³³~~
- ~~(2) The Board shall establish such licensure requirements for Pharmacy Interns and standards for Pharmacy practice experiences, or any other experiential program necessary to qualify~~

³¹ Boards of Pharmacy are strongly encouraged to utilize the North American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MPJE) for this purpose.

³² ~~As college-based Pharmacy practice experience programs become uniform under the most recent revision of the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs, and when boards of pharmacy are convinced that schools and colleges of pharmacy are meeting these Standards of Accreditation and the competency requirements set out by Boards, Boards should begin to broadly accept and recognize college-based Pharmacy practice experience programs completed by students in other jurisdictions and eliminate requirements that such students obtain additional Pharmacy practice experience hours in addition to those obtained as part of the college of pharmacy curriculum.~~

~~Because of the potential lack of uniformity among non-college-based Pharmacy practice experience programs, it is recommended that Boards exercise their prerogative to accept only at their discretion non-college-based Pharmacy practice experiences completed by Pharmacy Interns in other jurisdictions.~~

³³ ~~Although Boards of Pharmacy mandate a specified number of hours of Pharmacy practice experiences as a prerequisite to licensure, Boards of Pharmacy are also encouraged to deem those requirements met if Boards find that the college-based Pharmacy practice experiences meet or exceed the hourly Pharmacy practice experience requirements.~~

~~As indicated in the Model Rules for Pharmacy Interns, applicants for licensure as Pharmacists shall submit evidence that they have satisfactorily completed: (1) an objective assessment mechanism intended to evaluate achievement of desired competencies as delineated in the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs and (2) not less than 1,740 hours of Pharmacy practice experience credit under the instruction and supervision of a Preceptor. Boards may consider moving away from requiring a specific number of contact hours should it be determined that the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs result in appropriate preparation for students and objective assessment mechanisms demonstrate such.~~



an applicant for the licensure examination and shall also determine the qualifications of Preceptors used in practical experience programs.³⁴

Section 303. Pharmacy Practice Experience Program Standards; Pharmacy Intern Licensure.

- (a) The Board of Pharmacy shall establish standards for Pharmacy practice experience programs for the purpose of providing the practice experience necessary for licensure as a Pharmacist.³⁵
- (b) The Board shall grant a Pharmacy Intern license to Pharmacy students, authorizing those students to engage in the Practice of Pharmacy under the supervision of a Pharmacist.
- (c) The Board of Pharmacy shall adopt rules regarding the licensure of Pharmacy Interns and the standards for Pharmacy practice experience programs.³⁶
 - (1) All applicants for licensure by examination shall obtain practical experience in the Practice of Pharmacy concurrent with or after college attendance, or both, under such terms and conditions as the Board shall determine.³⁷
 - (2) The Board shall establish such licensure requirements for Pharmacy Interns and standards for Pharmacy practice experiences, or any other experiential program necessary to qualify

³⁴ Boards of Pharmacy are strongly encouraged to utilize the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs as a basis for establishment and revision of Board standards for Pharmacy practice experiences. These Standards of Accreditation also contain additional guidance on the desired behaviors, qualities, and values of preceptors.

³⁵ As college-based Pharmacy practice experience programs become uniform under the most recent revision of the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs, and when boards of pharmacy are convinced that schools and colleges of pharmacy are meeting these Standards of Accreditation and the competency requirements set out by Boards, Boards should begin to broadly accept and recognize college-based Pharmacy practice experience programs completed by students in other jurisdictions and eliminate requirements that such students obtain additional Pharmacy practice experience hours in addition to those obtained as part of the college of pharmacy curriculum.

Because of the potential lack of uniformity among non-college-based Pharmacy practice experience programs, it is recommended that Boards exercise their prerogative to accept only at their discretion non-college-based Pharmacy practice experiences completed by Pharmacy Interns in other jurisdictions.

³⁶ Boards of Pharmacy are strongly encouraged to utilize the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs as a basis for establishment and revision of board standards for Pharmacy practice experiences. These Standards of Accreditation also contain additional guidance on the desired behaviors, qualities, and values of preceptors.

³⁷ Although Boards of Pharmacy mandate a specified number of hours of Pharmacy practice experiences as a prerequisite to licensure, Boards of Pharmacy are also encouraged to deem those requirements met if Boards find that the college-based Pharmacy practice experiences meet or exceed the hourly Pharmacy practice experience requirements.

As indicated in the Model Rules for Pharmacy Interns, applicants for licensure as Pharmacists shall submit evidence that they have satisfactorily completed: (1) an objective assessment mechanism intended to evaluate achievement of desired competencies as delineated in the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs and (2) not less than 1,740 hours of Pharmacy practice experience credit under the instruction and supervision of a Preceptor. Boards may consider moving away from requiring a specific number of contact hours should it be determined that the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs result in appropriate preparation for students and objective assessment mechanisms demonstrate such.

an applicant for the licensure examination and shall also determine the qualifications of Preceptors used in practical experience programs.³⁸

Section 304. Qualifications for Licensure Transfer.³⁹

- (a) In order for a Pharmacist currently licensed in another jurisdiction to obtain a license as a Pharmacist by ~~license~~ licensure transfer in this State, an applicant shall:⁴⁰
- (1) have submitted an application in the form prescribed by the Board of Pharmacy;
 - (2) have attained the age of 18 years~~majority~~;
 - (3) have possessed at the time of initial licensure as a Pharmacist all qualifications necessary to have been eligible for licensure at that time in this State;
 - (4) have engaged in the Practice of Pharmacy for a period of at least one (1) year or have met the Pharmacy practice experience requirements of this State within the one (1) year period immediately preceding the date of such application;
 - (5) have presented to the Board proof of an active initial licensure by examination and proof ~~that such~~ license is in good standing;
 - (6) have presented to the Board proof that any other license granted to the applicant by any other state has not been Suspended, Revoked, or otherwise restricted for any reason, except nonrenewal or for the failure to obtain the required continuing education credits, in any state where the applicant is currently licensed but not engaged in the Practice of Pharmacy; and
 - (7) have paid the fees specified by the Board.
- (b) ~~No applicant shall be eligible for license licensure transfer unless the state in which the applicant was initially licensed as a Pharmacist also grants licensure transfer to Pharmacists duly licensed by examination in this State, under like circumstances and conditions.~~⁴¹

...

³⁸ Boards of Pharmacy are strongly encouraged to utilize the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs as a basis for establishment and revision of Board standards for Pharmacy practice experiences. These Standards of Accreditation also contain additional guidance on the desired behaviors, qualities, and values of preceptors.

³⁹ See the NABP Model Rules for Public Health Emergencies for language that addresses the temporary recognition of nonresident pharmacist licensure in the case of a declared State of Emergency issued due to a Public Health Emergency.

⁴⁰ It is intended that NABP's National Disciplinary Clearinghouse would be utilized by state Boards for verifying information provided by applicants.

⁴¹ ~~Endorsement states may wish to consider the removal of Subparagraph (b) in this Section.~~



NABP

Section 307. Licensure of Dispensing Practitioners.

- (a) In order to be licensed as Dispensing Practitioner⁴² in this State, an applicant shall:
- (1) have submitted an application in the form prescribed by the Board of Pharmacy;
 - (2) have undergone a state and federal fingerprint-based criminal background check as specified by Board rule;
 - (3) submit to an inspection of the Dispensing Practitioner's facility by the Board; and
 - (4) have paid the fees specified by the Board.

Section 3087. Renewal of Licenses.

- (a) Each Pharmacist, Pharmacy Intern, and Certified Pharmacy Technician shall apply for renewal of ~~his or her license~~ licensure annually [or at such interval determined by the Board], no later than the first day of _____. A Pharmacist or Pharmacy Intern who desires to continue in the Practice of Pharmacy in this State shall file with the Board an application in such form and containing such data as the Board may require for renewal of the license. ~~If the Board finds that the applicant has been licensed, and that such license has not been Revoked or placed under Suspension, that the applicant has attested that he or she has no criminal convictions or arrests, has paid the renewal fee, has continued his or her Pharmacy education in accordance with the rules of the Board, and is entitled to continue in the Practice of Pharmacy, the Board shall issue a license to the applicant.~~
- (b) If a Pharmacist fails to make application to the State Board of Pharmacy for renewal of licensure ~~his or her license~~ within a period of three years from the expiration of such licensure ~~his or her license~~, ~~he or she~~ the pharmacist must pass an examination for license renewal; except that a Person who has been licensed under the laws of this State and after the expiration of licensure ~~his or her license~~, has continually practiced Pharmacy in another State under a license issued by the authority of such State, may renew ~~his or her license~~ licensure upon payment of the designated fee.
- (c) The Board may extend a Pharmacist, Pharmacy Intern, or Certified Pharmacy Technician license renewal date in case of a State of Emergency or Significant Public Health Concern.

Section 3098. Continuing Pharmacy Education.

The Board shall, by rule, establish requirements for continuing education in Pharmacy, including the determination of acceptable program content and fees. The Board shall adopt rules necessary to carry out the stated objectives and purposes, to enforce the provisions of this Section, and to ensure continued

⁴² Licensed Dispensing Practitioners authorized under the laws of this State to Compound Drugs and to Dispense Drugs to their patients in the practice of their respective professions shall meet the same standards, record-keeping requirements, counseling, and all other requirements for the Compounding and the Dispensing of Drugs applicable to Pharmacists.

competence. The Board may extend the date of compliance with continuing pharmacy education provisions in the case of a State of Emergency or Significant Public Health Concern⁴³.

Article IV Licensing of Facilities

Introductory Comment to Article IV

The fourth Article of the Model Act concerns licensure of Pharmacies, Manufacturers, Wholesale Distributors, Repackagers, Third-Party Logistics Providers, and the like. The licensure requirements of this Article will provide a Board with knowledge of all facilities involved in the storage, Distribution, and sale of Drugs or Devices within the state and those located outside the state that are shipping Drugs or Devices into the state. They will permit a Board to verify compliance with federal requirements and better ensure against Drug or Device diversion from the legitimate channels of commerce and provide the necessary data for effective recalls and the dissemination of information.

Section 401. Unlawful Practice

- (a) No Business Entity designated in Section 402 of this Act shall operate until a license has been issued to said the Business Entity by the Board.
- (b) Except where otherwise permitted by state or federal law, it shall be unlawful for a Manufacturer, Repackager, Third-Party Logistics Provider, or Wholesale Distributor to Distribute or Deliver Drugs or Devices to any Business Entity or Person in this State not licensed under this statute. Any Manufacturer, Repackager, Third-Party Logistics Provider, or Wholesale Distributor who shall Distribute or Deliver Drugs or Devices to a Business Entity or Person not licensed shall be subject to a fine to be imposed by the Board for each offense in addition to such other disciplinary action the Board may take under this Act.

Section ~~401~~402. Licensing.

- (a) The following ~~Persons~~ Business Entities located within this State, and the following ~~Persons~~ Business Entities located outside this State that provide services to other Business Entities or patients within this State, shall be licensed by the Board of Pharmacy and shall annually periodically renew⁴⁴ their license with the Board:
 - (1) Pharmacies where Drugs or Devices are Dispensed, or Compounded, or Pharmacist Care Services are provided⁴⁶;

⁴³ Boards may consider waiving requirements for “live” continuing pharmacy education in the case of a State of Emergency or Significant Public Health Concern.

⁴⁴ The Board may delay a license renewal date in case of a State of Emergency or Significant Public Health Concern.

⁴⁵ State may require additional licensing/registration requirements.

⁴⁶ Includes remote dispensing machines and/or devices such as kiosks.



- (2) Dispensing ~~Practitioners and~~ Practitioners' facilities, including those engaged in nonsterile⁴⁷ Compounding;^{48, 49}
- (3) Manufacturers or Repackagers of Drugs or Devices;
- (4) Wholesale Distributors of Drugs or Devices;
- (5) Drug or Device Third-Party Logistics Providers;
- (6) Outsourcing Facilities;
- (7) Pharmacy Benefits Managers; and
- (8) Repository Programs

Where operations are conducted at more than one location, each such location shall be licensed by the Board of Pharmacy.

- (b) The Board shall establish by rule, under the powers granted to it under Section 212 and 213 of this Act and as may be required from time to time, under federal law, the criteria that each Person Business Entity must meet to qualify for licensure in each classification, as well as the required practice standards applicable to each type of activity and/or facility. The Board shall adopt definitions in addition to those provided in Article I, Section 105, where necessary to carry out the Board's responsibilities. The Board may issue licenses with varying conditions to such Persons Business Entity where the Board deems it necessary.⁵⁰
- (c) Each Pharmacy and/or Outsourcing Facility shall have a Pharmacist-in-Charge. ~~Whenever an applicable rule requires or prohibits action by a Pharmacy,~~ Joint responsibility for compliance with all laws and rules shall be that of the owner and/or ~~pharmacy~~ permit holder and the Pharmacist-in-Charge ~~of the Pharmacy~~, whether the owner and/or ~~pharmacy~~ permit holder is a sole partnership, association, corporation, or otherwise.
- (d) Each licensed Business Entity~~Person~~ located outside of this State which ships, mails, Dispenses, Distributes, Wholesale Distributes, or Delivers Drugs or Devices in this State, ~~or Pharmacy located outside of this State which ships, mails, Dispenses, Distributes, or Delivers Drugs or Devices in this State,~~ shall comply with the laws of patients' domicile, and shall designate a registered agent in this state for service of process. Any such licensed Business Entity~~Person or Pharmacy which that~~ does not so designate a registered agent shall be deemed to have designated the Secretary of State of this State to be its true and lawful attorney, upon whom

⁴⁷ ~~It is contemplated that dispensing Practitioners and Practitioners' facilities should only compound nonsterile human drug products and that sterile compounded human drug products should be obtained from Outsourcing Facilities.~~

⁴⁸ ~~It is contemplated that dispensing Practitioners and Practitioners' facilities should only compound nonsterile human drug products and that sterile compounded human drug products should be obtained from Outsourcing Facilities.~~

⁴⁹ Licensed Dispensing Practitioners' facilities authorized under the laws of this State to Compound Drugs and to Dispense Drugs to their patients in the practice of their respective professions shall meet the same standards, record-keeping requirements, counseling, and all other requirements for the Compounding and the Dispensing of Drugs applicable to Pharmacists.

⁵⁰ Section 401(b) contemplates that the criteria for licensure, beyond minimum requirements for all Persons and Pharmacies, established in an individual entity classification could differ. For example, the criteria that must be met by a nuclear Pharmacy will certainly differ from that of the community Pharmacy. This type of latitude places the responsibility on the Board to adopt appropriate rules to meet the situation at hand. It also provides a forum for change to meet the changing concepts of professional practice and the Distribution of Drugs and/or Devices.



NABP

may be served all legal process in any action or proceeding against such licensed Business Entity ~~Person~~ growing out of or arising from such shipping, mailing, Dispensing, Distribution, Wholesale Distribution, or Delivery of Drugs or Devices. A copy of any such service of process shall be mailed to such Business Entity ~~Person or Pharmacy~~ by the Board by certified mail, return receipt requested, postage prepaid, at the address such licensed Business Entity ~~Person~~ has designated on its application for licensure in this State, or by electronic means if permitted. If any such Business Entity ~~Person~~ is not licensed in this State, service on the Secretary of State only shall be sufficient service.⁵¹

- (e) The Board may enter into agreements with other states or with third parties for the purpose of exchanging information concerning the licensure and inspection of Business Entities ~~entities~~ located in this jurisdiction ~~State~~ and those located outside this State.
- (f) ~~The Board of Pharmacy may deny or refuse to issue or renew a license if it determines that the issuing or renewing of such license would not be in the public interest.~~
- (fg) For facilities that Compound and/or Repackage Sterile Drugs, an initial inspection shall be required prior to initial licensure or upon initiation of sterile Compounding activity. Thereafter, an annual inspection shall be required for licensure renewal. For facilities that do not Compound Sterile Drugs, an initial inspection, and thereafter an inspection that takes place not less than every 24 months, shall be required for purposes of licensure or licensure renewal⁵². Such inspection shall be performed by the following:
 - (1) the Board or its duly authorized agent; or
 - (2) a duly authorized agent of a third party approved by the Board⁵³; orFor Nonresident Pharmacies, the inspection shall be performed by the resident state Board of Pharmacy, if the resident Board's inspection is substantially equivalent to inspection in this State, or a duly authorized agent of a third party approved by the Board⁵⁴.
- (h) ~~Agents duly authorized to conduct inspections, whether agents of the Board or an approved third party, must be competent to inspect the facilities they are assigned to inspect to include training on any applicable State, Federal, and USP standards.~~

...

Section 4032. Application.⁵⁵

⁵¹ This section provides for service of process on any Person who Dispenses, Distributes, or Delivers Drugs or Devices within the State.

⁵² State resources may have to be considered when evaluating inspection scheduling in combination with risk assessment consideration.

⁵³ Boards of Pharmacy are strongly encouraged to utilize the NABP Verified Pharmacy Program for this purpose.

⁵⁴ Boards of Pharmacy are strongly encouraged to utilize the NABP Verified Pharmacy Program for this purpose.

⁵⁵ Boards may want to consider requesting the following information on applications for Pharmacy and Wholesale Distributor licensure:

- (a) personal information;
- (b) marital information;
- (c) family information (parents, siblings, in-laws);
- (d) education;



The Board shall specify by rule the licensure procedures to be followed, including but not limited to, specification of forms for use in applying for such licensure and times, places, and applicable fees.

- (b) Applicants for licensure to Dispense, Distribute, Wholesale Distribute, Manufacture, sell, purchase, transfer, and/or produce Drugs or Devices, and applicants for licensure as a Pharmacy Benefits Manager, shall file with the Board of Pharmacy a ~~verified~~ complete and accurate application containing such information as the Board requires of the applicant relative to the qualifications for a license.
- (c) The Board of Pharmacy shall require any pharmacy applicant for initial and renewal of licensure to state whether they engage or intend to engage in Compounding as defined in this Act.^{56, 57}
- (d) Licenses issued by the Board pursuant to this Act shall not be transferable or assignable.
- (e) The Board shall specify by rule minimum standards for responsibility of any Business Entity ~~Person~~, Pharmacy, or Pharmacy Benefits Manager that has employees or personnel engaged in the Practice of Pharmacy, or Manufacture, Distribution, Wholesale Distribution, production, sale, or use of Drugs or Devices in the conduct of their business. If the licensed Business Entity ~~Person~~ is a Pharmacy located in this State, that portion of the facility to which such license applies shall be operated only under the direct supervision of a Pharmacist licensed to practice in this State. If that Business Entity ~~Person~~ is an Outsourcing Facility, all Compounding

-
- (e) military information;
 - (f) arrests, detentions, litigations, and arbitrations;
 - (g) residences (past 25 years);
 - (h) employment (back to age 18);
 - (i) character references;
 - (j) safe deposit box or other depository information;
 - (k) privileged, occupational, or professional licensure;
 - (l) out-of-state business, venture, or industry licensure or financial interest in such;
 - (m) appearances before any licensing agency or similar authority in or outside the state;
 - (n) denials of a personal license, permit, certificate, or registration for a privileged, occupational, or professional activity;
 - (o) denials of a business or industry license or related finding of suitability, or participation in a group that has been denied a business or industry license or related finding of suitability;
 - (p) Administrative actions or proceedings related to the Drug industry or participation in a group that has been the subject of such administrative actions or proceedings;
 - (q) guilty findings or pleadings or pleas of nolo contendere to any offense, federal or state, related to prescription Drugs and/or controlled substances or participation in a group that has been found or pled guilty or that has pled nolo contendere to any such offense;
 - (r) surrender, voluntary or otherwise, of licensure, permit, or certificate of registration relating to the Drug industry, or participation in a group that has surrendered, voluntary or otherwise, any such licensure, permit, or certificate of registration; and
 - (s) any relatives within the fourth degree of consanguinity associated with or employed in the Drug or Drug-related industry.

⁵⁶ Applicants who engage or intend to engage in Compounding shall submit concurrently with their application for licensure responses to a questionnaire regarding the applicant's Compounding operations

⁵⁷ The questionnaire contemplated in 502(c) shall request, at a minimum, the following information: 1) The name and address of the location at which Compounding occurs or will occur; 2) Whether nonsterile Compounding occurs or will occur; 3) Whether sterile Compounding occurs or will occur; 4) Whether the applicant Compounds or will Compound with hazardous drugs; and 5) Whether the applicant ships or will ship compounded preparations across state lines.



- at the facility shall be under the direct supervision of a licensed Pharmacist and comply with Federal requirements applicable to Outsourcing Facilities.
- (f) A “surety” bond of not less than \$100,000, or other equivalent means of security acceptable to the Board, or a third party recognized by the Board such as insurance, an irrevocable letter of credit, or funds deposited in a trust account or financial institution shall be required for all Wholesale Distributor applicants. Such bond will be used to secure payment of any administrative penalties imposed by the Board and any fees or costs incurred by the Board regarding that licensee when ~~those penalties, fees, or costs are authorized under state law and the licensee fails to pay within thirty (30) days after the penalty, fee, or costs becomes final~~. A separate surety bond or other equivalent means of security is not required for each company’s separate locations or for affiliated companies/groups when such separate locations or affiliated companies/groups are required to apply for or renew their Wholesale Distributor license with the Board. The Board may make a claim against such bond or other equivalent means of security until one year after the Wholesale Distributor’s license ceases to be valid or until sixty (60) days after any administrative or legal proceeding before or on behalf of the Board that involves the Wholesale Distributor is concluded, including any appeal, whichever occurs later. ~~Manufacturers shall be exempt from securing a “surety” bond or other equivalent means of security acceptable to the Board or a third party recognized by the Board~~. The Board may waive the bond requirement, if the Wholesale Distributor:
- (1) has previously obtained a comparable surety bond or other equivalent means of security for the purpose of licensure in another state, where the Wholesale Distributor possesses a valid license in good standing; or
 - (2) is a publicly held company.

Section 4043. Notifications.

- (a) All licensed Business Entities or Persons shall report to the Board of Pharmacy the occurrence of any of the following:
- (1) permanent closing;
 - (2) change of ownership, management, location, or Pharmacist-in-Charge of a Pharmacy;
 - (3) any theft or loss of Drugs or Devices;
 - (4) any conviction of any employee of any State or Federal Drug laws;
 - (5) any criminal conviction or pleas of guilty or nolo contendere of all licensed or registered personnel;
 - (6) disasters, accidents, or any theft, destruction, or loss of records required to be maintained by State or Federal law;
 - (7) occurrences of Significant Quality-Related Events;
 - (8) ~~Significant Adverse Drug Reaction~~ Serious Adverse Drug Experience associated with Compounded Drugs;
 - (9) recalls of Compounded Drugs;



NABP

- (10) recalls of sterile Repackaged Drugs;
- (11) any temporary closing of a pharmacy for more than two consecutive calendar days outside of the Pharmacy's regular operating 48 hours shall be reported to the Board by the next business day along with contingency plans for accessing patient prescriptions and records.
- (12) ~~illegal use or disclosure of Protected Health Information; or~~
- (13) ~~any and all other matters and occurrences as the Board may require by rule.~~
- (b) Prior to commencing any sterile Compounding activity, a All licensed Business Entities and/or Persons shall report to the Board of Pharmacy, or its authorized agent, whether the licensed facility will be engaging in any sterile Compounding if they are engaging in any sterile Compounding activity conducted at a licensed facility prior to commencing of any sterile Compounding activity in a manner determined by the Board. The Board may establish by rule additional reporting requirements for sterile and nonsterile Compounding activities.
- (c) All licensed Business Entities and/or Persons shall report to the Board of Pharmacy, or its authorized agent, the occurrence of any Pharmacy or Pharmacy-related inspection conducted by any State or Federal regulatory agency or authorized agent thereof and shall provide a copy of the report of such inspection, including applicable documents relating to corrective actions within a timeframe determined by the Board.⁵⁸

~~Section 404. Grounds, Penalties, and Reinstatement.~~

- (a) ~~No Person, Pharmacy, or Pharmacy Benefits Manager designated in Section 401 of this Act shall operate until a license has been issued to said Person, Pharmacy, or Pharmacy Benefits Manager by the Board.~~
- (b) ~~Except where otherwise permitted by law, it shall be unlawful for a Manufacturer, Repackager, Third-Party Logistics Provider, or Wholesale Distributor to Distribute or Deliver Drugs or Devices to any Person in this State not licensed under this statute. Any Person who shall Distribute or Deliver Drugs or Devices to a Person not licensed shall be subject to a fine to be imposed by the Board not to exceed one thousand dollars (\$1,000) for each offense in addition to such other disciplinary action the Board may take under this Act. Except as otherwise indicated in this Act, each such violation shall also constitute a misdemeanor punishable upon conviction as provided in the criminal code of this State.~~
- (c) ~~The Board may Suspend, Revoke, deny, or refuse to renew the license of any Person, Manufacturer, Repackager, Third-Party Logistics Provider, Wholesale Distributor, Pharmacy, or Pharmacy Benefits Manager on any of the following grounds:~~⁵⁹

⁵⁸ This includes any report or inspectional observations and any related correspondence with the Federal or State agency. FDA Form 483 Inspectional Observations alone should not be grounds for discipline.

⁵⁹ The Prescription Drug Marketing Act of 1987 (PDMA) requires that the state licensing laws provide for the Suspension or Revocation of licenses upon conviction for violation of Federal, State, or local Drug laws or rules pertaining to the unlawful Distribution of Drugs at wholesale. The PDMA defines fines, imprisonment, or civil penalties.



- ~~(1) the finding by the Board of violations of any Federal, State, or local laws relating to the Practice of Pharmacy, Drug samples, Wholesale or retail Drug or Device Distribution, or Distribution of controlled substances;~~
- ~~(2) any felony convictions under Federal, State, or local laws;~~
- ~~(3) the furnishing of false or fraudulent material in any application made in connection with Drug or Device Manufacturing or Distribution;~~
- ~~(4) suspension or Revocation by Federal, State, or local government of any license currently or previously held by the applicant for the Manufacture or Distribution of any Drugs or Devices, including controlled substances;~~
- ~~(5) willfully and knowingly submitting false or fraudulent information or omitting information on due diligence questionnaires and/or attestation documents regarding the purchase or receipt of Drugs from Manufacturers, Repackagers, Third-Party Logistics Providers, and Wholesale Distributors.~~
- ~~(6) obtaining any remuneration by fraud, misrepresentation, or deception;~~
- ~~(7) affiliating with websites that may deceive or defraud patients or that violate Pharmacy or Drug laws of this State or rules and regulations pertaining thereto; or of laws, rules, and regulations of any other state; or of the Federal government;~~
- ~~(8) dealing with Drugs or Devices that he or she knows or should have known are or Counterfeit, Contraband, or stolen Drugs or Devices;⁶⁰~~
- ~~(9) purchasing or receiving of a Drug or a Device from a source other than a Person or pharmacy licensed under the laws of the State, except where otherwise provided;~~
- ~~(10) the transfer during any consecutive twelve (12)-month period by a Pharmacy to a Wholesale Distributor or to another Pharmacy of more than five percent (5%) of the total amount of Prescription Drugs or Devices purchased by the Pharmacy in the immediately preceding twelve (12)-month period. The following are not subject to the provisions of this subsection:~~
 - ~~(i) Prescription Drugs or Devices that are Returned by a pharmacy for credit, in an amount equal to or less than the actual purchase price, to the Wholesale Distributor or Manufacturer from which those Products were purchased;~~
 - ~~(ii) Intracompany sales;~~
 - ~~(iii) The sale, purchase, or trade of a Drug or an offer to sell, purchase, or trade a Drug among hospitals or other health care entities that are under common control;~~
 - ~~(iv) The sale, purchase, or trade of a Drug or the offer to sell, purchase, or trade a Drug by a charitable organization described in 503(c)(3) of the Internal Revenue Code of 1954 to a nonprofit affiliate of the organization to the extent otherwise permitted by law;~~

⁶⁰ This section restricts Distribution of Drugs or Devices to licensed entities to help ensure against clandestine Distribution to unauthorized and unlicensed Persons.



- ~~(v) The purchase or other acquisition by a hospital or other similar health care entity that is a member of a group purchasing organization of a Drug for its own use from the group purchasing organization or from other hospitals or similar health care entities that are members of these organizations; and~~
- ~~(vi) The transfer of Prescription Drugs or Devices between Pharmacies pursuant to a Centralized Prescription Processing or Filling agreement;~~
- ~~(11) the transfer during any consecutive twelve (12) month period by a Wholesale Distributor to a Wholesale Distributor of more than five percent (5%) of the total amount of prescription Drugs or Devices purchased by Wholesale Distributor in the immediately preceding twelve (12) month period;~~
- ~~(12) Wholesale Drug Distributors other than pharmacies Dispensing or Distributing Drugs or Devices directly to patients;~~
- ~~(13) violations of any of the provisions of this Act or of any of the Rules adopted by the Board under this Act; or~~
- ~~(14) illegal use or disclosure of Protected Health Information.~~
- ~~(15) Retaliating against or disciplining an employee for filing a complaint with a state board of pharmacy or other licensing body or reporting a suspected violation of state or federal statute or any ordinance or regulation of a political subdivision that the employee's employer has authority to correct. As used in this paragraph, retaliation or discipline of an employee includes, but is not limited to, the following:~~
 - ~~(i) Removing or suspending the employee from employment;~~
 - ~~(ii) Withholding from the employee salary increases or employee benefits to which the employee is otherwise entitled;~~
 - ~~(iii) Transferring or reassigning the employee;~~
 - ~~(iv) Denying the employee a promotion that otherwise would have been received;~~
 - ~~(v) Reducing the employee in pay or position.~~
- ~~(d) Reinstatement of a license that has been Suspended, Revoked, or restricted by the Board may be granted in accordance with the procedures specified by Section 401 of this Act.~~

Section 405. Criminal Offense; Forfeiture of Property.

- ~~(a) Violation of any of the provisions of Article IV of this Act by any person engaged in the Wholesale Distribution of Drugs and Devices shall constitute a Class three felony, provided that any such violation that results in the death of a Person shall constitute a Class one felony.~~
- ~~(b) A Person engaged in the Wholesale Distribution of Drugs and Devices convicted by a criminal court of this State of violating any of the provisions of Article IV may be ordered by the court to forfeit to the State any real or personal property:~~
 - ~~(1) used or intended to be used to commit, to facilitate, or to promote the commission of such offense; or~~
 - ~~(2) constituting, derived from, or traceable to the gross proceeds that the defendant obtained directly or indirectly as a result of the offense. Any property or assets subject to forfeiture~~

~~under this section may be seized pursuant to a warrant obtained in the same manner as a search warrant or as otherwise permitted by law, and held until the case against the defendant is adjudicated. Monies ordered forfeited, or proceeds from the sale of other assets ordered forfeited, shall be equitably divided between the Board and other agencies involved in the investigation and prosecution that led to the conviction. Other property ordered forfeited after conviction of the defendant may, at the discretion of the investigating agencies, be placed into official use by the Board or the agencies involved in the investigation and prosecution that led to the conviction.~~

Article V Discipline

Introductory Comment to Article V

At the very heart of any Pharmacy Act is the enforcement power of the Board of Pharmacy. The Board must have authority to discipline and/or prohibit Pharmacies, Pharmacists, Pharmacy Interns, Certified Pharmacy Technicians, or Certified Pharmacy Technician Candidates ~~who~~ and Business Entities and facilities that violate this Act or Rules from continuing to threaten the public if it is to fulfill its responsibilities. The Board must have the ability to stop wrongdoers, either permanently or temporarily, discipline them, and, where appropriate, to guide and assist errant licensees in rehabilitating themselves.

The Model Act disciplinary provisions are contained in Article V. They were drafted with the purpose of granting to the Board the widest possible scope within which to perform its disciplinary functions. Standardized disciplinary action terms and definitions were developed to facilitate the accurate reporting of disciplinary actions taken by Boards of Pharmacy and to avoid confusion associated with state-to-state variations in terms and definitions. The grounds for disciplinary action were developed to ensure protection of the public, while reserving to the Board the power to expand upon them and adapt them to changing or local conditions as necessary. The penalties permitted under the Model Act will afford the Board the flexibility to conform and relate discipline to offenses.

Section 501. Disciplinary Action Terms.

The following is a list of disciplinary actions that may be taken, issued, or assessed by the Board of Pharmacy: Revocation, Summary Suspension, Suspension, Probation, Censure, Reprimand, Warning, Cease and Desist, Fine/Civil Penalty, Costs/Administrative Costs.⁶¹

Section 502. Grounds, Penalties, and Reinstatement.⁶²

⁶¹ Guidelines for the imposition of sanctions for certain designated offenses can be found in Appendix C: Guidelines for Disciplinary Sanctions of the Model Act.

⁶² The penalties provided in Section 402 give the Board wide latitude to make the disciplinary action fit the offense. The “reasonable intervals” in 402(c) would be determined by the Board.



- (a) The Board of Pharmacy may refuse to issue or renew, or may Revoke, Summarily Suspend, Suspend, place on Probation, Censure, Reprimand, issue a Warning against, or issue a Cease and Desist order against, the licenses or the registration of, or assess a Fine/Civil Penalty or Costs/Administrative Costs against any ~~Business Entity or~~ Person pursuant to the procedures set forth in Section 503 herein below, upon one or more of the following grounds:
- (1) unprofessional conduct as that term is defined by the rules of the Board;⁶³
 - (2) incapacity that prevents a licensee from engaging in the Practice of Pharmacy or a registrant from assisting in the Practice of Pharmacy, with reasonable skill, competence, and safety to the public;⁶⁴
 - (3) being guilty of one (1) or more of the following:
 - (i) a felony; or
 - (ii) violations of the Pharmacy or Drug laws of this State or rules and regulations pertaining thereto; or of laws, rules, and regulations of any other state; or of the Federal government;⁶⁵
 - (4) disciplinary action taken by another state or jurisdiction against a license or other authorization to Practice Pharmacy based upon conduct by the licensee similar to conduct that would constitute grounds for actions as defined in this section, which involves or may result in direct patient impact or harm in states other than that of the initiating Board;
 - (5) failure to report to the Board any adverse action taken by another licensing jurisdiction (United States or foreign), government agency, law enforcement agency, or court for conduct that would constitute grounds for action as defined in this section;
 - (6) failure to report to the Board one's surrender of a license or authorization to Practice Pharmacy in another state or jurisdiction while under disciplinary investigation by any of

⁶³ It is particularly important to emphasize the need for specificity in defining the grounds upon which a Pharmacist's or Pharmacy Intern's license to practice Pharmacy, or a Certified Pharmacy Technician's or Certified Pharmacy Technician Candidate's registration to assist in the Practice of Pharmacy, may be Revoked or Suspended. The term "unprofessional conduct" is particularly susceptible to judicial challenge for being unconstitutionally vague. Each offense included within the meaning of this term must be capable of being understood with reasonable precision by the Persons regulated so that it can be readily enforced and relied upon during disciplinary proceedings, and so that those regulated by it may easily conform their professional conduct to its meaning(s).

These potential problems make it essential for Boards to issue appropriate rules making the grounds for disciplinary action specific, understandable, and reasonable. In addition, the Boards must ensure that such rules are published for the benefit of all licensees within their jurisdiction. Only by doing so can Boards be assured of authority to take successful and meaningful disciplinary actions that will not later be overturned by the courts.

This section must be examined in light of other state laws since some states, for example, restrict the circumstances under which a license may be denied to an individual because of the commission of a felony. In addition, an individual who has been convicted of a felony and who has paid his debt to society has restored constitutional protections that may curtail a strict application of Section 402(a)(3).

⁶⁴ Boards need to consider the issue of impairment if a registrant or licensee tests positive for a substance of misuse and/or abuse.

⁶⁵ It is contemplated that Boards of Pharmacy will consider state and federal law, including any discrepancies between state and federal law, when evaluating complaints against a registrant or licensee related to a positive result on a cannabinoid Drug test. It is also contemplated that any complaint of this nature will be assessed on a case-by-case basis.



- those authorities or bodies for conduct that would constitute grounds for action as defined in this section;
- (7) failure to report to the Board any adverse judgment, settlement, or award arising from a malpractice claim arising related to conduct that would constitute grounds for action as defined in this section;
 - (8) knowing or suspecting that a Pharmacist or Pharmacy Intern is incapable of engaging in the Practice of Pharmacy or that a Certified Pharmacy Technician or Certified Pharmacy Technician Candidate is incapable of assisting in the Practice of Pharmacy, with reasonable skill, competence, and safety to the public, and failing to report any relevant information to the Board of Pharmacy;
 - (9) misrepresentation of a material fact by a licensee in securing the issuance or renewal of a license or registration;
 - (10) fraud by a licensee in connection with the Practice of Pharmacy;
 - (11) affiliating with websites that may deceive or defraud patients or that violate Pharmacy or Drug laws of this State or rules and regulations pertaining thereto; or of laws, rules, and regulations of any other state; or of the federal government;
 - (12) engaging, or aiding and abetting an individual to engage in the Practice of Pharmacy without a license; assisting in the Practice of Pharmacy or aiding and abetting an individual to assist in the Practice of Pharmacy without being licensed by the Board of Pharmacy; or falsely using the title of Pharmacist, Pharmacy Intern, Certified Pharmacy Technician, or Certified Pharmacy Technician Candidate;
 - (13) requiring Pharmacy personnel to meet production and/or performance metrics and/or quotas that negatively impact patient safety.⁶⁶
 - (14) failing to pay the costs assessed in a disciplinary hearing pursuant to Section 213(c)(9);
 - (15) engaging in any conduct that subverts or attempts to subvert any licensing examination or the Administration of any licensing examination;⁶⁷

⁶⁶ This is not intended to include performance metrics that may be related to the ability and competency of Pharmacy personnel.

⁶⁷ It is recommended that the following rule be adopted defining subversion or the attempt to subvert any licensing examination.

- (a) Conduct which subverts or attempts to subvert any licensing examination or the administration of any examination shall include, but not be limited to, the following:
 - (1) Conduct which violates the security of the examination materials; removing from the examination room any examination materials without authorization; the unauthorized reproduction by any means of any portion of the actual licensing examination; aiding by any means the unauthorized reproduction of any portion of the actual licensing examination; paying or using professional or paid examination takers for the purpose of reconstructing any portion of the licensing examination; obtaining examination questions or other examination materials, except by specific authorization either before, during, or after an examination; or selling, Distributing, buying, receiving, or having unauthorized possession of any portion of a future, current, or previously administered licensing examination.
 - (2) Unauthorized communication of examination information with any other examinee during the administration of a licensing examination; copying answers from another examinee or permitting one's answers to be copied by another examinee; having in one's possession during the administration of the licensing examination any books, equipment, notes, written or printed materials, or data of any kind other than the examination materials Distributed, or otherwise authorized to be in one's



- (16) being found by the Board to be in violation of any of the provisions of this Act or rules adopted pursuant to this Act;
- (17) illegal use or disclosure of Protected Health Information;
- (18) impeding or subverting an investigation or failure to furnish to the Board, its investigators, or representatives any information legally requested by the Board;
- (19) willfully and knowingly submitting false or fraudulent information or omitting information on due diligence questionnaires and/or attestation documents regarding the purchase or receipt of Drugs from Manufacturers, Repackagers, Third-Party Logistics Providers, and Wholesale Distributors;
- (20) affiliating with websites that may deceive or defraud patients or that violate Pharmacy or Drug laws of this State or rules and regulations pertaining thereto; or of laws, rules, and regulations of any other state; or of the federal government;
- (21) illegal use or disclosure of Protected Health Information.
- (22) Retaliating against or disciplining an employee for filing a complaint with a state board of pharmacy or other licensing body or reporting a suspected violation of state or federal statute or any ordinance or regulation of a political subdivision that the employee's employer has authority to correct. As used in this paragraph, retaliation or discipline of an employee includes, but is not limited to, the following:
 - (i) Removing or suspending the employee from employment;
 - (ii) Withholding from the employee salary increases or employee benefits to which the employee is otherwise entitled;
 - (iii) Transferring or reassigning the employee;
 - (iv) Denying the employee a promotion that otherwise would have been received;
 - (v) Reducing the employee in pay or position.
- (23) the furnishing of false or fraudulent material in any application made in connection with Drug or Device Manufacturing or Distribution;
- (24) suspension or Revocation by federal, state, or local government of any license currently or previously held by the applicant for the Manufacture or Distribution of any Drugs or Devices, including controlled substances;
- (25) obtaining any remuneration by fraud, misrepresentation, or deception;
- (26) dealing with Drugs or Devices that he or she a Person knows or should have known are Suspect or Illegitimate Product or Counterfeit, Contraband, or stolen Drugs or Devices;⁶⁸
- (27) purchasing or receiving of a Drug from a source other than an authorized Trading Partner or a Device from a source other than a Person or pharmacy licensed under the laws of the State, except where otherwise provided;

possession during the examination; or impersonating any examinee or having an impersonator take the licensing examination on one's behalf.

⁶⁸ This section restricts Distribution of Drugs or Devices to licensed entities to help ensure against clandestine Distribution to unauthorized and unlicensed Persons.



- (28) the transfer by a Pharmacy to a Wholesale Distributor or to another Pharmacy without being licensed as a Wholesale Distributor. The following are not subject to the provisions of this subsection:
- (i) Prescription Drugs or Devices that are Returned by a pharmacy for credit, in an amount equal to or less than the actual purchase price, to the Wholesale Distributor or Manufacturer from which those Products were purchased;
 - (ii) Intracompany sales;
 - (iii) The sale, purchase, or trade of a Drug or an offer to sell, purchase, or trade a Drug among hospitals or other health care entities that are under common control;
 - (iv) The sale, purchase, or trade of a Drug or the offer to sell, purchase, or trade a Drug by a charitable organization described in 503(c)(3) of the Internal Revenue Code of 1954 to a nonprofit affiliate of the organization to the extent otherwise permitted by law;
 - (v) The purchase or other acquisition by a hospital or other similar health care entity that is a member of a group purchasing organization of a Drug for its own use from the group purchasing organization or from other hospitals or similar health care entities that are members of these organizations;
 - (vi) The transfer of Prescription Drugs or Devices between Pharmacies pursuant to a Centralized Prescription Processing or Filling agreement;
 - (vii) The transfer of a Drug from one Pharmacy to another for a specific patient need to fill a Prescription Drug Order for an identified patient;
 - (viii) The distribution of minimal quantities of product by a Pharmacy to a licensed practitioner for office use.
- (29) Wholesale Drug Distributors, other than pharmacies, Dispensing or Distributing Drugs or Devices directly to patients;
- (30) violations of any of the provisions of this Act or of any of the Rules adopted by the Board under this Act.
- (b) The Board of Pharmacy may deny or refuse to issue or renew a license if it determines that the issuing or renewing of such license would not be in the public interest, or as otherwise statutorily provided.
- (c) Reinstatement of a license that has been Suspended, Revoked, or restricted by the Board may be granted in accordance with the procedures specified by Section 401 of this Act.
- (d) The Board of Pharmacy shall require complainants to identify themselves in the complaint and make themselves available for an evidentiary interview. Complainants may request that their identity remain confidential during the preliminary investigatory process. The Board may take action on a complaint if the patient or complainant does not comply with the Board's investigation when the Board has probable cause sufficient evidence of a violation of law. It shall be an act of unprofessional conduct for any licensee to file a false or fraudulent complaint or report to the Board.



(b)(e)

Impaired Practice Licensees

- (1) The Board may defer action with regard to an impaired practice licensee who voluntarily signs an agreement, in a form satisfactory to the Board, agreeing not to practice Pharmacy and to enter an approved treatment and therapeutic monitoring program in accordance with this Section, provided that this Section should not apply to a licensee who has been convicted of, pleads guilty to, or enters a plea of nolo contendere to a felonious act prohibited by _____ or a conviction relating to a controlled substance in a court of law of the United States or any other state, territory, or country. A licensee who is physically or ~~mentally~~ behaviorally impaired due to ~~addiction to Drugs or alcohol~~ substance use may qualify as an impaired practice licensee ~~Pharmacist~~ and have disciplinary action deferred and ultimately waived only if the Board is satisfied that such action will not endanger the public and the licensee enters into an agreement with the Board for a treatment and therapeutic monitoring plan approved by the Board, progresses satisfactorily in such treatment and monitoring program, complies with all terms of the agreement and all other applicable terms of subsection (b)(2). Failure to enter such agreement or to comply with the terms and make satisfactory progress in the treatment and monitoring program shall disqualify the licensee from the provisions of this Section and the Board shall activate an immediate investigation and disciplinary proceedings. Upon ~~completion~~ successfully meeting the requirements of the rehabilitation treatment and therapeutic monitoring program in accordance with the agreement signed by the Board, the licensee may apply for permission to resume the Practice of Pharmacy upon such conditions as the Board determines necessary.
- (2) The Board may require a licensee to enter into an agreement that includes, but is not limited to, the following provisions:
 - (i) ~~Licensee agrees that his or her license shall be Suspended or Revoked indefinitely under subsection (b)(1).~~ Licensee agrees to voluntarily surrender his or her license for a period of time to be determined by the Board following commencement of the treatment and therapeutic monitoring program.
 - (ii) Licensee will enroll in a treatment and monitoring program that includes substance use disorder professionals and is approved by the Board.
 - (iii) Licensee agrees that failure to satisfactorily progress in such treatment and monitoring program shall be reported to the Board by the treating professional, who shall be immune from any liability for such reporting made in good faith.
 - (iv) Licensee consents to the treating physician or professional of the approved treatment and therapeutic monitoring program reporting to the Board on the progress of licensee at such intervals as the Board deems necessary and such Person making such report will not be liable when such reports are made in good faith.
- (3) The ability of an impaired practice licensee ~~Pharmacist~~ to practice shall only be restored and charges dismissed when the Board is satisfied by the reports it has received from the



approved treatment and therapeutic monitoring program that licensee can resume practice under a current approved treatment plan without danger to the public.

- (4) Licensee consents, in accordance with applicable law, to the release to the Board of any treatment information from ~~anyone within~~ the approved treatment program.
- (5) ~~The impaired licensee who has enrolled in an approved treatment and monitoring program and entered into an agreement with the Board in accordance with subsection (b)(1) hereof shall have his license Suspended or Revoked, but enforcement of this Suspension or Revocation shall be stayed by the length of time the licensee remains in the program and makes satisfactory progress, and complies with the terms of the agreement and adheres to any limitations on his practice imposed by the Board to protect the public. Failure to enter into such agreement or to comply with the terms and make satisfactory progress in the treatment and monitoring program shall disqualify the licensee from the provisions of this Section and the Board shall activate an immediate investigation and disciplinary proceedings.~~
- (6) Any Person Pharmacist who has substantial evidence that a licensee has an impairment due to a substance use disorder active addictive disease for which the licensee is not receiving treatment under a program approved by the Board pursuant to an agreement entered into under this Section, is diverting a controlled substance, or is mentally or physically incompetent to carry out their duties of his or her license licensure, shall make or cause to be made a report to the Board. Any Person who reports pursuant to this Section in good faith and without malice shall be immune from any civil or criminal liability arising from such reports. Failure to provide such a report within a reasonable time from receipt of knowledge may be considered grounds for disciplinary action against the licensee ~~so~~ for failing to report.

(ef) Any Person whose license to practice Pharmacy in this State has been denied renewal, voluntarily surrendered, Revoked, Summarily Suspended, Suspended, or Revoked placed on Probation, Censured, Reprimanded, issued a Warning against, or issued a Cease and Desist order against, the licenses or the registration of, or assessed a Fine/Civil Penalty or Costs/Administrative Costs against pursuant to this Act, whether voluntarily or by action of the Board, shall have the right, at reasonable intervals, to petition the Board for reinstatement of such license.⁶⁹ Such petition shall be made in writing and in the form as prescribed by the Board. Upon investigation and hearing, the Board may, at its discretion, grant or deny such petition, or it may modify its original finding to reflect any circumstances that have changed sufficiently to warrant such modifications. The Board, also at its discretion, may require such Person to pass an examination(s) for reentry into the Practice of Pharmacy.

(dg) Nothing herein shall be construed as barring criminal prosecutions for violations of this Act.

⁶⁹ A Pharmacist who is under investigation or who has been charged with a violation of the Pharmacy Practice Act may agree to voluntarily surrender ~~his or her~~ their Pharmacist license. When this occurs, the Board should formally enter stipulated findings and an order describing the terms and conditions of the surrender including any agreed upon time limitations. This establishes statutory grounds that would support disciplinary action and prevents a Pharmacist who has surrendered a license from applying for reinstatement within a time frame unacceptable to the Board.



NABP

- (eh) All final decisions by the Board shall be subject to judicial review pursuant to the Administrative Procedures Act.
- (fi) ~~Any individual or entity whose license to practice Pharmacy, or registration to assist in the Practice of Pharmacy, is Revoked, Suspended, or not renewed shall return his or her license or registration certificate to the offices of the State Board of Pharmacy within 10 days after receipt of notice of such action.~~

Section 503. Procedure.⁷⁰

- (a) Notwithstanding any provisions of the State Administrative Procedures Act, the Board may, without a hearing, Summarily Suspend a license for not more than 60 days if the Board finds that a Pharmacist, Pharmacy Intern, Certified Pharmacy Technician, ~~or~~ Certified Pharmacy Technician Candidate, Business Entity or facility has violated a law or rule that the Board is empowered to enforce, and if continued practice by the Pharmacist, Pharmacy Intern, Certified Pharmacy Technician, ~~or~~ Certified Pharmacy Technician Candidate, Business Entity or facility would create an imminent risk of harm to the public. The Suspension shall take effect upon written notice to the Pharmacist, Pharmacy Intern, Certified Pharmacy Technician, ~~or~~ Certified Pharmacy Technician Candidate, Business Entity or facility specifying the statute or rule violated. At the time it issues the Suspension notice, the Board shall schedule a disciplinary hearing to be held under the Administrative Procedures Act within 20 days thereafter. The Pharmacist, Pharmacy Intern, Certified Pharmacy Technician, ~~or~~ Certified Pharmacy Technician Candidate, Business Entity or Facility shall be provided with at least 10 days notice of any hearing held under this subsection.
- (b) Notwithstanding any provisions of the State Administrative Procedures Act, the Board may, in its own name, issue a Cease and Desist order to stop an individual from engaging in an unauthorized Practice of Pharmacy or violating or threatening to violate a statute, rule, or order that the Board has issued or is empowered to enforce. The Cease and Desist order must state the reason for its issuance and give notice of the individual's right to request a hearing under applicable procedures as set forth in the Administrative Procedures Act. Nothing herein shall be construed as barring criminal prosecutions for violations of this Act.

Model Rules for Pharmacy Interns and Pharmacy Practice Experience Programs⁷¹

⁷⁰ The procedures which must be followed before disciplinary action can be taken in many of the states are determined by the Administrative Procedures Act. The *Model Act* was drafted on the assumption that such an Act was in effect.

⁷¹ Boards of pharmacy are strongly encouraged to utilize the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs as a basis for the establishment and revision of Board standards for Pharmacy practice experiences.

Section 1. Licensure.

Every individual shall be licensed by the Board of Pharmacy before beginning Pharmacy practice experiences in this State.⁷² A license to practice Pharmacy as a Pharmacy Intern shall be granted only to those individuals who:

- (a) are enrolled in a professional degree program of a school or college of pharmacy that has been approved by the Board and satisfactorily progressing toward meeting the requirements for licensure as a Pharmacist; or
- (b) are graduates of an approved professional degree program of a school or college of Pharmacy or are graduates who have established educational equivalency by obtaining a Foreign Pharmacy Graduate Examination Committee™ (FPGEC®) Certificate, who are currently licensed by the Board of Pharmacy for the purpose of obtaining practical experience as a requirement for licensure as a Pharmacist; or
- (c) are qualified applicants awaiting examination for licensure or meeting Board requirements for re-licensure; or
- (d) are participating in a residency or fellowship program; and
- (e) have undergone a state and federal fingerprint-based criminal background check as specified by Board rule.

Section 2. Identification.

The Pharmacy Intern shall be so designated in all his or her professional relationships, and shall in no manner falsely assume, directly or by inference, to be a Pharmacist. The Board shall issue to the Pharmacy Intern a license for purposes of identification and verification of his or her the role of as a Pharmacy Intern, ~~which license shall be surrendered to the Board upon discontinuance of Pharmacy practice experiences for any reason including licensure as a Pharmacist.~~ No individual not properly licensed by the Board as a Pharmacy Intern shall take, use, or exhibit the title of Pharmacy Intern, or any other term of similar like or import.

Section 3. Supervision.

A Pharmacy Intern shall be allowed to engage in the Practice of Pharmacy provided that such activities are under the supervision of a Pharmacist. A Pharmacist shall be actively engaged in the supervision and instruction of the Pharmacy Intern during all professional activities throughout the entire Pharmacy practice experience period. The Pharmacist is responsible for supervising all the Practice of Pharmacy

⁷² See the most recent ACPE standards for professional degree programs leading to a Doctor of Pharmacy degree for Pre-Advanced Pharmacy Practice Experience (Pre-APPE) and Advanced Pharmacy Practice Experience (APPE) Curricula.

It is also encouraged that Boards of Pharmacy allow Pharmacy students to be registered as Pharmacy Interns as early as initial enrollment in a Board-approved professional program as long as the Pharmacy student has begun to take professional degree courses.



activities performed by the Pharmacy Intern, including but not limited to the accurate Dispensing of the Drug.⁷³

Section 4. Notification required.

- (a) All Pharmacy Interns shall notify the Board within 10 days immediately upon change of name, enrollment status, employment, and required contact information such as residential address and/or email address.
- (b) The Pharmacy Intern, excluding those who are currently enrolled in a professional degree program of a school or college of pharmacy approved by the Board and satisfactorily progressing toward meeting the requirements for licensure as a Pharmacist, shall notify the Board of Pharmacy within two weeks of beginning practice as a Pharmacy Intern, in a manner designated by the Board, of the identity of the Pharmacy practice experience site and of the Preceptor.

Section 5. Evidence of Completion.

Applicants for licensure as Pharmacists shall submit, or cause to be submitted, evidence that they have satisfactorily completed: (1) an objective assessment mechanism intended to evaluate achievement of desired competencies; and (2) not less than 1,740 hours of Pharmacy practice experience credit under the instruction and supervision of a Preceptor.⁷⁴

~~Model Standards for Pharmacy Practice Experience Programs~~

~~Section 1. Preceptor.~~

- (a) ~~The Pharmacy Intern, excluding those who are currently enrolled in a professional degree program of a school or college of pharmacy approved by the Board and satisfactorily progressing~~

⁷³ According to the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs, most Pharmacy practice experiences must be under the supervision of a qualified Pharmacist Preceptor licensed in the United States. Realizing that in some cases non-Pharmacist Preceptors can also provide valuable learning opportunities, it is hoped that Boards of Pharmacy recognize these experiences and that schools and colleges of pharmacy ensure, in most cases through faculty, that the desired competencies are being met.

Supervision includes an actual review of the Prescription Drug Order and the dispensed Drug or Product to ensure public protection.

⁷⁴ These requirements coincide with the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs. Boards of pharmacy are strongly encouraged to utilize these Standards of Accreditation as a basis for the establishment and revision of Board standards for Pharmacy practice experiences.

Introductory Pharmacy practice experiences, which are not less than 300 contact hours, are in addition to the advanced practice experiences taken during the final professional year, which account for not less than 25 % of the curricular length or 1,440 contact hours. The total Pharmacy practice experience hour requirement, therefore, is not less than 1,740 hours. Boards may consider moving away from requiring a specific number of contact hours should it be determined that the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs result in appropriate preparation for students and objective assessment mechanisms demonstrate such.



NABP

- toward meeting the requirements for licensure as a Pharmacist, shall notify the Board of Pharmacy within two weeks of beginning practice as a Pharmacy Intern, in a manner designated by the Board, of the identity of the Pharmacy practice experience site and of the Preceptor.
- (b) A Preceptor may be responsible for the training of more than one Pharmacy Intern. The number of Pharmacy Interns engaged in the Practice of Pharmacy at any time is limited to the number of Pharmacy Interns the Pharmacist can appropriately precept as approved by the Board.

Section 2. Pharmacy Practice Experience Programs.⁷⁵

- (a) The Pharmacy at which a Pharmacy Intern is being trained shall provide an environment that is conducive to the learning of the Practice of Pharmacy by a Pharmacy Intern. Pharmacy practice experience sites shall meet the standards approved by the Board.
- (b) Pharmacy practice experience in non-traditional practice sites (eg, industry-sponsored programs) must be approved by the Board of Pharmacy prior to granting of credit.
- (c) When a Pharmacy Intern desires to obtain credit for training received in a state other than this State, the Pharmacy Intern shall abide by all the provisions of the Pharmacy practice experience rules in that state, and shall provide evidence from that state's Board of Pharmacy of the number of clock hours of experience achieved by the Pharmacy Intern.

Section 3. Global Exchange Pharmacy Students.

A Global Exchange Pharmacy Student may participate in observation-only clinical learning experiences, not to exceed _____, provided:

- (a) the Global Exchange Pharmacy Student has been reviewed and qualified by the ACPE-accredited or Board-approved school or college of pharmacy as exists for Introductory Pharmacy Practice Experience (IPPE) and Advanced Pharmacy Practice Experience (APPE) experiential rotations; and
- (b) he or she is under the direct in-person supervision of a Pharmacist.
- +

Model Rules for the Practice of Pharmacy

Section 1. Pharmacy Licensure.

- (a) To obtain a license for a Pharmacy, an applicant shall:

⁷⁵ Boards of pharmacy are strongly encouraged to utilize the ACPE Standards of Accreditation for Doctor of Pharmacy Degree Programs as a basis for the establishment and revision of Board standards for Pharmacy practice experiences.



- (1) have submitted an application in the form prescribed by the Board of Pharmacy;
 - (2) have attained the age of 18 years ~~majority~~; and
 - (3) have paid the fees specified by the Board of Pharmacy for the issuance of the license.
- (b) The facility owner, if an individual, shall have undergone a state and federal fingerprint-based criminal background check ~~as specified by Board rule.~~
- (c) The facility shall have undergone a Pharmacy inspection by the Board or authorized agent thereof; ~~and~~
- (d) The Pharmacy shall have sufficient space, references, equipment, and storage to allow for the safe and proper storage of Prescription Drugs and for the safe and proper Compounding and/or preparing and Dispensing of Prescription Drug Orders. ~~meet the following minimum requirements:~~
- ~~(1) The Pharmacy shall be of sufficient size, as determined by the Board, to allow for the safe and proper storage of Prescription Drugs and for the safe and proper Compounding and/or preparation of Prescription Drug Orders.~~
 - ~~(2) The Pharmacy shall maintain an area designated for the provision of Patient Counseling services. This area shall be designed to provide a reasonable expectation of privacy of Protected Health Information.~~
 - ~~(3) The Pharmacy shall have ready access to references, to include at least one current reference⁷⁶ in each of the following categories, if applicable to the services provided::~~
 - ~~(i) State and Federal Drug laws relating to the Practice of Pharmacy and the legal Distribution of Drugs and any rules or regulations adopted pursuant thereto;~~
 - ~~(ii) pharmacology;~~
 - ~~(iii) dosage and toxicology;~~
 - ~~(iv) veterinary Drugs⁷⁷; and~~
 - ~~(v) general.~~
 - ~~(4) The Pharmacy shall maintain patient-oriented reference material for guidance in proper Drug usage.⁷⁸~~
 - ~~(5) Each Person involved in the development, maintenance, or use of a Drug formulary shall maintain a currently accepted reference containing guidelines for a sound Drug formulary system.~~
 - ~~(6) All areas where Drugs and Devices are stored shall be dry, well lighted, well ventilated, and maintained in a clean and orderly condition. Storage areas shall be maintained at temperatures which will ensure the integrity of the Drugs prior to their Dispensing as stipulated by the United States Pharmacopeia–National Formulary (USP–NF) and/or the Manufacturer’s or Distributor’s Product Labeling unless otherwise indicated by the Board.~~

⁷⁶ ~~Boards may wish to give examples in each of these categories of reference texts.~~

⁷⁷ ~~Such as Plumb’s Veterinary Drug Handbook.~~

⁷⁸ ~~Patient-oriented reference material can include publications such as Facts and Comparisons’ Patient Drug Facts, or the United States Pharmacopoeia Dispensing Information (USPDI).~~



NABP

- ~~(7) The Pharmacy shall have access to a sink with hot and cold running water that is convenient to the Compounding area for the purpose of hand scrubs prior to Compounding.~~
 - ~~(8) The Pharmacy shall carry and utilize the equipment and supplies necessary to conduct a Pharmacy in a manner that is in the best interest of the patients served and to comply with all State and Federal laws.~~
 - ~~(9) The Pharmacy shall provide a means for patients to prevent disclosure of Confidential Information or personally identifiable information that was obtained or collected by the Pharmacist or Pharmacy incidental to the Delivery of Pharmacist Care Services, other than as authorized by law or rules of the Board.~~
 - ~~(10) The Pharmacy, if conducting business over the Internet, shall be accredited by a program approved by the Board⁷⁹.~~
- (e) _____ The Pharmacy, if operating a website or other digital content ~~conducting the Practice of Pharmacy business over the Internet~~, shall be accredited by a program approved by the Board⁸⁰.
- (fe) Upon renewal, the licensee shall provide to the Board the NABP e-Profile ID of the Pharmacy and the Pharmacist-in-Charge.

Section 2. Security.

- (a) ~~Facility~~ Basic Provisions
- (1) Each Pharmacist, while on duty, shall be responsible for the security of the Pharmacy, including provisions for effective control against theft or diversion of Drugs and/or Devices.
 - (2) The Pharmacy shall be secured by either a physical barrier with suitable locks and/or an electronic barrier to detect entry at a time when the Pharmacist is not present. ~~Such barrier shall be approved by the Board of Pharmacy before being put into use.~~ In the event of separation of employment of an employee, ~~for cause, due to any confirmed Drug-related reason, including diversion, or other acts involving dishonesty,~~ suitable action shall be taken to ensure the security of the pharmacy.
 - (3) Prescription and other patient health care information shall be maintained in a manner that protects the integrity and confidentiality of such information ~~as provided by the rules of the Board.~~
 - (4) The Pharmacy shall implement and maintain processes and technologies that will aid in theft prevention, detection, and suspect investigation. ~~apprehension that may include:~~
 - ~~(i) video equipment positioned to identify individuals who may be involved in diversion or theft, if utilized, shall have adequate recording, storage, and retrieval capabilities; and~~
 - ~~(ii) monitored alarm system with backup mechanism.~~

⁷⁹ ~~Boards of Pharmacy are strongly encouraged to recognize the NABP Digital Healthcare Merchant Accreditation or, if a higher standard is desired, Digital Pharmacy Accreditation Approval Program for this purpose.~~

⁸⁰ ~~Boards of Pharmacy are strongly encouraged to recognize the NABP Digital Healthcare Merchant Accreditation or, if a higher standard is desired, the Digital Pharmacy Accreditation Approval Program for this purpose.~~



NABP

- (b) Internal Theft/Diversion Prevention
- (1) ~~the Pharmacist-in-Charge and owner/licensee (facility permit holder) shall ensure policies and procedures are in place that address the following are adopted, implemented, and maintained:~~
- ~~(i) inspection of shipments;~~
 - ~~(ii) receipt verification oversight and checking in shipments;~~
 - ~~(iii) reconciliation of orders; and~~
 - ~~(iv) inventory management including:~~
 - ~~(A) determination of Drugs that need to be monitored and controlled beyond existing systems such as controlled substances and Drugs of Concern; and~~
 - ~~(B) conducting quarterly reconciliations at a minimum, but which shall be more frequent, up to perpetual, depending on the potential for or incidence of diversion for a particular Drug.~~

Section 3. Personnel.

- (a) Pharmacist-in-Charge
- (1) ~~No Business Entity or~~ Person shall operate a Pharmacy without a Pharmacist-in-Charge. A Pharmacist may not serve as Pharmacist-in-Charge unless he or she is engaged physically present in the Pharmacy a sufficient amount of time to provide supervision and control. A Pharmacist may ~~not~~ serve as Pharmacist-in-Charge for more than one Pharmacy at any one time ~~except~~ upon obtaining ~~written~~ permission from the Board.
- (2) The Pharmacist-in-Charge has the following responsibilities:
- ~~(i) Developing or adopting, implementing, and maintaining:⁸¹~~
 - ~~(A) Policies and procedures addressing the following:~~
 - ~~(a) the provision of Pharmacy services;⁸²~~
 - ~~(b) the procurement, storage, security, and disposition of Drugs and Devices, particularly controlled substances and Drugs of Concern;~~
 - ~~(c) computerized record-keeping systems;~~
 - ~~(d) Automated Pharmacy Systems;~~
 - ~~(e) preventing the illegal use or disclosure of Protected Health Information, or verifying the existence thereof and ensuring that all employees of the Pharmacy read, sign, and comply with such established policies and procedures;~~

⁸¹ The owner and/or pharmacy permit holder, along with the Pharmacist in Charge, are responsible for these policies and procedures.

⁸² The Pharmacist in Charge, as part of the responsibilities to manage as effectively as possible a patient's therapy to avoid a harmful interruption of therapy because of a shortage or limited Distribution of Drugs, can proactively improve Pharmacy operations by developing a systematic approach to address such circumstances. References such as the American Society of Health System Pharmacists (ASHP) Guidelines in Managing Drug Product Shortages could be used as resources for developing policies and procedures if appropriate. Additionally, Food and Drug Administration maintains a list of current and resolved Drug shortages, as well as discontinued Drugs on the agency's Drug Shortages Web page at www.fda.gov/cder/drug/shortages.



- ~~(-ef-)~~ operation of the Pharmacy in the event of a fire, flood, pandemic, or other natural or man-made disaster or emergency, to the extent that the Pharmacy can be safely and effectively operated and the Drugs contained therein can be safely stored and Dispensed. Such policies and procedures shall include reporting to the Board the occurrence of any fire, flood, or other natural or man-made disaster or emergency within 10 days of such occurrence⁸³;
- ~~(-g-)~~ the proper management of Drug recalls which may include, where appropriate, contacting patients to whom the recalled Drug Product(s) have been Dispensed;
- ~~(-h-)~~ the duties to be performed by pharmacy personnel. The duties and responsibilities of these personnel shall be consistent with their education, training, experience, and license and shall address the method and level of necessary supervision specific to the practice site.
- ~~(-i-)~~ actions to be taken to prevent and react to pharmacy robberies and thefts, including but not limited to coordinating with law enforcement, training, mitigation of harm, and protecting the crime scene.
- ~~(-j-)~~ restrictions and control over and access to the locks, barriers, and systems used to secure the pharmacy and pharmacy systems in accordance with state laws and regulations.
- ~~(-k-)~~ The prevention and detection of Drug diversion.⁸⁴
- ~~(B)~~ Policies and procedures that address the following activities related to prescription Drug shipment by mail or common carrier:
 - ~~(-a-)~~ properly transferring prescription information to an alternative Pharmacy of the patient's choice in situations where the Drug is not Delivered or Deliverable;
 - ~~(-b-)~~ verifying that common carriers have in place security provisions, such as criminal background checks and random drug screens on its employees who have access to prescription Drugs;
 - ~~(-c-)~~ tracking all shipments; and

⁸³ States should recognize that hospitals, in order to prepare for a disaster or emergency, may be stocking emergency supplies of Drugs in areas outside the licensed pharmacy. Hospitals should be encouraged to expand the space allotted to the licensed pharmacy area to accommodate the need to store emergency supplies.

⁸⁴ The Pharmacist-in-Charge, if the practice setting warrants, may also consider implementing diversion prevention and detection policies and procedures that address the following: periodic reviews of employee access to any secure controlled substance storage areas, which may include:

- alarm codes and lock combinations;
- passwords; and
- keys and access badges.



NABP

- ~~(d) — ensuring that Drugs do not become adulterated in transit.~~
- ~~(C) — Quality assurance programs addressing the following:~~
 - ~~(a) — Pharmacy services. The quality assurance program should be designed to objectively and systematically monitor and evaluate the quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems;~~
 - ~~(b) — Automated Pharmacy Systems. The quality assurance program should monitor the performance of the Automated Pharmacy System, ensure the Automated Pharmacy System is in good working order and accurately Dispenses the correct strength, dosage form, and quantity of the Drug prescribed, while maintaining appropriate record keeping and security safeguards.~~
- (ii) Ensuring that all Pharmacists, Pharmacy Interns, Certified Pharmacy Technicians, and Certified Pharmacy Technician Candidates employed at the Pharmacy are currently licensed by the Board of Pharmacy.⁸⁵
- (iii) Notifying the Board of Pharmacy, as required, ~~immediately and in writing~~, of any of the following⁸⁶ changes:
 - (A) change of employment or responsibility as the Pharmacist-in-Charge;
 - (B) the separation of employment of any Pharmacist, Pharmacy Intern, Certified Pharmacy Technician Candidate, or Certified Pharmacy Technician for any confirmed Drug-related reason, including but not limited to, Adulteration, abuse, theft, or diversion, and shall include in the notice the reason for the termination: if it is the employment of the Pharmacist-in-Charge that is terminated, the owner and/or pharmacy permit holder shall notify the Board of Pharmacy;
 - (C) change of ownership of the Pharmacy;
 - (D) change of address of the Pharmacy;
 - (E) permanent closing of the Pharmacy;
 - (F) Significant Quality-Related Events;
 - (G) the installation or removal of Automated Pharmacy Systems. Such notice must include, but is not limited to:

⁸⁵While it is strongly encouraged that all Pharmacy personnel be licensed, there may still be jurisdictions that allow non-licensed individuals, such as cashiers, to work in a Pharmacy, and in such instances the Pharmacist-in-Charge is responsible for their supervision.

⁸⁶ If states require the Pharmacist-in-Charge or other Person in charge of the Pharmacy to submit information regarding the separation of employment of licensees, especially in circumstances of suspected or confirmed abuse, theft, or diversion of Drugs, states should also be aware of confidentiality and employment laws that may restrict the release of information and be cautioned that the release of such information may create a liability for the reporting Pharmacy.

In instances where the Pharmacist-in-Charge and the owner and/or pharmacy permit holder are the same Person and that Person is no longer employed or designated as the Person in charge, then the Board must take action to cease operation of the Pharmacy.



NABP

- (-a-) the name and address of the Pharmacy;
 - (-b-) the location of the Automated Pharmacy System; and
 - (-c-) the identification of the responsible Pharmacist.
 - (-d-) Such notice must occur prior to the installation or removal of the system.
- (iv) Making or filing any reports required by state or federal laws and rules.
- (v) Reporting any theft, suspected theft, diversion, or other Significant Loss of any Prescription Drug within one business day of discovery to the Board of Pharmacy and as required by Drug Enforcement Administration (DEA) or other State or federal agencies for Prescription Drugs and controlled substances.
- (vi) Responding to the Board of Pharmacy regarding any minor violations ~~brought to his or her attention.~~
- (3) The Pharmacist-in-Charge shall be assisted by a sufficient number of Pharmacists, Certified Pharmacy Technicians, and Certified Pharmacy Technician Candidates as may be required to competently and safely provide Pharmacy services.
 - (i) ~~The Pharmacist in Charge shall maintain and file with the Board of Pharmacy, on a form provided by the Board, a current list of all Certified Pharmacy Technicians and Certified Pharmacy Technician Candidates assisting in the provision of Pharmacy services.~~
 - (ii) The Pharmacist-in-Charge shall develop or adopt, implement, and maintain written policies and procedures to specify the duties to be performed by Certified Pharmacy Technicians and Certified Pharmacy Technician Candidates. The duties and responsibilities of these personnel shall be consistent with their education, training, and experience and shall address the method and level of necessary supervision specific to the practice site.
 - (iii) ~~The Pharmacist-in-charge shall develop or adopt, implement, and maintain a Certified Pharmacy Technician training program that is site-specific to the practice setting of which he or she the Pharmacist is in charge for all individuals employed by the Pharmacy, who will assist in the Practice of Pharmacy. The Pharmacist in Charge shall utilize a Certified Pharmacy Technician training manual as part of the training program. The Pharmacist in Charge shall be responsible for maintaining a record of all Certified Pharmacy Technicians and Certified Pharmacy Technician Candidates successfully completing a site-specific training program and an objective assessment mechanism. The Pharmacist in Charge shall attest to the Board of Pharmacy, in a timely manner, those persons who, from time to time, have met the training requirements necessary for licensure by the Board.~~⁸⁷

(b) Professional Performance Evaluation

⁸⁷ All training programs should be subject to approval by the Board of Pharmacy.



NABP

Each Pharmacist who performs any of the acts described within the definition of “Practice of Pharmacy” is responsible for ensuring that he or she is the subject of a Professional Performance Evaluation at least once each year. Each Pharmacy is responsible for ensuring that every Pharmacist who practices at the Pharmacy for more than 40 hours during any twelve (12)-month period and who performs any of the acts described within the definition of “Practice of Pharmacy” is the subject of a Professional Performance Evaluation at least once each year.

(b) Policies and Procedures.

The Pharmacist-in-Charge is responsible for developing or adopting, implementing, and maintaining⁸⁸ policies and procedures addressing the following:

- (1) the provision of Practice of Pharmacy services;⁸⁹
- (2) the procurement, storage, security, and disposition of Drugs and Devices, particularly controlled substances and Drugs of Concern;
- (3) computerized record retention-keeping systems;
- (4) Automated Pharmacy Systems;⁹⁰
- (5) Shared Pharmacy Services;⁹¹
- (6) preventing the illegal use or disclosure of Protected Health Information, or verifying the existence thereof and ensuring that all employees of the Pharmacy read, sign, and comply with such established policies and procedures;
- (7) operation of the Pharmacy in the event of a fire, flood, pandemic, or other natural or man-made disaster or emergency, to the extent that the Pharmacy can be safely and effectively operated and the Drugs contained therein can be safely stored and Dispensed. Such policies and procedures shall include reporting to the Board. the occurrence of any fire, flood, or other natural or man-made disaster or emergency within 10 days of such occurrence⁹²;
- (8) the proper management of Drug recalls which may include, where appropriate, contacting patients to whom the recalled Drug Product(s) have been Dispensed;

⁸⁸ The owner and/or pharmacy permit holder, along with the Pharmacist-in-Charge, are responsible for these policies and procedures.

⁸⁹ The Pharmacist-in-Charge, as part of the responsibilities to manage as effectively as possible a patient’s therapy to avoid a harmful interruption of therapy because of a shortage or limited Distribution of Drugs, can proactively improve Pharmacy operations by developing a systematic approach to address such circumstances. References, such as the American Society of Health-System Pharmacists (ASHP) Guidelines in Managing Drug Product Shortages, could be used as resources for developing policies and procedures if appropriate. Additionally, Food and Drug Administration maintains a list of current and resolved Drug shortages, as well as discontinued Drugs on the agency’s Drug Shortages web page at www.fda.gov/cder/drug/shortages.

⁹⁰ See Section 9. Automated Pharmacy Systems.

⁹¹ See Section Shared Pharmacy Services.

⁹² States should recognize that hospitals, in order to prepare for a disaster or emergency, may be stocking emergency supplies of Drugs in areas outside the licensed pharmacy. Hospitals should be encouraged to expand the space allotted to the licensed pharmacy area to accommodate the need to store emergency supplies.



- (9) the duties to be performed by Pharmacy personnel. The duties and responsibilities of these personnel shall be consistent with their education, training, experience, and license and shall address the method and level of necessary supervision specific to the practice site.
- (10) activities related to prescription Drug shipment by mail or common carrier:
 - (i) properly transferring prescription information to an alternative Pharmacy of the patient's choice in situations where the Drug is not Delivered or Deliverable;
 - (ii) verifying that common carriers have in place security provisions, such as criminal background checks and random drug screens on its employees who have access to prescription Drugs;
 - (iii) tracking all shipments; and
 - (iv) ensuring taking measures to prevent Drugs from becoming Adulterated in transit
- (11) quality assurance programs addressing Pharmacy services and equipment.:
 - (i) Pharmacy services. The quality assurance program should be designed to objectively and systematically monitor and evaluate the quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems;
 - (ii) Automated Pharmacy Systems. The quality assurance program should monitor the performance of the Automated Pharmacy System, ensure the Automated Pharmacy System is in good working order and accurately Dispenses the correct strength, dosage form, and quantity of the Drug prescribed, while maintaining appropriate record keeping and security safeguards.
- (12) activities related to security, internal theft, and diversion, including:
 - (i) inspection of shipments;
 - (ii) receipt verification oversight and checking in shipments;
 - (iii) reconciliation of orders; and
 - (iv) inventory management, including:
 - (A) determination of Drugs that need to be monitored and controlled beyond existing systems such as controlled substances and Drugs of Concern; and
 - (B) conducting quarterly reconciliations at a minimum but shall be more frequent up to perpetual, depending on the potential for or incidence of diversion for a particular Drug.
 - (v) restrictions and control over and access to the locks, barriers, and systems used to secure the pharmacy and pharmacy systems in accordance with state laws and regulations.
 - (vi) actions to be taken to prevent and react to pharmacy robberies and thefts, including but not limited to coordinating with law enforcement, training, mitigation of harm, and protecting the crime scene.



(vii) the prevention and detection of Drug diversion.⁹³

(13) operational aspects of the computerized record-keeping system, including:

(i) examples of all required output documentation provided by the computerized record-keeping system;

(ii) steps to be followed when the computerized record-keeping system is not operational due to scheduled or unscheduled system interruption;

(iii) regular and routine backup file procedures and file maintenance;

(iv) audit procedures, personnel code assignments, and personnel responsibilities; and

(v) a quality assurance mechanism for data entry validation.

(14) the pharmacy Continuous Quality Improvement Program;

(15) compliance with all applicable federal and state law.

(c) Pharmacy Labor Standards/Shift Lengths and Breaks

- (1) A pharmacy licensed under this Act shall not require a Pharmacist, Pharmacist Intern, Certified Pharmacy Technician, or Certified Pharmacy Technician Candidate to work longer than 12 continuous hours in any 24-hour period per day, inclusive of the breaks required under subsection (2).
- (2) A Pharmacist who works 6 continuous hours or longer per day shall be allowed to take, at a minimum, one 30-minute uninterrupted meal break and one 15-minute break during that 6-hour period. If such Pharmacist is required to work 12 continuous hours in any 24-hour period per day, at a minimum, ~~he or she~~ the Pharmacist qualifies for an additional 15-minute break.
- (3) A Pharmacy may, but is not required to, close when a Pharmacist is allowed to take a break under subsection (2). If the Pharmacy does not close, the Pharmacist shall either remain within the Pharmacy or within the establishment in which the Pharmacy is located in order to be available for emergencies. In addition, the following applies:
 - (i) Certified Pharmacy Technicians, Certified Pharmacy Technician Candidates, and Pharmacist Interns authorized by the Pharmacist on duty may continue to perform duties as allowed under this Act;
 - (ii) no duties reserved to Pharmacists and Pharmacist Interns under this Act, or that require the professional judgment of a Pharmacist, may be performed by Certified Pharmacy Technicians or Certified Pharmacy Technician Candidates;
 - (iii) only Prescription Drug Orders that have received final verification ~~by a Pharmacist~~ may be Dispensed while the Pharmacist is on break, except those Prescription Drug Orders

⁹³The Pharmacist-in-Charge, if the practice setting warrants, may also consider implementing diversion prevention and detection policies and procedures that address the following: periodic reviews of employee access to any secure controlled substance storage areas, which may include:

- alarm codes and lock combinations;
- passwords; and
- keys and access badges.

that require counseling by a Pharmacist, including all new Prescription Drug Orders and those refilled Prescription Drug Orders for which a Pharmacist has determined that counseling is necessary and/or is conducted pursuant to counseling laws and/or regulations;⁹⁴ and

(iv) a Pharmacist using his/her professional judgment may waive Subsections (1) and (2).

- (d) If any action of the Pharmacy is deemed to contribute to or cause a violation of any provision of this section, the Board may hold the owner and/or Pharmacy permit holder responsible and/or absolve the Pharmacist-in-Charge from the responsibility of that action.

Section 4. Prescription Drug Order Processing.

- (a) Prescription Drug Order
A Prescription Drug Order shall contain the following information at a minimum:
- (1) full name, date of birth, and street address of the patient
 - (2) name, prescribing Practitioner's license designation, address, and, if required by law or rules of the Board, DEA registration number of the prescribing Practitioner;
 - (3) date of issuance;
 - (4) name, strength, dosage form, and quantity of Drug prescribed;
 - (5) directions for use;
 - (6) refills authorized, if any;
 - (7) if a written Prescription Drug Order, prescribing Practitioner's signature;
 - (8) if an electronically transmitted Prescription Drug Order, prescribing Practitioner's electronic or digital signature;
 - (9) if a hard copy Prescription Drug Order generated from electronic media, prescribing Practitioner's electronic or manual signature. For those with electronic signatures, such Prescription Drug Orders shall be applied to paper that utilizes security features⁹⁵ that will ensure the Prescription Drug Order is not subject to any form of copying and/or alteration.
- (b) Manner of Issuance of a Prescription Drug Order for a controlled substance should comply with federal regulations.⁹⁶
A Prescription Drug Order, to be valid, must be issued for a legitimate medical purpose by a Practitioner acting within the course of legitimate professional practice. The responsibility for the proper prescribing and Dispensing of controlled substances is upon the prescribing

⁹⁴ The pharmacy shall have policies and procedures to ensure that the patient is provided an opportunity to receive counseling.

⁹⁵ Examples of security features for prescription paper include those that prevent copying, such as hidden background words or darker-colored areas of the paper (which, when photocopied appear as black), those that prevent adulteration, such as solvent dye and brownstain features, and those that verify authenticity, such as the incorporation of fluorescent threads or watermarks.

⁹⁶ Electronically transmitted prescriptions should be transmitted from prescriber to Pharmacy with no intervening Persons making illegal alterations that may be considered as engaging in the Practice of Pharmacy without the authority to do so or without being licensed to do so to such prescriptions. Evolving technologies and systems have alleviated previous concerns regarding the routes by which electronic prescriptions are transmitted, but any attempts to return to illegal prescription altering practices will be halted.



Practitioner, but a corresponding responsibility rests with the Pharmacist who fills the prescription.⁹⁷

- ~~(1) A Prescription Drug Order must be communicated to a Pharmacist, or when recorded in such a way that the Pharmacist may review the Prescription Drug Order as transmitted, to a Pharmacy Intern or a Certified Pharmacy Technician, in a licensed Pharmacy. This may be accomplished in one of the following ways. A Prescription Drug Order, including that for a controlled substance listed in Schedules II through V, may be communicated in written or electronic form. A Prescription Drug Order, including that for a controlled substance listed in Schedules III through V, and, in certain situations, that for a controlled substance listed in Schedule II, may be communicated orally (including telephone voice communication),⁹⁸ or issued electronically.^{99, 100}~~
- ~~(2) The Pharmacist shall not dispense a Prescription Drug if the Pharmacist knows or reasonably should know that the Prescription Drug Order was issued solely on the basis of an Internet-based questionnaire, an Internet-based consultation, or a telephonic consultation, all without a valid Patient-Practitioner relationship.~~
- ~~(3) If communicated orally, the Prescription Drug Order shall be immediately reduced to a form by the Pharmacist, the Pharmacy Intern, or the Certified Pharmacy Technician that may be maintained for the time required by laws or rules.~~
- ~~(4) A Prescription Drug Order for a Schedule II controlled substance may be communicated orally only in the following situations and/or with the following restrictions. Otherwise, a Prescription Drug Order for a Schedule II controlled substance must be communicated in written form or issued electronically.
 - ~~(i) A Prescription Drug Order for a Schedule II controlled substance may be communicated by the Practitioner or the Practitioner's agent by way of Electronic Transmission, provided the original written, signed Prescription Drug Order is presented to the Pharmacist for review prior to the actual Dispensing of the controlled substance, except as noted in paragraph (ii) or (iii) of this Section 3(b)(3). The original Prescription Drug Order shall be maintained in accordance with state and federal record-keeping requirements.~~~~

⁹⁷ While Pharmacists have a corresponding responsibility to ensure that a controlled substance is Dispensed only pursuant to a valid Prescription Drug Order written for a legitimate medical purpose, this should not impede patients from receiving legitimately prescribed controlled substances or non-controlled substances, as patient care should be the primary consideration.

⁹⁸ Policies and procedures should also provide guidance for properly identifying agents of the prescribing Practitioner who are trained and competent in communicating Prescription Drug Orders.

⁹⁹ If a state requires prescriptions to be electronically transmitted, it may consider waiving such requirement and allow issuance of paper prescriptions during a State of Emergency, in compliance with Federal Law.

¹⁰⁰ Electronically transmitted prescriptions should be transmitted from prescriber to Pharmacy with no intervening Persons making illegal alterations that may be considered as engaging in the Practice of Pharmacy without the authority to do so or without being Licensed to do so to such prescriptions. Evolving technologies and systems have alleviated previous concerns regarding the routes by which electronic prescriptions are transmitted, but any attempts to return to illegal prescription altering practices will be halted.



- (ii) ~~In the case of an Emergency Situation, a Prescription Drug Order for a Schedule II controlled substance may be communicated by the Practitioner orally, provided that:~~
 - (A) ~~the quantity prescribed and Dispensed is limited to the amount adequate to treat the patient during the emergency period (Dispensing beyond the emergency period must be pursuant to a Prescription Drug Order either written and signed or electronically issued by the prescribing Practitioner);~~
 - (B) ~~the orally communicated Prescription Drug Order shall be immediately reduced to writing by the Pharmacist if necessary, and shall contain the information required by state and federal law;~~
 - (C) ~~if the prescribing Practitioner is not known to the Pharmacist, he or she must make a reasonable effort to determine that the oral authorization came from a registered Practitioner, which may include a callback to the Practitioner using the Practitioner's phone number as listed in the telephone directory and/or other good faith efforts to ensure his or her identity; and~~
 - (D) ~~within seven days after authorizing an emergency oral Prescription Drug Order, the Practitioner shall cause a written Prescription Drug Order for the emergency quantity prescribed to be delivered to the Dispensing Pharmacist. The Prescription Drug Order shall have written on its face "Authorization for Emergency Dispensing," and the date of the orally transmitted Prescription Drug Order. The written Prescription Drug Order may be delivered to the Pharmacist in person or by mail, but if delivered by mail, it must be postmarked within the seven (7)-day period. Upon receipt, the Dispensing Pharmacist shall attach this written Prescription Drug Order to the emergency oral Prescription Drug Order, which had earlier been reduced to writing. The Pharmacist shall notify the nearest office of the DEA if the prescribing Practitioner fails to deliver a written Prescription Drug Order.~~
- (iii) ~~The prescribing Practitioner may authorize his or her agent to communicate~~
 - ~~a Prescription Drug Order orally or by way of Electronic Transmission via facsimile to a Pharmacist in a licensed Pharmacy, provided that the identity of the transmitting agent is included in the order. In an Institutional Facility, the prescribing Practitioner's agent must be authorized by and in accordance with written policies and procedures of the Facility and applicable state and federal laws.~~
- (5) ~~A Prescription Drug Order for a Schedule II narcotic substance to be Compounded for the direct Administration to a patient by parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion may be communicated by the Practitioner or the Practitioner's agent to the Home Infusion Pharmacy via facsimile. The hard copy of such faxed prescription serves as the original, written Prescription Drug Order and it shall be maintained in accordance with state and federal record-keeping requirements.~~
- (6) ~~A Prescription Drug Order for a Schedule II controlled substance for a resident of a Long-Term Care Facility may be communicated by the Practitioner or the Practitioner's agent via~~



~~facsimile. The hard copy of such faxed prescription serves as the original, written Prescription Drug Order and it shall be maintained in accordance with state and federal record-keeping requirements.~~

- ~~(7) All Prescription Drug Orders for a Schedule III-V controlled substance communicated by way of Electronic Transmission via facsimile shall:
 - ~~(i) be transmitted to a Pharmacist, Pharmacy Intern, or Certified Pharmacy Technician in a licensed Pharmacy of the patient's choice;~~
 - ~~(ii) identify the transmitter's phone number or any other suitable means to contact the transmitter for verbal and/or written confirmation, the time and date of transmission, and the identity of the Pharmacy intended to receive the transmission, as well as any other information required by federal or state law;~~
 - ~~(iii) be transmitted by an authorized Practitioner or his or her designated agent; and~~
 - ~~(iv) be deemed the original Prescription Drug Order, provided it meets the requirements of this subsection.~~~~
- ~~(8) All Prescription Drug Orders for a Schedule II-V controlled substance issued and processed electronically shall be in compliance with existing federal or state laws and rules.~~
- ~~(9) The Pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the Prescription Drug Order issued electronically or by facsimile to ensure it is consistent with existing federal or state laws and rules.~~
- ~~(10) All electronic equipment for receipt of Prescription Drug Orders issued electronically or by facsimile shall be maintained so as to ensure against unauthorized access.~~
- ~~(11) Persons other than those bound by a confidentiality agreement shall not have access to Pharmacy records containing Protected Health Information concerning the Pharmacy's patients.~~

...

(d) Drug Product Selection by the Pharmacist

- (1) A Pharmacist Dispensing a Prescription Drug Order for a Drug Product prescribed by its brand name may select any Equivalent Drug Product provided that the Manufacturer or Distributor holds, if applicable, either an approved New Drug Application (NDA) or an approved Abbreviated New Drug Application (ANDA), unless other approval by law or from the Federal Food and Drug Administration is required.
- (2) The Pharmacist shall not select an Equivalent Drug Product if the Practitioner instructs otherwise, either orally or in writing, on the Prescription Drug Order.
- (3) The Pharmacist shall notify the patient or patient's agent if a Drug other than the brand name Drug prescribed is Dispensed.

(e) Labeling

- (1) All Drugs Dispensed to ambulatory or outpatients, including Drugs Dispensed by Practitioners, shall have a Label affixed to the container in which such Drug is Dispensed. The Label shall conform with the USP chapter addressing prescription container labeling.



Section 5. Record Keeping.

(a) Patient Records¹⁰¹

- (1) A patient record system shall be maintained by all Pharmacies and Dispensing Practitioners for patients for whom Prescription Drug Orders are Dispensed. The patient record system shall provide for the immediate retrieval of information necessary for the Dispensing Pharmacist to identify previously Dispensed Drugs at the time a Prescription Drug Order is presented for Dispensing, and be created and stored in a manner to protect against illegal use or disclosure of Protected Health Information. The Pharmacist shall make a reasonable effort to obtain, record, and maintain the following information:
 - (i) full name of the patient for whom the Drug is intended;
 - (ii) street address and telephone number of the patient;
 - (iii) patient's age or date of birth;
 - (iv) patient's gender;
 - (v) a list of the Drugs taken by the patient during the preceding 24 months; and
 - (vi) Pharmacist comments relevant to the individual's Drug therapy, including any other information peculiar to the specific patient or Drug.
- (2) The Pharmacist shall make a reasonable effort to obtain from the patient or the patient's agent and shall record any known allergies, Drug reactions, ~~idiosyncrasies~~, and chronic conditions or disease states of the patient and the identity of any other Drugs, including over-the-counter Drugs or Devices currently being used by the patient which may relate to Prospective Drug Review.
- (3) A patient record shall be maintained for a period of not less than ten years from the date of the last entry in the profile record. This record may be a hard copy or a computerized form.
- ~~(4) Protected Health Information may be used or disclosed as allowed under state and federal privacy rules.~~
- ~~(45) Significant Adverse Drug Reactions~~ Serious Adverse Drug Experiences shall be reported to the Practitioner and an appropriate entry shall be made in the patient's record.

(b) Records of Dispensing/Delivery¹⁰²

¹⁰¹ The Pharmacist should have access to clinical and laboratory data concerning each patient and should monitor each patient's response to ~~his or her~~ Drug therapy. Any unexpected or untoward response should be reported to the prescribing physician. If the Pharmacist is not doing this monitoring, the identity of the health care provider that has assumed this responsibility should be documented in the patient's profile.

It is acceptable for new Prescription Drug Order data to be added to the patient profile, but original entries may not be altered.

¹⁰² If a Board requires the presentation of identification or patient signature in order for a patient to receive prescribed Drugs, it may consider waiving such requirements during a State of Emergency, in compliance with Federal Law.



- (1) Records of receipt, Dispensing, Delivery, Distribution, or other disposition of all Drugs or Devices are to be made in accordance with federal law and kept by Pharmacies for five years¹⁰³ and shall include, but not be limited to:
 - (i) quantity Dispensed for original and refills, if different from original;
 - (ii) date of receipt, Dispensing, Delivery, Distribution, or other disposition;
 - (iii) serial number (or equivalent if an institution);
 - (iv) the identification of the Pharmacist, Certified Pharmacy Technician, or Certified Pharmacy Technician Candidate responsible for Dispensing;
 - (v) name and Manufacturer of Drug Dispensed if Drug Product selection occurs; and
 - (vi) records of refills to date.
 - (2) Pharmacies that ship Drugs by mail, common carrier, or other type of Delivery service shall implement a mechanism to verify that a patient or caregiver has actually received the Delivered Drug.¹⁰⁴
- (c) Electronic Record Keeping
- ~~(1) Systems Policies and Procedures~~
- ~~— An up-to-date policy and procedure manual shall be developed by the Pharmacist in-Charge that explains the operational aspects of the computerized record-keeping system and shall:~~
- ~~(i) include examples of all required output documentation provided by the computerized record-keeping system;~~
 - ~~(ii) outline steps to be followed when the computerized record-keeping system is not operational due to scheduled or unscheduled system interruption;~~
 - ~~(iii) outline regular and routine backup file procedure and file maintenance;~~
 - ~~(iv) outline audit procedures, personnel code assignments, and personnel responsibilities; and~~
 - ~~(v) provide a quality assurance mechanism for data entry validation.~~
- ~~(12) Data Storage and Retrieval.~~
- (i) The system shall provide online retrieval of original Prescription Drug Order information. Such information shall include, but not be limited to, the Prescription Drug Order requirements and records of Dispensing as indicated in Section 3 of this Rule; and
 - (ii) The storage and retrieval of refill information for original paper prescription orders for controlled substances in Schedule III and IV are subject to federal regulations.~~the following conditions:~~

¹⁰³ States should check federal laws and ensure that the number of years the state requires Dispensing records to be maintained are at least as many as federal requirements.

¹⁰⁴ States that require pharmacies that ship Drugs by mail, common carrier, or other type of Delivery service to implement a mechanism to verify that the patient or caregiver has actually received the Delivered Drug may want to consider allowing the mechanism to include a waiver provision that allows the patient or caregiver to request Delivery without verification and advises the patient or caregiver of the possible consequences of receiving Delivery without verification.



- (A) The system must provide online retrieval of original prescription order information for those prescription orders that are currently authorized for refilling. This shall include, but is not limited to, data such as the original prescription number; date of issuance of the original prescription order by the Practitioner; full name and address of the patient; name, address, and DEA registration number of the Practitioner; and the name, strength, dosage form, quantity of the controlled substance prescribed (and quantity dispensed if different from the quantity prescribed), and the total number of refills authorized by the prescribing Practitioner;
- (B) The system must also provide online retrieval the current refill history for Schedule III or IV controlled substance prescription orders (those authorized for refill during the past six months). This refill history shall include, but is not limited to, the name of the controlled substance, the date of refill, the quantity Dispensed, the identification code, or name or initials of the Dispensing Pharmacist for each refill and the total number of refills Dispensed to date for that prescription order;
- (C) Documentation of the fact that the refill information entered into the computer each time a Pharmacist refills an original prescription order for a Schedule III or IV controlled substance is correct must be provided by the individual pharmacist who makes use of such an application. If such an application provides a hard copy printout of each day's controlled substance prescription order refill data, that printout shall be verified, dated, and signed by the individual Pharmacist who refilled such a prescription order. The individual Pharmacist must verify that the data indicated are correct and then sign this document in the same manner as he would sign a check or legal document (eg, J.H. Smith, or John H. Smith). This document shall be maintained in a separate file at that Pharmacy for a period of two years from the Dispensing date. This printout of the day's controlled substance prescription order refill data must be provided to each Pharmacy using such a computerized application within 72 hours of the date on which the refill was Dispensed. It must be verified and signed by each Pharmacist who is involved with such dispensing. In lieu of such a printout, the Pharmacy shall maintain a bound logbook, or separate file, in which each individual Pharmacist involved in such Dispensing shall sign a statement (in the manner previously described) each day, attesting to the fact that the refill information entered into the computer that day has been reviewed by him or her and is correct as shown. Such a book or file must be maintained at the pharmacy employing such an application for a period of two years after the date of Dispensing the appropriately authorized refill;
- (D) The electronic record-keeping system shall have the capability of producing a printout of any Prescription Drug Order data. The system shall provide a refill by-



~~refill audit trail for any specified strength and dosage form of any Drug. Such an audit trail shall be by printout, and include the name of the prescribing Practitioner, name and location of the patient, quantity Dispensed on each refill, date of Dispensing of each refill, name or identification code of the Dispensing Pharmacist, and unique identifier of the Prescription Drug Order; and~~

~~(E) Any facility maintaining centralized prescription records shall be capable of sending a requested printout to the Pharmacy within 48 hours.~~

~~(iii) if a prescription is created, signed, transmitted, and received electronically, all records related to that prescription must be retained electronically and are subject to the following:~~

~~(A) records must be maintained electronically for _____ years from the date of their creation or receipt;~~

~~(B) records regarding controlled substances prescriptions must be readily retrievable from all other records. Electronic records must be easily readable or easily rendered into a format that a person can read;~~

~~(C) records required by this section part must be made available to the state and federal agencies upon request;~~

~~(D) if the Pharmacy discontinues or changes the electronic prescription service provider or transfers the electronic Prescription Drug Order records to another Pharmacy, the Pharmacy must ensure that the records are stored in a format that can be retrieved, displayed, and printed in a readable format; and~~

~~(E) digitally signed prescription records must be transferred or migrated with the digital signature.~~

(23) Security

To maintain the confidentiality of patient records, the system shall have adequate security and systems safeguards designed to prevent and detect unauthorized access, modification, or manipulation of patient records. Once the Drug has been Dispensed, any alterations in Prescription Drug Order data shall be documented, including the identification of the Pharmacist responsible for the alteration.

(34) System Backup (Auxiliary Records Maintenance)

(i) In the event of an unscheduled system interruption, sufficient patient data and Prescription Drug Order data should be available to permit reconstruction of such data as soon as possible ~~within a two-hour time period~~ for the Pharmacist to Dispense Drugs with sound professional judgment.

(ii) An auxiliary system shall be established for the documentation of refills if the automated data processing system is inoperative for any reason and to ensure that all refills are authorized by the original Prescription Drug Order and that the maximum number of refills is not exceeded.

(iii) The auxiliary system shall be in place to provide for the maintenance of all necessary patient Drug information (as outlined in this rule) until the automated system

becomes operational. However, nothing in this section shall preclude the Pharmacist from using professional judgment for the benefit of a patient's health and safety.

- (iv) When the automated system is restored to operation, the information regarding Prescription Drug Orders Dispensed and refilled during the inoperative period shall be entered into the automated system as soon as possible. ~~within 96 hours.~~
- (v) Routine backup systems and procedures (hard copy, copy, disk, etc) shall be in place and operational to ensure against loss of patient data.
- (vi) In the event that permanent Dispensing information is lost due to unscheduled system interruption, the Board of Pharmacy shall be notified as soon as possible. ~~within 24 hours~~

Section 6. Pharmacist Care Services.

~~Pharmacist Care Services may include, but are not limited to, Patient assessment and evaluation; assessing health plan and Drug eligibility and coverage; Prescribing and Administering Drugs, Devices, vaccines, or biologicals; Prescribing and Dispensing for emergency use¹⁰⁵; performing Peer Review and peer consultations; reviewing, selecting, and developing formularies or plan/practice guidelines; performing therapeutic substitution¹⁰⁶; consulting with other health care professionals; providing patient referrals; performing Medication Therapy Management; ordering and performing Clinical Laboratory Improvement Amendments of 1988-waived lab tests and prescribing associated Drugs and Biologicals¹⁰⁷; as provided by State and Federal law, and reporting results and follow-up treatment.~~

- (a) Pharmacist Care Services are services intended to achieve patient outcomes related to the treatment or prevention of disease, elimination or reduction of symptoms, and promotion of health and wellness.¹⁰⁸ Pharmacist Care Services include but are not limited to:
 - (1) Drug Utilization Review
 - (2) Medication Adherence Monitoring Service
 - (3) emergency use Prescribing and Dispensing¹⁰⁹
 - (4) Medication therapy management (MTM)
 - (5) reviewing, selecting, and developing formularies and/or practice guidelines

¹⁰⁵ Pharmacist may prescribe drugs for emergency use pursuant to specific statewide protocols or standing orders.

¹⁰⁶ Providing it is within the same FDA drug class and not prohibited by the prescriber.

¹⁰⁷ Pharmacist may prescribe associated Drugs pursuant to specific statewide protocols or standing orders.

¹⁰⁸ ~~Pharmacist Care Services should be provided by all Pharmacists within the Standard of Care to the extent of their abilities regardless of the practice setting.~~

¹⁰⁹ Pharmacist may prescribe Drugs for Emergency Use pursuant to specific statewide protocols or standing orders.



- (6) performing drug product selection, substitution, Therapeutic Interchange¹¹⁰prescription adaptation or continuation of therapy,
- (7) ordering, interpreting laboratory tests, and performing Clinical Laboratory Improvement Amendments-waived¹¹¹ lab tests.

(a**b**) **Prospective Drug Utilization Review (DUR)¹¹²**

A Pharmacist shall obtain and review the patient records and medical history for each Prescription Drug Order for:

- (1) known allergies;
- (2) rational therapy contraindications;
- (3) reasonable dose, duration of use, and route of Administration, considering age, gender, and other patient factors;
- (4) reasonable directions for use;
- (5) potential or actual adverse Drug reactions;
- (6) Drug-Drug interactions;
- (7) Drug-food interactions;
- (8) Drug-disease contraindications;
- (9) therapeutic duplication;
- (10) proper utilization (including over- or under-utilization), and optimum therapeutic outcomes; and
- (11) abuse/misuse.

Upon recognizing any of the above, which may also include information obtained from reviewing data found in the prescription monitoring program, the Pharmacist shall take appropriate steps to avoid or resolve the problem which, if necessary, includes consultation with the Practitioner.

(b**c**) **Patient Counseling¹¹³**

- (1) Upon receipt of a Prescription Drug Order and following a review of the patient's record, a Pharmacist shall ~~personally initiate~~ engage in discussion of matters which will enhance or optimize Drug therapy with each patient or caregiver of such patient. Such discussion shall be in Person, whenever practicable, or by telephone or other audio/visual means of ~~electronic~~ communication and shall include appropriate elements of Patient Counseling. Such elements may include the following:

¹¹⁰ Provided it is within the same FDA Drug class and not prohibited by the prescriber.

¹¹¹ Most recent version

¹¹² Pharmacists should be permitted to use computer software, if available, to accomplish this review.

¹¹³ The intent of this Section is to require that the Pharmacist personally initiate counseling for all new Prescriptions and to exercise ~~his or her~~ professional judgment for refills. Situations may arise, however, where the prescriber specifically indicates that a patient should not be counseled. In such circumstances, it is the responsibility of the Pharmacist to provide the best patient care through appropriate communication with the prescriber and to document the reason(s) for not providing counseling to the patient.



NABP

- (i) the name and description of the Drug;
 - (ii) the dosage form, dose, route of Administration, and duration of Drug therapy;
 - (iii) intended use of the Drug and expected action;
 - (iv) special directions and precautions for preparation, Administration, and use by the patient;
 - (v) common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur;
 - (vi) techniques for self-monitoring Drug therapy;
 - (vii) proper storage and appropriate disposal method(s) of unwanted or unused medication;
 - (viii) prescription refill information;
 - (ix) action to be taken in the event of a missed dose; and
 - (x) Pharmacist comments relevant to the individual's Drug therapy, including any other information peculiar to the specific patient or Drug.
- (2) An offer for Patient Counseling can be made by a Certified Pharmacy Technician or Certified Pharmacy Technician Candidate ~~when it is not required by law or deemed necessary that it be done by the Pharmacist.~~
- (3) Alternative forms of patient information may be used to supplement Patient Counseling when appropriate. Examples include written information leaflets, pictogram labels, video programs, etc.
- (4) Patient Counseling, as described above and defined in this Act, shall not be required for inpatients of a hospital or institution where other licensed health care professionals are authorized to Administer the Drug(s).
- (5) A Pharmacist shall not be required to counsel a patient or caregiver when the patient or caregiver refuses such consultation.
- (~~de~~) Medication Adherence Monitoring Services and Patient Intervention Programs, Medication Adherence Monitoring Services and Patient Intervention Programs designed to promote improved medication use behaviors, such as compliance and adherence, appropriate monitoring and self-reporting, increased patient knowledge, and improved therapy options, shall comply with federal and state law addressing the privacy of Protected Health Information.
- (~~de~~) Collaborative Pharmacy Practice
- (1) Collaborative Pharmacy Practice Agreement
- A Pharmacist planning to engage in Collaborative Pharmacy Practice shall have on file at ~~his or her~~ their place of practice the ~~written~~ Collaborative Pharmacy Practice Agreement. ~~The initial existence and subsequent termination of any such agreement and a~~ Any additional information the Board may require concerning the Collaborative Pharmacy Practice Agreement, including the agreement itself, shall be made available to the Board for review upon request. The Agreement may allow the Pharmacist, within the Pharmacist's Scope of



Practice Pursuant to the Collaborative Pharmacy Practice Agreement, to conduct activities approved by the Practitioner in good standing, and as defined by law and by the Rules of the Board. The collaboration that the Practitioner agrees to conduct with the Pharmacist must be within the scope of the Practitioner's current practice. ~~Patients or caregivers shall be advised of such agreement.~~

(2) Contents

The Collaborative Pharmacy Practice Agreement shall include:

- (i) identification of the Practitioner(s) and Pharmacist(s) who are parties to the Agreement;
- (ii) the types of decisions that the Pharmacist is allowed to make;
- (iii) a process for generating any necessary Medical Orders, including Prescription Drug Orders, required to initiate allowed activities;
- (iv) a method for the Practitioner to monitor compliance with the Agreement and clinical outcomes and to intercede where necessary;
- (v) a description of the Continuous Quality Improvement Program used to evaluate effectiveness of patient care and ensure Positive Patient Outcomes;
- (vi) a provision that allows the Practitioner to override a Collaborative Practice decision made by the Pharmacist whenever ~~he or she~~ the Pharmacist deems it necessary or appropriate;
- (vii) a provision that allows either party to cancel the Agreement by written notification;
- (viii) an effective date;
- (ix) signatures of all collaborating Pharmacists and Practitioners who are party to the Agreement, as well as dates of signing; and
- (x) a procedure for periodic review and renewal within a time frame that is clinically appropriate.

(3) Amendments to a Collaborative Pharmacy Practice Agreement must be documented, signed, and dated.

(4) Documentation of Pharmacist Activities

Documentation of allowed activities must be kept as part of the patient's permanent record and be readily available to other health care professionals who are providing care to that patient and who are authorized to receive it. ~~Documentation of allowed activities shall be considered Protected Health Information.~~

(f) Emergency use Prescribing and Dispensing

Prescribing and Dispensing Drugs for emergency use shall be pursuant to a Pharmacist-issued Prescription and include appropriate Patient Counseling. Drugs or Devices for emergency use include, but are not limited to:

- (1) Opioid overdose reversal agents, such as naloxone;
- (2) Epinephrine;
- (3) Antidote kits;
- (4) Short-acting beta agonist inhalers; and



- (5) Medication for Opioid Use Disorder-assisted Treatment for the purpose of initiating therapy for opioid use disorder. The Pharmacist must:
- (i) obtain a DEA registration and a state controlled substance license or registration, if required; and
 - (ii) use professional judgment to assess the clinical appropriateness of the patient's request and the length of time until the patient obtains treatment from an authorized Practitioner.¹¹⁴
- (g) Emergency Refills
- A Pharmacist may ~~Prescribe~~ authorize and Dispense a refill of a Prescription Drug, ~~not to exceed a thirty (30) day supply,~~ without Practitioner authorization if:^{115, 446}
- (1) in the Pharmacist's professional judgment, the Prescription Drug is essential to the maintenance of the Patient's life or to the continuation of therapy;
 - (2) the Pharmacist makes a good faith effort to reduce the information to a form that may be maintained for the time required by law or rule, indicates it is an "Emergency Refill Prescription," and maintains the record as required by state and federal law, as well as state and federal disaster agencies for consideration for possible reimbursement programs implemented to ensure continued provision of care during a disaster or emergency;
 - (3) the Pharmacist informs the Patient or the Patient's agent at the time of Dispensing that the Prescription Drug is being provided without the Practitioner's authorization and that authorization of the Practitioner is required for future refills; and
 - (4) the Pharmacist informs the Prescriber of the emergency refill as soon as practicable.
- Unit-of-use quantities may be dispensed when appropriate.

Section 7. Continuous Quality Improvement Program.

- (a) Continuous Quality Improvement Program
- (1) Compliance with this section may be considered by the Board as a mitigating factor in the investigation and evaluation of a Quality-Related Event (QRE).
 - (2) Each Pharmacy shall establish a Continuous Quality Improvement (CQI) Program for the purpose of detecting, documenting, assessing, and preventing QREs. At a minimum, a CQI Program shall include provisions to:
 - (i) designate an individual or individuals responsible for implementing, maintaining, and monitoring the CQI Program; ~~which is managed in accordance with written policies and procedures maintained in the pharmacy in an immediately retrievable form;~~

¹¹⁴ It is contemplated that for long-term treatment, Pharmacists should be prescribing under a collaborative practice agreement rather than under an emergency use provision.

¹¹⁵ Boards may consider contacting the US Drug Enforcement Administration ahead of time to ensure these provisions are applicable to controlled substances.

⁴⁴⁶ ~~Boards may consider extending beyond a thirty (30) day supply.~~



- (ii) initiate documentation of QREs as soon as possible, but no more than three days, after determining their occurrence;
 - (iii) analyze data collected in response to QREs to assess causes and any contributing factors such as staffing levels, workflow, and technological support;
 - (iv) use the findings of the analysis to formulate an appropriate response and develop pharmacy systems and workflow processes designed to prevent QREs and increase good outcomes for patients;
 - ~~(v) provide ongoing CQI education at least annually to all pharmacy personnel;~~
 - (vi) for those Persons utilizing a Drug formulary, a periodic review of such formulary shall be undertaken to ensure that appropriate Drugs are being offered/selected in the best interest of patients.
- (3) As a component of its CQI Program, each Pharmacy shall ensure that periodic meetings are held, at least annually, by staff members of the Pharmacy to consider the effects on quality of the Pharmacy system due to staffing levels, workflow, and technological support. Such meetings shall review data showing evidence of the quality of care for patients served by the Pharmacy and shall develop plans for improvements in the system of Pharmacy Practice so as to increase good outcomes for patients.
- (4) Appropriately-blinded incidents of QREs shall be reported to a nationally recognized error reporting program designated by the Board.
- (5) Quality Self-Audit
Each Pharmacy shall conduct a Quality Self-Audit at least quarterly to determine whether the occurrence of QREs has decreased and whether there has been compliance with preventative procedures, and to develop a plan for improved adherence with the CQI Program in the future. Each pharmacy shall conduct a Quality Self-Audit upon change of Pharmacist-in-Charge to familiarize that Person with the Pharmacy's CQI Program.
- ~~(6) Consumer Survey~~
~~As a component of its CQI Program, each Pharmacy should conduct a Consumer Survey of patients who receive Drug Products and services at the Pharmacy. A Consumer Survey should be conducted at least once per year. A statistically valid sampling technique may be used in lieu of surveying every patient. Each Pharmacy should use the results of its Consumer Survey to evaluate its own performance at a particular time and over a period of time.~~
- (67) Protection from Discovery¹¹⁷
All information, communications, or data maintained as a component of a pharmacy CQI Program are privileged and confidential and not subject to discovery in civil litigation¹¹⁸.

¹¹⁷ Boards of pharmacy may have more or less authority to inspect CQI records, depending on state law. When authorizing the implementation of CQI Programs the extent of authority needed to obtain these materials must be determined.

¹¹⁸ States should continue efforts to develop and implement requirements for CQI programs in pharmacies recognizing that CQI programs enhance patient safety and operate most effectively when privilege of discovery laws or rules protecting CQI data and information are enacted and included as a component of CQI.



This shall not prevent review of a pharmacy's CQI Program and records maintained as part of a system by the Board, pursuant to subpoena, as necessary to protect the public health and safety. All information, communications, or data furnished to any Peer Review Committee, and any findings, conclusions, or recommendations resulting from the proceedings of such committee, board, or entity are privileged. The records and proceedings of any Peer Review Committee, are confidential and shall be used by such committee, and the members thereof, only in the exercise of the proper functions of the committee and shall not be public records nor be available for court subpoena or for discovery proceedings. The disclosure of confidential, privileged Peer Review Committee information during advocacy, or as a report to the Board of Pharmacy, or to the affected Pharmacist or Pharmacy auxiliary personnel under review does not constitute a waiver of either confidentiality or privilege.

(78) Compliance with Subpoena

All persons shall comply fully with a subpoena issued by the Board for documents or information as otherwise authorized by law. The disclosure of documents or information under subpoena does not constitute a waiver of the privilege associated with a CQI Program. Failure to comply with the subpoena is grounds for disciplinary action against the Person by the appropriate licensing board.

Section 8. Shared Pharmacy Services.

(a) General Requirements^{119, 120}

- (1)** The Pharmacy must possess a resident or nonresident permit issued by the Board prior to engaging in Shared Pharmacy Services.¹²¹
- (2)** A Pharmacy may provide or utilize Shared Pharmacy Services only if the Pharmacies involved:
 - (i)** have the same owner; or
 - (ii)** have a written contract or agreement that outlines the services provided and the shared responsibilities of each Pharmacy in complying with federal and state pharmacy laws and rules; and
 - (iii)** share a common electronic file or technology that allows access to information necessary or required to perform Shared Pharmacy Services in conformance with the Pharmacy Act and the Board's rules.

¹¹⁹ The Board may want to consider the extent to which this General Requirements Section is applicable to institutional-based Shared Pharmacy Services Pharmacies, as such application may be subject to interpretation of existing state and federal law governing Institutional Facilities.

¹²⁰ In order to ensure accountability, the Pharmacist-in-Charge of a Pharmacy engaging in Shared Pharmacy Services must possess a license to practice Pharmacy in all jurisdictions that he/she is engaging in such series until such a time in which provisions for multistate practice exist.

¹²¹ Often the terms "licensure," "registration," and "permit" are used interchangeably throughout the *Model Act*. In the case of Shared Pharmacy Services Pharmacies that utilize Automated Pharmacy Systems, Boards may determine that it is appropriate to issue a permit for the Automated Pharmacy System but not for the physical site where the Automated Pharmacy System is located.



- (3) A Pharmacy engaged in Shared Pharmacy Services shall comply with appropriate federal and state controlled substance registrations for each Pharmacy if controlled substances are maintained.
 - (4) ~~A Pharmacy engaged in Shared Pharmacy Services shall notify the Board in writing within 10 days of a change of location, discontinuance of service, or closure of a Pharmacy.~~
- (b) Operations
- (1) Pharmacies engaging in Shared Pharmacy Services, or a Pharmacist acting independently of a Pharmacy and participating in Shared Pharmacy Services shall:
 - (i) maintain records identifying, individually, for each Prescription Drug Order processed, the name of each Pharmacist or Pharmacy Intern who took part in the Drug Utilization Review, refill authorization, or therapeutic intervention functions performed at that Pharmacy and the name of any Certified Pharmacy Technician or Certified Pharmacy Technician Candidate if they assisted in any of those functions;
 - (ii) maintain records identifying individually, for each Prescription Drug Order filled or Dispensed, the name of each Pharmacist or Pharmacy Intern who took part in the filling, Dispensing, and counseling functions performed at that Pharmacy and the name of any Certified Pharmacy Technician or Certified Pharmacy Technician Candidate if they assisted in any of those functions;
 - (iii) report to the Board as soon as practical the results of any disciplinary action taken by another state's Board of Pharmacy involving Shared Pharmacy Services;
 - (iv) maintain a mechanism for tracking the Prescription Drug Order during each step of the processing and filling procedures performed at the Pharmacy;
 - (v) maintain a mechanism for the patient to identify all Pharmacies involved in filling the Prescription Drug Order; and
 - (vi) be able to obtain for inspection any required record or information within 72 hours of any request by the Board or its designee.
 - ~~(2) Notification to Patients~~
 - ~~(i) Pharmacies engaging in Shared Pharmacy Services shall notify patients that their Prescription Drug Orders may be processed or filled by another Pharmacy unless the Prescription Drug is delivered to patients in Institutional Facilities where a licensed health care professional is responsible for administering the Prescription Drug to the patient.~~
- (c) Drug Storage and Security
- (1) Drugs shall be stored in compliance with state and federal laws and in accordance with these Rules, including those addressing temperature, proper containers, and the handling of outdated drugs.
 - ~~(2) Drugs stored at Shared Pharmacy Services Pharmacies shall be stored in an area that is:~~
 - ~~(i) separate from any other Drugs used by the health care facility; and~~
 - ~~(ii) secured, so as to prevent access by unauthorized personnel.~~



- (3) Access to the area where Drugs are stored at the Shared Pharmacy Services Pharmacy must be limited to:
 - (i) Pharmacists, Certified Pharmacy Technicians, Certified Pharmacy Technician Candidates, or Pharmacy Interns who are employed by the Shared Pharmacy Services Pharmacy; or
 - (ii) Personnel employed at the Institutional Facility or clinic where the Shared Pharmacy Services Pharmacy is located who:
 - (A) are licensed health care providers;
 - (B) ~~are designated in writing~~ are documented by the Pharmacist-in-Charge or the Person responsible for the supervision and on-site operation of the facility where the ~~Automated Pharmacy System~~ Shared Services Pharmacy is located; and
 - (C) have completed documented training concerning their duties associated with the Shared Pharmacy Services Pharmacy.
- (4) Shared Pharmacy Services Pharmacies shall have adequate security to:
 - (i) comply with federal and state laws and regulations; and
 - (ii) Protect the confidentiality and integrity of Protected Health Information.
- (d) Policies and Procedures
 - (1) Each Pharmacy in Shared Pharmacy Services shall jointly develop, implement, review, revise, and comply with joint policies and procedures for Shared Pharmacy Services. Each Pharmacy is required to maintain the portion of the joint policies and procedures that relate to that Pharmacy's operations. The policies and procedures shall:
 - (i) outline the responsibilities of each Pharmacy;
 - (ii) include a list of the name, address, telephone numbers, and all license and permit numbers of the pharmacies involved in Shared Pharmacy Services; and
 - (iii) include ~~policies and procedures~~ processes for:
 - (A) notifying patients that their Prescription Drug Orders may be processed or filled by another Pharmacy and providing the name of the Pharmacy;
 - (B) protecting the confidentiality and integrity of Protected Health Information;
 - (C) dispensing Prescription Drug Orders when the filled Prescription Drug Order is not received or the patient comes in before the Prescription Drug Order is received;
 - (D) maintaining required manual or electronic records to identify the name, initials, or identification code and specific activity or activities of each Pharmacist, Certified Pharmacy Technician, Certified Pharmacy Technician Candidate, or Pharmacy Intern who performed any Shared Pharmacy Services;
 - (E) complying with federal and state laws; and
 - (F) operating a Continuous Quality Improvement Program for Shared Pharmacy Services, designed to objectively and systematically monitor and evaluate the



NABP

quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems.

(e) Individual Practice

- (1) Nothing in this Section shall prohibit an individual Pharmacist licensed in the state, who is an employee of or under contract with a Pharmacy, or a licensed Certified Pharmacy Technician, Certified Pharmacy Technician Candidate, or Pharmacy Intern, working under the supervision of the Pharmacist, from accessing that Pharmacy's electronic database from inside or outside the Pharmacy and performing the Prescription Drug Order processing functions permitted by the Pharmacy Act, if both of the following conditions are met:

- (i) the Pharmacy establishes controls to protect the confidentiality and integrity of Protected Health Information; and
- (ii) no part of the database is duplicated, downloaded, or removed from the Pharmacy's electronic database.

~~(f) Practice of Telepharmacy—Remote Dispensing Site Requirements¹²²~~

~~A Remote Dispensing Site:~~

- ~~a. Shall submit an Application to the Board.~~
- ~~b. The Pharmacist in Charge of the Shared Pharmacy Services Pharmacy shall be responsible for all operations of the Remote Dispensing Site.~~
- ~~c. Shall have a written contract or agreement that outlines the services provided and the responsibilities of each Pharmacy in complying with Federal and State pharmacy laws and rules.~~
- ~~d. The Pharmacist in Charge shall oversee monthly inspections, maintenance, and reconciliation of all controlled substances, including maintaining a perpetual inventory for all Schedule II controlled substances.~~
- ~~e. A Pharmacist must be designated to be available within () hours, in case of emergency.~~
- ~~f. A functioning video and audio communication system that provides for effective communication between the Shared Pharmacy Services Pharmacy and the Remote Dispensing Site personnel and patients, and their agents or caregivers, must be maintained. The system must provide an adequate number of views of the entire site, facilitate adequate pharmacist supervision, and allow the appropriate exchanges of visual, verbal, and written communications for patient counseling and other matters involved in the lawful transaction or Delivery of Drugs. The Remote Dispensing Site must retain a recording of the facility surveillance, excluding patient communications, for a minimum of () days.~~

¹²² For Boards of Pharmacy that have yet to add rules for the Practice of Telepharmacy and/or require more specificity, see Appendix F Model Rules for the Practice of Telepharmacy.

~~g. Unless a Pharmacist is present, a Remote Dispensing Site must not be open or its employees allowed access during times the Shared Pharmacy Services Pharmacy is closed or during a system outage.~~

Section 9. Automated Pharmacy Systems.

- (a) Automated Pharmacy Systems can be utilized in licensed pharmacies and Shared Pharmacy Services Pharmacies and other locations approved by the Board. A Pharmacist is not required to be physically present at the site of the Automated Pharmacy System if the system is supervised electronically by a Pharmacist. Automated Pharmacy Systems shall comply with the following provisions.
- (1) Documentation as to type of equipment, serial numbers, content, policies and procedures, and Shared Pharmacy Services Pharmacy location shall be maintained in the Pharmacy for review. Such documentation shall include, but is not limited to:
 - (i) name and address of the Pharmacy and the Shared Pharmacy Services Pharmacy where the Automated Pharmacy System is being used;
 - (ii) Manufacturer's name and model;
 - (iii) description of how the Automated Pharmacy System is used;
 - (iv) quality assurance procedures to determine continued appropriate use of the Automated Pharmacy System;
 - ~~(v) policies and procedures for system operation, safety, security, accuracy, patient confidentiality, access, and malfunction; and~~
 - (vi) documentation evidencing that the Automated Pharmacy System has been tested prior to initial use and on a periodic basis at each location to ensure that the Automated Pharmacy System is operating properly.
 - ~~(2) Automated Pharmacy Systems should be used only in settings where there is an established program of Pharmacist Care Services that ensures Medical Orders or Prescription Drug Orders are reviewed by a Pharmacist in accordance with established policies and procedures and good Pharmacist Care Services.¹²³~~
 - ~~(2i)~~ A Pharmacist shall be accessible to respond to inquiries or requests pertaining to Drugs Dispensed from the Automated Pharmacy System.¹²⁴
 - ~~(3ii)~~ Any Pharmacy that maintains an Automated Pharmacy System for the purposes of remote Dispensing to outpatients¹²⁵ shall maintain an interactive video/auditory

¹²³ Each state should determine whether or not the Dispensing of a "first dose" or an "emergency dose" may take place without prior order review by a Pharmacist but with appropriate security and patient Medication Therapy Management controls in place.

¹²⁴ In order to facilitate communication between the Pharmacy and the site where the Automated Pharmacy System is located, a Pharmacy should provide a toll-free telephone number so that the Pharmacist is accessible at all times the Automated Pharmacy System is operational.

¹²⁵ Although an "outpatient" generally refers to a Person who receives Drugs for use outside of an Institutional Facility, the definition of "outpatient" must be defined by each state. For example, although the *Model Act* classifies penal institutions as a type of Institutional Facility and therefore its inmates as inpatients, the Pharmacist is exempt from providing Patient Counseling. However, some states may consider inmates of penal



communication system to provide for effective communication between the patient and the Pharmacist; the video/auditory communication system shall allow for the appropriate exchange of oral and written communication and Patient Counseling; if the video/auditory communication system malfunctions, then all operations of the Automated Pharmacy System shall cease until the system is fully functional.

- ~~(3) All policies and procedures must be maintained in the Pharmacy responsible for the Automated Pharmacy System and, if the Automated Pharmacy System is being used at a different location, at that location as well.~~
- (4) Automated Pharmacy Systems shall have adequate security systems and procedures, evidenced by written policies and procedures¹²⁶, to:
 - (i) prevent unauthorized access;
 - (ii) comply with federal and state regulations; and
 - (iii) prevent the illegal use or disclosure of Protected Health Information.
- (5) Records and/or electronic data kept by Automated Pharmacy Systems shall meet the following requirements.
 - (i) All events involving the contents of the Automated Pharmacy System must be recorded electronically.
 - (ii) Records must be maintained by the Pharmacy and must be readily available to the Board. Such records shall include:
 - (A) identity of system accessed;
 - (B) identification of the individual accessing the system;
 - (C) type of Transaction;
 - (D) name, strength, dosage form, and quantity of the Drug accessed;
 - (E) name of the patient for whom the Drug was ordered; and
 - (F) such additional information as the Pharmacist-in-Charge may deem necessary.
- ~~(6) Defined as Access to and limits on access (eg, security levels) to the Automated Pharmacy System shall be defined must be defined by policy and procedures and must comply with state and federal regulations.~~¹²⁷
- (7) The Pharmacist-in-Charge shall have the responsibility to:
 - (i) assign, discontinue, or change access to the system;
 - (ii) ensure that access to the Drugs complies with state and federal regulations;

institutions as outpatients and therefore should decide if a video/audio communication system is required in such facilities so that the Pharmacist is able to provide Patient Counseling.

¹²⁶ ~~The use of Automated Pharmacy Systems requires written policies and procedures in place prior to installation to ensure safety, environmental controls, accuracy, security, and patient confidentiality and to define access and limits to access to equipment and Drugs.~~

¹²⁷ This section anticipates that decisions regarding which health care professionals may access the Automated Pharmacy System and the level of access allowed (eg, access to Drugs, access to patient profiles for viewing only, access to patient profiles for modification) will be left up to the individual(s) responsible for the Automated Pharmacy System; however, states may decide to take on this responsibility and define those who may have access to the system and the levels of access allowed.



- (iii) ensure that the Automated Pharmacy System is filled/stocked accurately ~~and in accordance with established, written policies and procedures.~~
- (8) The filling/stocking of all Drugs in the Automated Pharmacy System shall be accomplished by qualified personnel under the supervision of a licensed Pharmacist.
- (9) A record of Drugs filled/stocked into an Automated Pharmacy System shall be maintained and shall include identification of the persons filling/stocking and checking for accuracy.¹²⁸
- (10) All containers of Drugs stored in the Automated Pharmacy System shall be packaged and labeled in accordance with federal and state laws and regulations.
- (11) All aspects of handling controlled substances shall meet the requirements of all state and federal laws and regulations.
- (12) The Automated Pharmacy System shall provide a mechanism for securing and accounting for Drugs removed from and subsequently returned to the Automated Pharmacy System, all in accordance with existing state and federal law.¹²⁹
- (13) The Automated Pharmacy System shall provide a mechanism for securing and accounting for wasted or discarded Drugs in accordance with existing state and federal law.

(b) Policies and Procedures

- (1) The Pharmacist-in-Charge is responsible for developing or adopting, implementing, and maintaining Automated Pharmacy Systems policies and procedures that address the following:
 - (g) system operation, safety, stocking accuracy, patient confidentiality, access and limits to access, environmental controls, and malfunction;
 - (ii) provision of Pharmacist Care;
 - (iii) security, including:
 - (A) preventing unauthorized access;
 - (B) prevention of the illegal use or disclosure of Protected Health Information.
- (2) All policies and procedures ~~shall~~ must be maintained in the Pharmacy responsible for the Automated Pharmacy System and, if the Automated Pharmacy System is being used at a different location, at that location as well.

Section 10. Return and Reuse of Prescription Drugs.

- (a) Prescription Drugs may only be returned and reused providing that the Prescription Drugs were packaged in:

¹²⁸ This section anticipates that states will allow non-Pharmacist personnel to fill/stock Automated Pharmacy Systems under a Pharmacist's supervision; however, the state may decide to only allow a Pharmacist to perform this function. Should the State allow non-Pharmacist personnel to perform this function, it should define the level of Pharmacist supervision necessary (eg, immediate, direct, or general).

¹²⁹ The State may require that each licensed Pharmacy or facility have in place written policies and procedures to address situations in which Drugs removed from the system remain unused and must be secured and accounted for.



NABP

- (1) the original, sealed, and tamper-evident bulk, unit-of-use,¹³⁰ or unit dose packaging; or
- (2) the Dispensing Pharmacy's original packaging that maintains the Product quality.
- (b) All returned packaging must indicate that the Prescription Drug's integrity and stability has been maintained.
- (c) All returned Prescription Drugs must be evaluated by appropriate Pharmacy staff to ensure such Prescription Drugs are not adulterated or misbranded.
- (d) ~~A state-licensed Pharmacist must verify ensure compliance with all of the above elements.~~

Section 11. Prescription Drug Repository Programs.

- (a) Repository Programs must have written policies and procedures, which include at a minimum:
 - (1) Qualifications of acceptable Drugs for reuse. Such qualifications must include the following provisions:
 - (i) only non-controlled Drugs will be accepted;¹³¹
 - (ii) all Drugs will be inspected by ~~a Pharmacist~~ appropriate Pharmacy staff and determined to be:
 - (A) unadulterated;
 - (B) unexpired; and
 - (C) in unopened unit dose or manufacturer's tamper-evident original packaging, or otherwise approved by the Board of Pharmacy;
 - (iii) maintenance of a separate physical inventory;
 - (iv) completion of a monthly expiration date review for all Drugs;
 - (v) prohibition for charging or accepting compensation for Drugs except for administrative or minimal dispensing fees;
 - (vi) Dispensing by a pharmacist or a practitioner within the practitioner's scope of practice; and
 - (vii) record keeping, including the source and dispensation of all Drugs.
 - (2) A requirement that the patient receives notification that the Drug is being Dispensed by a Repository Program.

Section 12. Disposal of Controlled Substances.¹³²

- (a) Any Persons legally authorized to possess controlled substances in the course of their professional practice or the conduct of their business shall dispose of such Drugs ~~by the following procedures and~~ in compliance with federal law.

¹³⁰ Unit-of-use is not intended to include co-mingled, multi-Drug unit-of-use packages also known as compliance packs.

¹³¹ Except for federally scheduled controlled substance Drugs that may be prescribed for substance use disorders and as allowed by federal and state laws and regulations.

¹³² Boards may give hospitals the authority to dispose of wasted quantities of controlled substances without prior authorization under specified conditions.



- ~~(1) The responsible individual shall send the Board of Pharmacy a list of the controlled substances to be disposed of, including the name(s) and quantity of the Drug(s).~~
- ~~(2) The Board shall authorize and instruct the applicant to dispose of the controlled substances in one of the following manners:~~
 - ~~(i) by Delivery to an agent of the Board of Pharmacy or the Board of Pharmacy office;~~
 - ~~(ii) by destruction of the Drugs in the presence of a Board of Pharmacy officer, agent, inspector, or other authorized individual; or~~
 - ~~(iii) by such other means as the Board of Pharmacy may determine to ensure that the Drugs do not become available to unauthorized Persons.~~

Section 13. PrRepackaging.

- (a) A Pharmacy may PrRepackage Drugs under the following circumstances:
 - ~~(1) written policies and procedures have been developed that address the processes of Prrepackaging within the Pharmacy;~~
 - (1) containers utilized for PrRepackaging shall meet, as a minimum requirement, Class B container standards as referenced by USP;
 - (2) the PrRepackaging processes are conducted under conditions that ensure the integrity of the Drug and under the direct supervision of a Pharmacist;
 - (3) the PrRepackaged Drugs are labeled with the following components:
 - (i) Drug Name;
 - (ii) Drug Strength;
 - (iii) Pharmacy Control and Manufacturer lot number;
 - (iv) Name of the Manufacturer or Distributor of the Drug or the National Drug Code; and
 - (v) Beyond-Use Date, which shall be the Manufacturer's expiration date or one that is required under the most current USP standards, whichever is earlier;
 - (4) Records of all PrRepackaging operations are maintained and include the following:
 - (i) the name (nonproprietary and proprietary name), strength, dosage form, quantity per container, and quantity of containers of the Drug being PrRepackaged;
 - (ii) the name of the Manufacturer or Distributor of the Drug;
 - (iii) Pharmacy Control and Manufacturer lot number;
 - (iv) expiration date of the Drug according to the original Manufacturer or Distributor container and the Beyond-Use Date;
 - (v) the name, initials, or identification codes of the Certified Pharmacy Technician or Certified Pharmacy Technician Candidate that PrRepackaged the Drug and the name or initials of the Pharmacist that verified the appropriateness of the PrRepackaged Drug; and
 - (vi) the date the Drug is PrRepackaged.
 - (5) All Drugs PrRepackaged are stored at appropriate temperatures and under appropriate conditions in accordance with requirements, if any, in the labeling of such Drugs, or with requirements in the current edition of an official compendium.



- (b) Pharmacies that store Drugs within an automated counting device or Automated Pharmacy System may, in place of the required Label, maintain records of lot numbers and Beyond-Use Dates that are required on the Label as long as they are fully traceable and is readily retrievable.
- (c) The Pharmacist-in-Charge is responsible for developing or adopting, implementing, and maintaining¹³³ policies and procedures addressing Repackaging processes.
- (d) The PrRepackaging of Drugs shall follow applicable state and federal law.

Section 14. Telepharmacy

(a) General Requirements

(1) The Pharmacy shall:

- (i) obtain a resident or nonresident permit issued by the Board prior to engaging in the Practice of Telepharmacy;
- (ii) comply with appropriate federal and state controlled substance laws and rules for each Pharmacy if controlled substances are maintained;
- (iii) maintain additional policies and procedures specific to Telepharmacy.

(b) Remote Dispensing Site Requirements

- (1) The Pharmacy shall submit an application to the Board.
- (2) The Pharmacist-in-Charge of the supervising pharmacy shall be responsible for all operations.
- (3) The Pharmacy shall have a written contract or agreement that outlines the services provided and the responsibilities of each party in complying with federal and state pharmacy laws and rules.
- (4) The Pharmacist-in-Charge shall oversee monthly inspections, maintenance, and reconciliation of all controlled substances, including maintaining a perpetual inventory for all Schedule II controlled substances.
- (5) A Pharmacist must be designated to be available within () hours, in case of emergency.
- (6) Unless staffed by a Pharmacist, a Remote Dispensing Site must be staffed by at least one (1) Certified Pharmacy Technician. All Certified Pharmacy Technicians and Certified Pharmacy Technician Candidates shall be under the supervision of a Pharmacist at the supervising Pharmacy at all times that the remote site is operational. The Pharmacist shall supervise Telepharmacy operations electronically from the supervising Pharmacy.
- (7) The Remote Dispensing Site and the supervising Pharmacy must utilize a common electronic record-keeping system that must be capable of the following:
 - (i) Electronic records must be available to, and accessible from, both the supervising pharmacy and the Remote Dispensing Site at all times of operations; and
 - (ii) Prescriptions dispensed at the Remote Dispensing Site must be distinguishable from those dispensed from the supervising Pharmacy.

¹³³ The owner and/or pharmacy permit holder, along with the Pharmacist-in-Charge, are responsible for these policies and procedures.



- (8) Controlled substance records must be maintained at the registered location unless specific approval is granted for central storage as permitted by, and in compliance with, state and federal law.
- (9) A supervising Pharmacy of a Remote Dispensing Site must maintain a video and audio communication system that provides for effective communication between the supervising Pharmacy and the Remote Dispensing Site personnel and patients or caregivers. The system must provide an adequate number of views of the entire site, facilitate adequate pharmacist supervision and allow the appropriate exchanges of visual, verbal, and written communications for patient counseling and other matters involved in the lawful transaction or Delivery of Drugs. The Remote Dispensing Site must retain a recording of facility surveillance, excluding patient communications, for a minimum of () days.
 - (i) Adequate supervision by the pharmacist in this setting is maintaining uninterrupted visual supervision and auditory communication with the site and full supervisory control of the automated system, if applicable, and must not be delegated to another Person-or-entity.
 - (ii) Each component of the communication system must be in good working order. Unless a pharmacist is present onsite, the Remote Dispensing Site must be, or remain, closed to the public if any component of the communication system is malfunctioning, until system corrections or repairs are completed.
 - (iii) The video and audio communication system used to counsel and interact with each patient or patient's caregiver must be secure and compliant with state and federal confidentiality requirements.
- (10) Unless a Pharmacist is present, a Remote Dispensing Site must not be open or its employees allowed access to it during times the supervising Pharmacy is closed. The security system must allow for tracking of entries into the Remote Dispensing Site, and the Pharmacist-in-Charge must periodically review the provision of access and record of entries.
- (11) If Drugs are maintained or dispensed from the Remote Dispensing Site, Drug transfers to the Remote Dispensing Site must comply with applicable state and federal requirements.
- (12) A Remote Dispensing Site must display a sign, easily visible to the public, that informs patients:
 - (i) this is a remote site
 - (ii) location of supervising Pharmacy; and
 - (iii) that a Pharmacist will counsel the patient using audio and video communication systems each time a new Drug is Dispensed and on a refill, if necessary, at a Remote Dispensing Site.

- (13) The Remote Dispensing Site must use Telepharmacy technology that confirms that the Drug selected to fill the prescription is the same as indicated on the prescription label and Prescription Drug Order.

Section 154. Provision of Pharmacist Care Services Outside of a Licensed Pharmacy.

- (a) In order for a Pharmacist to provide Pharmacist Care Services outside the premises of a licensed Pharmacy, an applicant shall:
- (1) register/license with the Board(s) or, if located out of state, have an active NABP Verify credential;
 - (2) have appropriate security and protections in place to ensure the confidentiality of records or other patient-specific information;
 - (3) maintain such records in readily retrievable form; and
 - (4) follow the patient care process approved by the Board.¹³⁴

...

Section 176. Unprofessional Conduct.

Unprofessional conduct shall include, but is not limited to, the following acts of a Pharmacist or Pharmacy:

- (a) the publication or circulation of false, misleading, or otherwise deceptive statements concerning the Practice of Pharmacy;
- (b) unreasonably refusing to Compound or Dispense Prescription Drug Orders that may be expected to be Compounded or Dispensed in Pharmacies by Pharmacists;
- (c) attempting to circumvent the Patient Counseling requirements, or discouraging the patient from receiving Patient Counseling concerning their Prescription Drug Orders;
- (d) the illegal use or disclosure of Protected Health Information;
- (e) failure to maintain adequate records, systems, and security to protect against the illegal use or disclosure of Protected Health Information;
- (f) failure to maintain adequate records to account for disclosures of Protected Health Information;
- (g) selling, giving away, or otherwise disposing of accessories, chemicals, or Drugs or Devices found in illegal Drug traffic when the Pharmacist knows or should have known of their intended use in illegal activities;
- (h) engaging in conduct likely to deceive, defraud, or harm the public, or demonstrating a willful or careless disregard for the health, welfare, or safety of a patient, or engaging in conduct which substantially departs from the Standards of Care ordinarily exercised by a Pharmacist, with proof of actual injury not having to be established;
- (i) selling a Drug for which a Prescription Drug Order from a Practitioner is required, without having received a Prescription Drug Order for the Drug;

¹³⁴ It is anticipated that Boards use the current *Pharmacists' Patient Care Process* approved ~~in May 2014~~ by the Joint Commission of Pharmacy Practitioners.



NABP

- (j) willfully and knowingly failing to maintain complete and accurate records of all Drugs received, Dispensed, or disposed of in compliance with the Federal laws and regulations and State laws and rules;
- (k) obtaining any remuneration by fraud, misrepresentation, or deception, including, but not limited to, receiving remuneration for amending or modifying, or attempting to amend or modify, a patient's Pharmacist Care Services, absent a clear benefit to the patient, solely in response to promotion or marketing activities;
- (l) willfully and knowingly completing and submitting inaccurate due diligence questionnaires and attestation documents regarding the purchase or receipt of Drugs from Manufacturers, Repackagers, Third-Party Logistics Providers, and Wholesale Distributors.
- ...



Model Rules for the Practice of Telepharmacy

- (a) ~~General Requirements~~
 - (1) ~~The Pharmacy shall:~~
 - (i) ~~obtain a resident or nonresident permit issued by the Board prior to engaging in the Practice of Telepharmacy;~~
 - (ii) ~~comply with appropriate federal and state controlled substance laws and rules for each Pharmacy if controlled substances are maintained;~~
 - (iii) ~~maintain additional policies and procedures specific to Telepharmacy.~~
- (b) ~~Remote Dispensing Site Requirements~~
 - (10) ~~The Pharmacy Sshall submit an application to the Board.~~
 - (11) ~~The Pharmacist in Charge of supervising pharmacy shall be responsible for all operations.~~
 - (12) ~~The Pharmacy Sshall have a written contract or agreement that outlines the services provided and the responsibilities of each party in complying with federal and state pharmacy laws and rules.~~
 - (13) ~~The Pharmacist in Charge shall oversee monthly inspections, maintenance and reconciliation of all controlled substances, including maintaining a perpetual inventory for all Schedule II controlled substances.~~
 - (14) ~~A Pharmacist must be designated to be available within () hours, in case of emergency.~~
 - (15) ~~Unless staffed by a Pharmacist, a Remote Dispensing Site must be staffed by at least one (1) Certified Pharmacy Technician. All Certified Pharmacy Technicians and Certified Pharmacy Technician Candidates shall be under the supervision of a Pharmacist at the supervising Pharmacy at all times that the remote site is operational. The Pharmacist shall supervise Telepharmacy operations electronically from the supervising Pharmacy.~~
 - (16) ~~The Remote Dispensing Site and the supervising Pharmacy must utilize a common electronic record-keeping system that must be capable of the following:~~
 - (iii) ~~Electronic records must be available to, and accessible from, both the supervising pharmacy and the Remote Dispensing Site at all times of operations; and~~
 - (iv) ~~Prescriptions dispensed at the Remote Dispensing Site must be distinguishable from those dispensed from the supervising Pharmacy.~~
 - (17) ~~Controlled substance records must be maintained at the registered location unless specific approval is granted for central storage as permitted by, and in compliance with, state and federal law.~~
 - (18) ~~A supervising Pharmacy of a Remote Dispensing Site must maintain a video and audio communication system that provides for effective communication between the supervising Pharmacy and the Remote Dispensing Site personnel and patients or caregivers. The system must provide an adequate number of views of the entire site, facilitate adequate pharmacist supervision and allow the appropriate exchanges of visual, verbal, and written communications for patient counseling and other matters involved in~~



the lawful transaction or Delivery of Drugs. The Remote Dispensing Site must retain a recording of facility surveillance, excluding patient communications, for a minimum of () days.

- (iv) _____ Adequate supervision by the pharmacist in this setting is maintaining uninterrupted visual supervision and auditory communication with the site and full supervisory control of the automated system, if applicable, and must not be delegated to another person or entity.
- (v) Each component of the communication system must be in good working order. Unless a pharmacist is present onsite, the Remote Dispensing Site must be, or remain, closed to the public if any component of the communication system is malfunctioning, until system corrections or repairs are completed.
- (vi) The video and audio communication system used to counsel and interact with each patient or patient's caregiver must be secure and compliant with state and federal confidentiality requirements.
- (10) Unless a Pharmacist is present, a Remote Dispensing Site must not be open or its employees allowed access to it during times the supervising Pharmacy is closed. The security system must allow for tracking of entries into the Remote Dispensing Site, and the Pharmacist in Charge must periodically review the provision of access and record of entries.
- (11) If Drugs are maintained or dispensed from the Remote Dispensing Site, Drug transfers to the Remote Dispensing Site must comply with applicable state and federal requirements.
- (12) A Remote Dispensing Site must display a sign, easily visible to the public, that informs patients:
 - (iv) this is a remote site
 - (v) location of supervising Pharmacy; and
 - (vi) that a Pharmacist will counsel the patient using audio and video communication systems each time a new Drug is Dispensed, and on a refill, if necessary, at a Remote Dispensing Site.
- (13) The Remote Dispensing Site must use Telepharmacy technology that confirms that the Drug selected to fill the prescription is the same as indicated on the prescription label and Prescription Drug Order.

...

Model Rules for Outsourcing Facilities

Section 1. Purpose and Scope.

The purpose of this section is to ensure that Outsourcing Facilities are regulated by this State in a manner consistent with Federal law and to ensure this State has appropriate authority over such facilities.

Section 2. Registration.

- (a) Any Outsourcing Facility located in this State or that Distributes Compounded Drugs to this State must be inspected and registered as an Outsourcing Facility by FDA prior to applying for a license/registration with the Board; and
- (b) The facility must undergo an inspection by the Board or a third party recognized by the Board such as Drug Distributor Accreditation¹³⁵ if the facility is registered with FDA but has not received an FDA inspection as an Outsourcing Facility.

Section 3. Notification.

- (a) All licensed/registered Outsourcing Facilities shall report to the Board the biannual reports they are required to provide to FDA identifying the Drugs Compounded in the previous six (6)-month period, including the Drug's Active Ingredients, strength, and dosage form.

Section 4. Requirements.

Outsourcing Facilities must:

- (a) Designate a Pharmacist-in-Charge. Whenever an applicable rule requires or prohibits action by a Pharmacy, responsibility shall be that of the owner and/or permit holder and the Pharmacist-in-Charge, whether the owner and/or permit holder is a sole proprietor, partnership, association, corporation, or otherwise;
- ~~(a)~~ Compound Drugs by or under the direct supervision of a licensed Pharmacist;
- ~~(b)~~ Compound Drugs in accordance with current Good Manufacturing Practice (cGMP) as required by Federal law;
- ~~(c)~~ Ensure that Pharmacists conducting or overseeing Compounding at an Outsourcing Facility must be proficient in the art of Compounding and shall acquire the education, training, and/or experience to maintain that proficiency through participation in seminars, studying appropriate literature, and consulting colleagues, and/or by becoming certified by a Compounding certification program approved by the Board.
- ~~(d)~~ Label Compounded Drugs with:
 - (i) required Drug and ingredient information,
 - (ii) facility identification, and
 - (iii) the following or similar statement: "This is a compounded drug. For office use only" or "Not for resale"; and

¹³⁵ States may require authentication and tracking of Product, whereby the exchange of information for Compounded Product is traced.



NABP

(ef)

Only Compound using bulk Drug substances that meet specified FDA criteria. May also compound Drugs that appear on an FDA shortage list if the bulk drug substances used comply with the aforementioned specified criteria.

Appendix A€

Guidelines for Disciplinary Sanctions

Improperly Obtaining or Attempting to Obtain a License

1. Fraud or Misrepresentation in applying for or procuring a license issued by the board of pharmacy or in connection with applying for or procuring periodic reregistration of such license.
Range of action: from Fine to Revocation or denial
2. Cheating on or attempting to subvert the Pharmacist licensure examination(s).
Range of action: Revocation or denial

Misdemeanors/Felonies

3. The commission or conviction of a gross misdemeanor or a felony, whether or not related to the Practice of Pharmacy, or the entry of a guilty or nolo contendere plea to a gross misdemeanor or a felony charge.
Range of action: from Probation to Revocation

Deception/Fraud/Misrepresentation

4. Conduct likely to deceive, defraud, or harm the public.
Range of action: from Censure to Revocation
5. Making a false or misleading statement regarding one's skill or the efficacy or value of the medicine, treatment, or remedy Dispensed in the treatment of any disease or other condition of the body or mind.
Range of action: from Probation to Revocation
6. The use of any false, fraudulent, or deceptive statement in any document connected with the Practice of Pharmacy.
Range of action: from Warning to Revocation
7. Practicing Pharmacy under a false or assumed name.
Range of action: from Probation to Revocation

Patient Confidentiality/Records

8. Improper management of Pharmacy patient records, including illegal use or disclosure of Protected Health Information.
Range of action: from Warning to Suspension

Negligence/Incompetence/Disability/Malpractice

9. Negligence in the Practice of Pharmacy as determined by the Board.
Range of action: from Warning to Revocation
10. Being found mentally incompetent or insane by any court of competent jurisdiction.
Range of action: from Suspension to Revocation
11. Being physically or mentally unable to engage safely in the Practice of Pharmacy.
Range of action: from Probation to Revocation
12. Demonstration of incapacity or incompetence to practice Pharmacy.
Range of action: from Probation to Revocation
13. Any adverse judgment, award, or settlement against the licensee resulting from a professional malpractice claim related to conduct that would constitute grounds for action as defined in this section.
Range of action: from Censure to Revocation

Sexual Misconduct

14. Commission of any act of sexual abuse, misconduct, or exploitation related to a licensee's Practice of Pharmacy.
Range of action: from Probation to Revocation

Drug- and Alcohol-Related Offenses

15. Being dependent on or habituated to a Drug or intoxicant.
Range of action: from Probation to Revocation
16. Dispensing, prescribing, selling, Administering, Distributing, ordering, or giving any Drug legally classified as a controlled substance or recognized as an addictive or dangerous Drug for any purposes other than medically accepted as therapeutic.
Range of action: from Probation to Revocation
17. Except as otherwise permitted by law, Dispensing, prescribing, selling, Administering, Distributing, ordering, or giving to an habitué, addict, or any Person previously Drug dependent



NABP

any Drug legally classified as a controlled substance or recognized as an addictive or dangerous Drug.

Range of action: from Probation to Revocation

18. Violating any State or Federal law or regulation relating to controlled substances.
Range of action: from Warning to Revocation

Misuse of License

19. Aiding or abetting the Practice of Pharmacy by an unlicensed, incompetent, or impaired Person.
Range of action: from Reprimand to Revocation
20. Allowing another Person ~~or organization~~ to use one's license to practice Pharmacy.
Range of action: from Reprimand to Revocation

Disciplinary Action by Other Jurisdictions

21. Disciplinary action of another state or jurisdiction against a license or other authorization to practice Pharmacy based upon conduct by the licensee similar to conduct that would constitute grounds for action as defined in this Section.
Range of action: same as for similar offense in this State

Failure to Report to and/or Cooperate with Board

22. Failure to report to the Board any adverse action taken by another licensing jurisdiction (United States or foreign), government agency, law enforcement agency, or court for conduct that would constitute grounds for action as defined in this Section.
Range of action: from Censure to Revocation
23. Failure to report to the Board one's surrender of a license or authorization to practice Pharmacy in another state or jurisdiction while under disciplinary investigation by any of those authorities or bodies for conduct that would constitute grounds for action as defined in this section.
Range of action: from Censure to Revocation
24. Failure to report to the Board any adverse judgment, settlement, or award arising from a malpractice claim related to conduct that would constitute grounds for action as defined in this section.
Range of action: from Censure to Suspension
25. Failure to cooperate with a lawful investigation conducted by the Board.
Range of action: from Censure to Revocation



NABP

26. Failure to furnish to the Board, its investigators, or representatives any information legally requested by the Board.
Range of action: from Censure to Revocation

Other Violations

27. Violation of any provision(s) of the Pharmacy Practice Act, any rules and regulations of the Board, or any action, stipulation, or Agreement of the Board.
Range of action: corresponds to related actions above.

...

Appendix D

Community Pharmacy Quality-Related Event (QRE) Data Collection Form

QRE Prescription Data		
Attach copy of: <input type="checkbox"/> prescription <input type="checkbox"/> label <input type="checkbox"/> photo of vial (mark all available)		
Original Rx date: _____	Refill date: _____	Date/time reported: _____
Drug Prescribed (name, strength, and dosage form): Directions: Drug indication:		
Prescription was received by the pharmacy via: <input type="checkbox"/> telephone, by whom: _____ <input type="checkbox"/> written <input type="checkbox"/> computer <input type="checkbox"/> fax		

QRE Data	
QRE Type: (select all that apply) A. Prescription processing error: <input type="checkbox"/> Incorrect drug (1) <input type="checkbox"/> Incorrect strength (2) <input type="checkbox"/> Incorrect dosage form (3)	B. A failure to identify and manage <input type="checkbox"/> Over/under-utilization (1) <input type="checkbox"/> Therapeutic duplication (2) <input type="checkbox"/> Drug-disease contraindications (3) <input type="checkbox"/> Drug-drug interactions (4)



NABP

☐ Incorrect patient (4)

☐ Inaccurate or incorrect packaging, labeling, or directions (5)

☐ Other (6):

☐ Incorrect duration of treatment (5)

☐ Incorrect dosage (6)

☐ Drug-allergy interaction (7)

☐ Clinical abuse/misuse (8)

QRE Contributing Factors

Day of the week and time of QRE:

No. of new prescriptions: _____ No. of refill prescriptions: _____

RPh to tech ratio:

RPh staff status: ☐ regular staff ☐ part-time/substitute staff

length of employment:

No. of hours RPh on duty: _____ Average No. of prescriptions filled per hour:

No. of other RPhs on duty: _____ No. of support staff on duty:

Automation ☐ yes ☐ no Type:

☐ Computer software ☐ Environmental (lighting/noise/distractions/workspace)

☐ Equipment failure ☐ Failure to supervise

☐ Legibility ☐ Increased Rx volume as compared to normal

☐ Shift change ☐ Policies and/or procedure not followed

☐ Staff shortage ☐ Sound alike/look alike Drugs

☐ Other, explain

Describe factors checked above and/or other preliminary root contributors:

Counseling was offered: ☐ yes ☐ no Counseling was given: ☐ yes ☐ no



NABP

Documentation of offer: ☐ yes ☐ no — Documentation of counseling: ☐ yes ☐ no

Pharmacist Information

Name of verifying pharmacist:

Name(s) of other person(s) and title(s) involved in processing the prescription:

Describe remedial action taken:

If patient received Drug, complete Patient and Prescriber Information sections.

Patient Information

Patient's name: _____ Prescription was dispensed to: _____

Address: _____ Telephone No.: _____

Patient DOB: _____

Sex: M or F

If minor, name of parent(s)/guardian(s): _____

Who discovered the error/relationship to patient?: _____

Did patient ingest Drug? ☐ yes ☐ no — If yes, how many doses?: _____



NABP

- ☐ Not harmed _____ ☐ Received treatment and/or increased monitoring
- ☐ Seriously harmed, explain _____
- ☐ Did not survive, explain _____

Prescriber Information

Was the prescriber informed: ☐ yes ☐ no _____ If yes, provide date: _____

Prescriber's name: _____ Telephone No.: _____

Prescriber's instructions/comments: _____

Report Affirmation

Additional comments: _____

Name and title of preparer of this report: _____

Signature: _____ Date: _____

Community Pharmacy Continuous Quality Improvement Program Inspection Form

General Information

Pharmacy name: _____

License No.: _____

Address: _____

Phone No.: _____



NABP

Pharmacist-in-charge (PIC):		PIC License No.:	
Date/time:		Date of previous inspection:	
		Attach copy of previous inspection	
Purpose of inspection <input type="checkbox"/> Complaint <input type="checkbox"/> Routine <input type="checkbox"/> Follow-up <input type="checkbox"/> New pharmacy <input type="checkbox"/> Change in owner <input type="checkbox"/> Other Comment:			

Pharmacy Staff			
(Include pharmacist, intern, certified pharmacy technician, certified pharmacy technician candidate, and cashier)			
Name	Title	License No.	Present

P=Present A=Absent N/A= Not applicable
--



NABP

CQI Program	P	A	N/A
Policy and procedures in place			
Periodic CQI meetings held			
Quality Related Events (QRE) recorded			
Sentinel Events			
Workload compiled			
Staffing needs analyzed/addressed			
Outcome-based certified pharmacy technician training conducted			
Technology utilized in current/updated			
Pharmacist Care Services initiatives in place			
Consumer survey policy in place			
Professional performance evaluation policy in place			
Comments: 			
Recommendations: 			
Report Affirmation			
Additional comments: 			

**NABP**

Pharmacist signature: _____	Date: _____
Surveyor signature: _____	Date: _____

Community Pharmacy Quality Self-Audit

Each pharmacy shall conduct a quality self-audit at least quarterly and upon change of pharmacist-in-charge. The goals of the quality self-audit are to monitor changes in the number of quality-related events (QRE) over time, to evaluate compliance with CQI procedures, and to develop a plan for improved adherence with the CQI Program.

General Information	
Date: _____	Quarterly <input type="checkbox"/> — Change of pharmacist in charge
Pharmacy name: _____	Address: _____
Telephone: _____	License No.: _____
Pharmacist in charge: _____	Date of previous self-audit: _____

Pharmacy Staff			
(Include pharmacist, intern, certified pharmacy technician and certified pharmacy technician candidate, cashier)			
Name	Title	License No.	Start Date



NABP

Staffing/Workload Date			
Staffing			Yes/No/Answer
Number of pharmacist hours allocated per week			
Number of certified pharmacy technician hours allocated per week			
Number of certified pharmacy technician candidate hours allocated per week			
Number of other pharmacy support staff hours allocated per week			
Number of certified pharmacy technicians			
Number of certified pharmacy technician candidates			
Outcome-based certified pharmacy technician training program (If yes, check all applicable)			
<input type="checkbox"/> Cash register <input type="checkbox"/> Prescription intake <input type="checkbox"/> Prescription filling			
<input type="checkbox"/> Inventory <input type="checkbox"/> Returning stock bottles to shelf <input type="checkbox"/> Clean room			
<input type="checkbox"/> Computer data entry <input type="checkbox"/> Pharmaceutical calculations <input type="checkbox"/> Knowledge of practice settings			
<input type="checkbox"/> Identifying drugs, doses, routes of Administration, dosage forms, etc			
<input type="checkbox"/> Pharmaceutical and medical terminology <input type="checkbox"/> Other			
Workload			Yes/No/Answer

**NABP**

Number of hours pharmacy department is open during the week	
Average number of prescriptions filled per week	
Usual ratio of pharmacist to technicians	
Policy is in place that requires increased staffing if workload increases	
Automation	Yes/No/Answer
Type	

CQI Program Data	
General	Yes/No/Answer
Pharmacy has a CQI policy and procedure manual	
Employees must verify review of policy and procedure manual	
Periodic CQI Meetings	Yes/No/Answer
Pharmacy holds CQI meetings (if yes, indicate frequency)	
Average length of CQI meetings in minutes	
Staff attending CQI meetings <input type="checkbox"/> Pharmacists <input type="checkbox"/> Technicians <input type="checkbox"/> Manager <input type="checkbox"/> Pharmacy supervisor <input type="checkbox"/> Owner <input type="checkbox"/> Other	
Program Documentation Methods	Yes/No/Answer
QRE forms utilized	
Method used to document interaction in relation to CQI program	



NABP

<input type="checkbox"/> Computer database <input type="checkbox"/> On prescription <input type="checkbox"/> Custom-made form <input type="checkbox"/> Standard form <input type="checkbox"/> Other	
Method used to verify drug product with prescription label <input type="checkbox"/> Bar code <input type="checkbox"/> NDC code <input type="checkbox"/> Name of product <input type="checkbox"/> Other	
First time refills are checked against hardcopy	
Consumer Surveys	Yes/No/Answer
Consumer survey policy in place, if yes, indicate frequency	
Other technique in place to evaluate performance, if yes, describe	
Method of conducting consumer survey <input type="checkbox"/> Distributed at time of dispensing <input type="checkbox"/> Mail <input type="checkbox"/> Telephone <input type="checkbox"/> Other	
Consumer survey feedback utilized to improve delivery of pharmacy services	
Outcome-Based Professional Performance Evaluation	
Frequency <input type="checkbox"/> Annually <input type="checkbox"/> Biannually <input type="checkbox"/> Quarterly <input type="checkbox"/> Other	
Staff required to have outcome-based professional performance evaluations <input type="checkbox"/> All employees <input type="checkbox"/> Full-time pharmacists <input type="checkbox"/> Part-time pharmacists <input type="checkbox"/> Other	
Self-audit includes:	
<input type="checkbox"/> Number of overridden drug-drug interaction warnings	
<input type="checkbox"/> Number of patients that received duplicative drug therapy	
<input type="checkbox"/> Number of patients that received extensive counseling	



NABP

☐ Number of QREs tracked over time. Indicate time period

QRE Incidents

Utilizing QRE Data Collection Sheets, compile the data below.

Date								
QRE type (eg, A(1)= incorrect drug dispensed)								
Drug name and strength								
Rx received via:								
New or refill								
Day of week/time								
RPh to tech ratio								
RPh staff status								
No. of hrs RPh on duty								
No. of other pharmacists on duty								
No. of other support staff								
Average No. of prescriptions/hour								



NABP

Responsible pharmacist's name								
Patient received Drug								
Prescriber notified								
Counseling offered								
Counseling accepted								